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A. Introduction* 
 
 
Graphical 
Abstract: 
 
 
Solid-phase synthesis is a convenient and established method for the preparation of 
peptide based compounds. However, solid-phase synthesis of inorganic complexes is a 
rather new discipline and was established by Heinze, Metzler-Nolte, Reedijk and 
others.1 Earlier attempts to use solid-phase synthesis, e.g. to obtain (2,2´bispyridine)-
dichloro complexes of platinum(II) by Gallop, failed at the cleavage step,2 due to the 
more labile metal-ligand bonds of organometallic building blocks compared to typical 
covalent bonds of organic molecules. Coordination and organometallic chemistry on 
solid-phase were typically studied in the context of catalyst performance.3 Recently, 
solid-phase synthesis using insoluble resins as solid support was used to synthesize 
metal complexes based on peptide backbone ligands. These coordination compounds 
find applications in biochemistry as well as in medicinal chemistry. Resin-bound 
chelates were prepared in such a manner that upon the addition of suitable metal salts 
the target metal complexes were selectively released from the resin and used e.g. in 
fluorescence or radio imaging or oligonucleotide DNA/RNA binding studies. Other 
approaches incorporated beforehand prepared metal-complex building blocks in solid-
phase peptide synthesis which leads e.g. to peptide-platinum complex conjugates with 
anticancer activity. This versatile approach to incorporate pendant protected amino acid 
functionalities, offers several advantages over solution phase or post solid-phase peptide 
synthesis conjugation.4 It provides the flexibility to incorporate a metal ion chelator 
with exclusive site specificity in any amino acid sequence, not just terminally or at one 
or more lysine or cysteine side chains.5 Additionally, peptides are often prepared most 
effective via automated solid-phase synthesis.  
                                                 
* This introduction is published as a micoreview: G. Dirscherl, B. König  Eur. J. Org. Chem. 2007, in 
press. 
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Scope and Limitations 
This introduction will summarize recent reports on the preparation of metal complex – 
peptide conjugates by solid-phase synthesis methods. The focus of the introduction lies 
on the synthetic methodology to prepare the building blocks and peptides rather than 
applications of the metal complex – peptide conjugates. The survey is structured by the 
metal ions used for complex formation, and the discussion distinguish between 
examples of solid phase ligand synthesis with subsequent metallation6 and the use of 
metal containing amino acids for synthesis.  
 
1. Chromium, Molybdenum and Tungsten  
(Group 6) Metal Complex – Peptide Conjugates 
1.1 Nδ,N,O-L-Histidinate (His) molybdenum conjugate 
Metzler-Nolte and co-workers reported oligopeptide bioconjugates with 
organometallic Mo carbonyl complexes.7 The conjugates were prepared in excellent 
yield and purity by two different solid-phase synthesis strategies. In one approach the 
neuropeptide enkephalin (enk) Tyr-Gly-Gly-Phe-Leu, which is a natural ligand to the 
opiate receptor, was synthesized by standard Fmoc solid-phase methods on NovaSyn 
TGA resin with an HMBA linker. The metal complex Mo(Nε-C2H4CO2H-
His)(allyl)(CO)2 was coupled to the resin-bound, fully deprotected enkephalin 9 and 
afterwards cleaved from the resin by treatment with saturated NH3 solution in MeOH 
(Scheme 1). 
2) Cleave from resin
H Enk
1
NN
NH2
Mo
O
O
O
Tyr-Gly-Gly-Phe-Leu-NH2
2CO CO
NN
NH2
Mo
O
O
O
OH
CO
CO
1)
+ TBTU
 
Scheme 1. Solid-phase synthesis of Mo(His)Enk conjugate 2 using a metal complex 
acid. 
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1.2 Bis(2-picolyl)amine (bpa) molybdenum conjugate 
In case when the attachment of a metal complex to the peptide on the solid support is 
not desirable, e.g. with radioactive metal isotopes, an innocent anchoring group can be 
attached to the peptide during solid-phase synthesis. The ligand–peptide conjugate is 
then cleaved from the resin, purified and the metal label is only added in solution 
immediately prior to use of the bioconjugate. Metzler-Nolte et al. provided an example 
for this procedure using the Mo(CO)3 fragment and bpa as a ligand (Scheme 2).7 
2) Cleave from resin
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Scheme 2. Synthesis of Mo(bpa)-Enk conjugate 4 by subsequent metallation. 
1.3 Bidentate schiff base metal conjugates 
A solid-phase synthesis approach for molybdenum carbonyl complexes was developed by 
Heinze (Scheme 3).8 We include this example, although neither peptide coupling nor metallated 
amino acids are used, because it illustrates that complex organometallic transformations are 
possible on solid support. A specific resin and linker system allows coordination and 
organometallic chemistry under solid-phase reaction conditions and the cleavage of the metal 
complex from the solid support. Bidentate Schiff base 5-R was used as the ligand. The phenolic 
hydroxyl group allows the attachment to the solid support. A silyl ether9 based linker was 
chosen due to its stability under basic and acidic conditions and the possibility to cleave with 
fluoride ions, which are expected to be unreactive towards most metal complexes. In solution 
high temperature and rather harsh oxidative reaction conditions are necessary to synthesize the 
desired tricarbonyl compounds. Such harsh conditions have to be avoided in solid-phase 
chemistry with polystyrene resins as the molybdenum precursors can react with the aromatic 
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residues of the support. Heinze and co-workers used [(CH3CN)3Mo(CO)3] as a Mo(CO)3 source 
and under mild reaction conditions the intensely blue coloured complexes 6-R – 7-R formed 
rapidly and cleanly in excellent yields. However, acetonitrile, a rather poor solvent for resin-
swelling, had to be used in a mixture with toluene. Otherwise the complexation led to formation 
of the immobilised tetracarbonyl complex instead of the desired tricarbonyl complex. The 
cleavage was performed with tetra-n-butylammonium fluoride in dichloromethane and resulted 
in deeply coloured solutions of the deprotonated complexes. 
OR
N
N
OR
N
N
Mo(CO)3(NCCH3)
OR
N
N
Mo(CO)3L
[(CH3CN)3Mo(CO)3]
CH3CN
L
- CH3CN
R = H, TMS, polystyrene
L = CO, CNtBu, PPh3
5-R 6-R 7-R
 
Scheme 3. Synthesis of molybdenum tricarbonyl complexes on solid support. 
Heinze et al. used their molybdenum carbonyl complexes, as the molybdenum-
carbonyl and molybdenum-isonitrile bonds are substitutionally inert metal-ligand bonds, 
to synthesize di- and trimetallic homonuclear complexes (Scheme 4).10 Finally mixed-
metal dinuclear complexes prepared from chromium, molybdenum and tungsten and a 
directional bridging ligand were assembled stepwise on solid-phase and cleaved from 
the support.11 
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Scheme 4. Synthesis of mixed-metal dinuclear complexes on solid support. 
Solution synthesis, although straightforward, requires purification of the products and 
intermediates, which is rather difficult, and makes this approach less suitable for longer-
chain complexes. The solid-phase synthesis needs more reaction steps (ligand 
immobilisation and product release) and differently optimised reaction conditions. 
However, it is much easier to accomplish, and solubility problems and purification of 
intermediates can be disregarded. 
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2. Manganese, Technetium and Rhenium (Group 7) Metal Complex – Peptide 
Conjugates 
The manganese family comprises the most used metals for peptide complexation. Its 
applications range from rhenium and technetium labeled radiopharmaceuticals12 to 
organometallic PNA oligomers with rhenium and their interaction with complementary 
DNA and to peptide-manganese complexes with catalytic activity. 
The transition metals technetium and rhenium are among the most commonly used 
radioisotopes in medicine due to the favorable emission energies and decay properties 
of radioactive isotopes Tc-99m, Re-186 and Re-188.13 As a result, methods of attaching 
these radionucleides to peptide sequences have been developed. Solid-phase synthesis 
strategy was employed to optimize the receptor binding affinity and biodistribution of 
technetium labeled peptides14 as it allows the preparation of analogues of a particular 
peptide-ligand bioconjugate in parallel.15  
2.1 Bpa metal conjugate 
Valliant and co-workers prepared the single amino acid chelate (SAAC) 17 and Re-
SAAC-peptide derivatives 19 using solid-phase synthesis.16 Fmoc protected dipyridyl 
chelate 13 and its Re complex 14 were incorporated into the growing peptide linked to a 
SASRIN resin using HBTU as the coupling agent (Scheme 5).  
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Scheme 5. Solid-phase synthesis of ligand 17 and rhenium complex 19 using a 
metallated amino acid. 
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In 2005 Valliant et al.17 published a solid-phase methodology which aimed to 
incorporate lysine into the backbone of a peptide in such a manner that the ε-nitrogen 
could be selectively liberated and a metal-bpa-chelate added, while the peptide was still 
linked to the resin. Dde was used as lysine side chain protecting group, because it is 
stable to the conditions used in typical Fmoc solid-phase synthesis, and it can be 
selectively liberated without affecting Boc protecting groups.18 This approach is 
applicable to bifunctional chelating systems containing a pendent acid group. After the 
removal of the Dde protecting group, a series of dipyridyl amine ligands 23-25 with 
linker arms varying in length were coupled to the resin-bound peptides using HBTU and 
DIPEA (Scheme 6). However, stable Tc(I) and Re(I) complexes were not obtained for 
all of the ligands. In case of peptide conjugate 27 degradation is likely caused by 
elimination to give an α,β-unsaturated amide 28, which concomitantly results in 
liberation of a neutral metal complex 29 (Scheme 7). 
H N
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H
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N
H
H
N
N
H
O
O
O
O
O
O
OH
S
NH
N O
N
N
23: n = 1
24: n = 2
25: n = 3
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O
N
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NHFmoc
O
NH O
O
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O
N
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NH2
N
H
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N
N
H
H
O
O
O
O
S
1) bpa-derivatives,
    HBTU, DIPEA
2) TFA, EDT, TIS, H2O
20
21
22
26: n= 3
 
Scheme 6. Synthesis of peptide-technetium conjugate 26 by metallation after solid-
phase ligand preparation. 
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Scheme 7. Proposed mechanism for the degradation of the Re(I)-peptide conjugate 27. 
2.2 Quinoline-2-aldehyde (Q2A) metal conjugate 
To obtain a fluorescent SAAC-type Re-complex with retaining its ability to bind 
99mTc, Valliant et al. reacted Fmoc-L-lysine with Q2A in the presence of Na(OAc)3BH 
to yield the bifunctional ligand 31 (Scheme 8).19  The objective was to develop a 
method for preparing bioconjugates that can deliver the ligand to specific receptors. The 
SAACQ ligand and the SAACQ-Re complex represent such amino acid analogues 
which can be incorporated in peptide sequences by solid-phase peptide synthesis. The 
rhenium complex 32, prepared by complexation with Re(CO3)Br3, was integrated in the 
peptide fMLF (N-formyl-L-methionine-L-leucine-L-phenylalanine), a targeting 
sequence which has been used to guide radiopharmaceuticals to the formyl peptide 
receptor (Figure 1). The work is an example of the use of metal containing amino acids 
in solid phase peptide synthesis. 
FmocHN
O
N
N N
OH
FmocHN
O
N
N NRe
COOC
CO
+
OH
NaBH(OAc)3, Q2A [NEt4]2[Re(CO3Br3]
FmocHN
O
NH2
OH
32
31
30
 
Scheme 8. Synthesis of fluorescent SAAC-type Re-complex 32. 
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+33
M = Re, 99mTc  
Figure 1. Bioconjugate complex fMLF[(SAACQ-M(CO)3)+]G 33.  
2.3 NxSy Metal conjugates 
Many studies have shown that ligand systems containing nitrogen and thiol sulphur 
atoms are effective for the coordination of Tc and Re.20 In 1997 Quinn and co-workers 
appended a rhenium-bound peptide to the N-terminus of receptor binding α-melanocyte 
stimulating hormone fragments as the last step of a conventional solid-phase peptide 
synthesis.21 This diaminedithiol (N2S2) chelator was also assembled at the N-terminus 
of short peptides in a two-step procedure by Gariépy et al.22 The deprotected terminal 
amino group was first reacted with di-Fmoc-diaminopropionic acid 35 (Scheme 9) and 
the two protected amino groups were then simultaneously deprotected and subsequently 
reacted with S-benzoylthiolglycolic acid to generate a protected N2S2 chelator 38. The 
resulting constructs were cleaved from the resin support and labelled with 99mTc-
pertechnetate (Scheme 10). 
H2N
OH
O
NH2
* HCl
34
Fmoc-Cl
10% Na2CO3
FmocHN
OH
O
NHFmoc
35  
Scheme 9. Preparation of di-Fmoc protected amino acid derivative 35. 
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Scheme 10. Synthetic scheme for the preparation of N2S(benzoyl)2-containing peptides 
by ligand synthesis on solid support and subsequent metallation. 
Okarvi used a pre-labeling method23 in which the radionucleide binds to the chelate in 
a separate step prior to the attachment of a peptide.24 Monoamide monoamine 
(MAMA)25 forms neutral, stable and well defined complexes with both Tc(V) and 
Re(V), and it can be easily derivatized, regioselectively and with a wide range of 
different functional groups.26 Resin bound peptide-MAMA conjugates were prepared in 
such a manner that upon the addition of suitable Re(V) and Tc(V) precursor 42 the 
target metal complexes 43 were selectively released from the resin.27  
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Scheme 11. Synthesis of Re(V) and Tc(V) peptide conjugates on solid support; release 
from resin occurs on metallation. 
Although it is conceivable to build peptides using the carboxylic acid funtionalized 
MAMA derivative, automated peptide synthesis is typically performed starting from a 
primary amine using Fmoc-protected amino acids. Valliant et al. therefore prepared a 
primary amine functionalized MAMA chelate by coupling a diamine to the carboxylic 
acid of 4425 (Scheme 12). Compound 45 was used to synthesize a model peptide with 
standard Fmoc/HBTU protection and coupling methods. The peptide-functionalized 
resin 47 was subsequently treated with [TBA][ReOCl4] and heating released the 
complex 48 from the resin. The target peptide is the n-butyl urea derivative of Phe-Leu-
Nle, which is an antagonist for the formyl peptide receptor (FPR).28This ligand is of 
interest because radiolabeled compounds that are capable of binding selectively to the 
FPR on white blood cells can be used to image sites of infection and inflammation.29  
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Scheme 12. Synthesis of Re (V) and Tc(V)-Mama peptide conjugates 48; metallation 
releases the complex from the solid support. 
Valliant and co-workers also prepared a bombesin derived peptide-99mTc chelate 
conjugate 55 using solid-phase synthesis methodology. 30 Bombesin is a 14-amino acid 
peptide hormone. 
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Scheme 13. Solid phase synthesis of a N2SN´ technetium chelate peptide conjugate 55 
derived from bombesin using metal containing amino acid 52 for peptide coupling. 
The reported approach involved linking a prefabricated bifunctional N2SN´ 
technetium chelate complex 51 to a resin bound peptide sequence 53 derived from 
bombesin, which has been shown to bind to the gastrin-releasing peptide (GRP) 
receptor. Bombesin (BBN) is an analogue of human GRP that binds to GRP receptors 
(GRPr) with high affinity and specificity.31 The GRPr is overexpressed on a variety of 
human cancer cells, including prostate, breast, lung, and pancreatic cancers. The 
synthesis of a series of bombesin derivatives was reported by Hofman et al.32 They 
describe the design of BBN agonist analogues in which the radiometal chelate is linked 
either directly to the N-terminal amine group of BBN[7-14]NH2 56 (Figure 2) or via 
hydrocarbon spacer groups 57 – 60 (Figure 3). In a “posttransmetalation” manner, 99mTc 
was introduced to the triamido-thiol (N3S) bifunctional chelating agent and the effects 
of varying the length of hydrocarbon spacer groups were determined (Scheme 14). 
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Figure 2. Radiometal chelate linked directly to the N-terminal amine group of BBN[7-
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Scheme 14. Posttransmetalation of triamido-thiol bifunctional chelate with 99mTc. 
2.4 Hydrazinonicotinyl acid (HYNIC) technetium conjugate 
Blower and co-workers recently described a novel solid-phase synthesis approach in 
which a HYNIC derivative 61 of Fmoc-lysine was used as a metal-binding amino acid 
analogue.33 The N-protected HYNIC derivative was successfully incorporated in a 
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bioactive peptide using standard Fmoc solid-phase peptide chemistry. Fmoc-N-ε-
(Hynic-Boc)-Lys is a highly versatile technetium-binding amino acid and it was used to 
synthesize a technetium-99m-labeled salmon calcitonin with the HYNIC-linked amino 
acid in place of lysine-18. α-Fmoc-protected lysine 60 was treated with the NHS (N-
hydroxysuccinimide) ester of Boc-protected HYNIC 61 to give the α-Fmoc-protected 
amino acid 62. A trifluoroacetate group protected the HYNIC during alkaline oxidation 
to the cyclic disulfide and was readily removed by mild acid treatment. After 
deprotection and cleavage of the 32-amino acid sequence from the resin the peptide 63 
was oxidized with air in 0.1 M NaHCO3 under high dilution to form the respective 
disulfide-cyclized peptide 64. After removal of the TFA-protecting group the peptide 
conjugate was labeled with Tc-99m. 
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Scheme 15. Synthesis of Fmoc lysine-HYNIC derivative 62 and its use in peptide  
synthesis and subsequent Tc-99m labeling. 
2.5 3,3-Bis(2-imidazolyl) propionic acid (bip-OH) rhenium conjugate 
Metzler-Nolte et al. have reported the preparation of an organometallic metal-PNA 
conjugate.34 Solid-phase synthesis was used to couple Re(bip)(CO)3 fragments to PNA 
decamers on Tentagel resin with PAL linker and their interaction with complementary 
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DNA was studied. Such metal-PNA conjugates are of interest for the detection of 
complementary DNA or RNA due to the excellent hybridization properties of PNA.  
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Scheme 16. Synthesis of rhenium-PNA conjugate applying a rhenium carboxylic acid to 
solid-phase peptide synthesis. 
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3. Iron, Ruthenium and Osmium (Group 8) Metal Complex – Peptide Conjugates 
3.1 4´-Aminomethyl-2,2´-bipyridyl-4-carboxylic acid (Abc) ruthenium conjugate 
Tris-diimine metal complexes of 4´-aminomethyl-2,2´-bipyridyl-4-carboxylic acid 
(Abc) are of interest, since they possess a number of favourable properties including 
high stability, inertness to ligand exchange reactions, tuneable electronic structures, 
long lifetimes in fluid solution, and high quantum yields. Site-specific labeled 
ruthenium oligonucleotides were prepared by DNA solid-phase synthesis using a 
ruthenium-nucleoside phosphoramidite,35 but this example lies not in the scope of this 
review. Another approach used bipyridyl amino acids and in particular Boc and Fmoc-
protected Abc, which were incorporated into a hexapeptide.36 
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Scheme 17. Synthesis and metal complexation of Abc 74 and Boc/Fmoc protected 
derivatives. 
Solid-phase synthesis of these metallopeptides was performed on MBHA resin using 
BOP and ByBOP as coupling reagents to provide high-affinity binding sites for 
ruthenium(II). Metal complexation occurred in solution followed by cleavage of the 
peptide from the solid support. The Abc residue bears the bipyridyl group not in a side 
chain but in the main peptide chain and is used as a tetradentate ligand to octahedrally 
coordinate and asymmetrically encapsulate a ruthenium(II) ion, creating a novel 
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peptide-caged redox-active metal complex. To prepare the Abc 74, a dual oxidation 
strategy was employed (Scheme 17). First, 4,4´-dimethyl-2,2´-bipyridine 70 was 
selectively oxidized to the 4´-monocarboxylic acid derivative 71. Second, the 4´-methyl 
group of 71 was oxidized with excess selenium dioxide to the aldehyde acid 4´-formyl-
2´2-bipyridine-4-carboxylic acid 72. Oxime formation with hydroxyl-amine in 
ethanol/pyridine smoothly converted 72 into compound 73. Lastly, oxime acid 73 was 
transformed into the desired amino acid Abc 74 by catalytic hydrogenation. Amino acid 
74 was converted into both Boc and Fmoc-derivatives for use in solid-phase peptide 
synthesis. Treatment of the Abc•HCl salt with di-(tert-butyl)dicarbonate provided Boc-
Abc-OH 75 and similarly the reaction of Abc•HCl with Fmoc-succinimide furnished 
Fmoc-Abc-OH 76. The metal complexation properties of bipyridyl solid-phase peptide 
synthesis of building blocks 75 and 76 were confirmed by the synthesis of their 
respective ruthenium(II) octahedral mixed-ligand complexes. Reaction of 75 and 76 
with dichlorobis(2,2´-bipyridine)ruthenium(II) (Rub2Cl2) gave the bis-heteroleptic 
complexes 77 and 78. To demonstrate the utility of Abc 74 in solid-phase peptide 
synthesis, a heptapeptide containing two Abc residues was synthesized to serve as a 
tetradentate caging peptide ligand for ruthenium(II) ions (Scheme 18). Two 
aminohexanoic acid residues (Ahx) were arranged as a bridging tether just long enough 
to form cis-bridged meridonal metal complexes. The C-terminal Gly residue was 
included to facilitate attachment of the bipyridine 77 or 78 to the sterically hindered 
MBHA resin, since direct coupling of Abc-OH to MBHA resin proved sluggish.  
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Scheme 18. Preparation of heteroleptic tris(bipyridyl) complex RuII(Aha)(bpy). 
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The acetylated hexapeptide amide Aha 79 was prepared by Boc/TFA strategy from 
Boc-Abc-OH 75 and other Boc amino acids using conventional reagents and procedures 
for manual solid-phase peptide synthesis. Coupling times and yields of 77 to the Gly-
MBHA resin were remarkably improved by addition of stoichiometric amounts of the 
acylation catalyst DMAP. Following the assembly, apopetide 79 was cleaved from the 
resin with anhydrous HF and subsequent conversion of RuII(Aha)Cl2 to the heteroleptic 
tris(bipyridyl) complex RuII(Aha)(bpy) 80 was performed in solution. 
3.2 Metallocene (ferrocene)37 conjugate 
Ferrocene-containing tripeptides with one or two ferrocene building blocks were 
prepared by solid-phase peptide synthesis.38 Heinze et al. incorporated the solid-phase 
peptide synthesis-compatible ferrocene building block Fmoc-protected 1´-
aminoferrocene-1-carboxylic acid (Fca)39 into the backbone of tripeptides. The coupling 
was performed using DIC/HOBt for activation and TentaGel-Wang, which turned out to 
be superior to polystyrene/divinyl resin, as solid support. Cleavage of the resulting 
tripeptides from the support with trifluoroacetic acid gave the mono- (Scheme 19) or 
diferrocene peptides. Reversible on-bead oxidation allows switching between the 
neutral ferrocene (low-affinity state) and charged ferrocenium ion (high affinity state), 
which results in superior anion-binding affinities. 
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Metallocene-modified tri- to penta-peptides were identified to have antibacterial 
activities,40 although the highest activity is still one order of magnitude lower than the 
minimum inhibitory concentration (MIC) values found for most naturally occurring 
antimicrobial peptides (AMPs). First Metzler-Nolte and co-workers synthesized 
metallocene-peptide bioconjugates where the amino acid sequence ranged from three to 
five residues by solid-phase peptide synthesis. The ferrocene and the cobaltocenium 
groups were introduced at the N-terminus by reacting ferrocene carboxylic acid 
hexafluorophosphate with the free amino group of the peptide 87, while the peptide was 
attached to the solid support. Attention has to be taken during the cleavage from the 
Rink amide resin. Decomposition, that is loss of a ferrocenoyl moiety, occurs when 
TFA/H2O/TIS cleavage mixture is used. However, this problem can be circumvented by 
the use of phenol rather than water. 
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1) Fmoc -Deprotection
H Rink
2) Coupling to amino acid
Phe RinkFmoc
3) Repeat steps 1 and 2
three times
Phe RinkTrpFmoc Arg Arg
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Phe RinkTrp Arg Arg
O
Fe
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O
Fe
6) Cleavage and
side-chain deprotection
86 87 88
89
90 91  
Scheme 20. Solid-phase peptide synthesis of metallocene-peptide bioconjugates. 
Later, Metzler-Nolte and co-workers hoped to arrive at small, readily available 
artificial AMPs with activity comparable to the best naturally occurring AMPs by 
adding metallocenes to more active peptide sequences.41 Arg- and Trp-containig 
hexapeptide sequences which were shown to have good antibacterial properties42 were 
selected and modified by replacing the N-terminal amino acid with a ferrocenyl (and a 
cobaltocenium) group. The metallocene peptide conjugates were prepared on Rink 
amide resin whereas the ferrocene carboxylic acid was attached by forming an amide 
bond with the free N-terminal amino group of the solid support. The ferrocene moiety is 
stable towards deprotection reagents and to resin cleavage, however, the ferrocenoyl 
peptides are only stable when phenol rather than water is used in the cleavage mixture. 
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Indeed, the activity of the resulting metallocene-pentapeptide conjugate [Fe(Cp)(C5H4)-
C(O)-WRWRW-NH2] 93 increased and was even better than 20 amino acid naturally 
occurring pilosulin, which was used as a positive control. 
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Figure 4. Metallocene-pentapeptide conjugate 92 and 93. 
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4. Cobalt and Rhodium (Group 9) Metal Complex – Peptide Conjugates 
4.1 Metallocene (cobaltocenium) conjugate 
Although much work has been devoted to ferrocene bioconjugates,35,43 the closely 
related cobaltocenium group has received considerably less attention although the 
cobaltcenium cation has a much higher redox potential and better chemical stability 
than ferrocene. Its unique electrochemical properties have, however, been exploited in 
enzyme biosensors and DNA detection,44 and in a more recent study on the cellular 
uptake and directed nuclear delivery of a cobaltocenium-NLS peptide bioconjugate.45 
The lipophilic nature of the ferrocenyl moiety acts as a mimic for the bulky Trp residue, 
whereas the positively charged cobaltocenium moiety is isostructural to the neutral 
ferrocene thus allowing an assessment of additional positive charge, and thus acts as a 
bulky Arg-mimetic.46 Capping the N-terminus of Arg- and Trp-containing hexapeptide 
sequences results in a net loss of one unit of positive charge in the case of the 
ferrocenoyl bioconjugates, but the cobaltocenium analogues retain the overall charge of 
the peptide, which is favorable for their antibacterial activity.  
Metzler-Nolte and co-workers reported the first nonradioactive organometallic–
peptide conjugate47 which specifically delivers the organometallic species into the 
nucleus of a cell. Solid-phase peptide synthesis was used to prepare the cobaltocenium 
conjugate of a nuclear localization signal peptide. The cobaltocenium–NLS conjugate 
significantly accumulates in the nucleus of HepG2 cells. The heptapeptide H-Pro-Lys-
Lys-Lys-Arg-Lys-Val-OH48 was chosen as the antigen NLS which serves as an “address 
label” for proteins, and indicates their destination as being the cell nucleus. In addition, 
this heptapeptide enables the active transport of a variety of substrates through the 
nuclear pore complex.49 An additional protected lysine residue was introduced at the N-
terminus of the NLS peptide using Wang resin as solid support. Fluorescein 
isothiocyanate (FITC) was used as a label to visualize the metal conjugate inside the 
cells. For this purpose, the N-terminal lysine residue was modified with a Mtt protecting 
group. After coupling of the cobaltocenium moiety to the peptide, the N-terminal Fmoc-
protecting group was cleaved and cobaltocenium carboxylic acid was coupled by use of 
TBTU. Cleavage from the resin and deprotection of all amino acid side chains were 
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accomplished by concentrated trifluoroacetic acid yielding the cobaltocenium-NLS 
peptide bioconjugate 94 (Figure 5). 
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Figure 5. Cobaltocenium-NLS peptide bioconjugate 94. 
4.2 Phenanthrenequinone diimine (phi) rhodium conjugate 
Barton and co-workers have focused on the development of peptide conjugates of 
rhodium(III) complexes as models for sequence-selective DNA binding proteins.50 For 
this issue, a family of rhodium-peptide complexes (Figure 6) was synthesized by 
coupling short oligopeptides to the intercalating ([Rh(phi)2(phen´)]3+ (phi = 
phenanthrenequinone diimine; phen = phenanthroline) to explore whether the side-chain 
functionalities of small peptides may be used to augment metal complex recognition.51 
To summarize this work, DNA site-specificity depends on the peptide side-chain 
functional groups. Moreover, the phi complexes of rhodium cleave DNA upon 
photoactivation. 
Barton and co-workers used two complementary solid-phase peptide synthesis 
strategies for the covalent attachment of phi complexes of rhodium(III) complexes to a 
specific site on synthetic peptides.52 All natural amino acids except methionine were 
used in the synthesis, and peptides ranging from 5 to 30 amino acids were successfully 
coupled to the rhodium complex by standard solid-phase synthesis. The metal-peptide 
conjugates were either synthesized using the coordination method or by direct coupling. 
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In the coordination strategy the chelating ligand is first coupled onto the amino terminus 
of the peptide on the resin. Then, the resin-bound peptide containing the chelating 
ligand is reacted with [Rh(phi)2(DMF)2](OTf)3, in a manner similar to the synthesis of 
the parent rhodium complex. In the direct coupling strategy, the coordinatively saturated 
metal complex is assembled first. Then the functionalized metal complex and the 
terminal amine of the peptide bound to the resin are condensed in a way that is 
analogous to the addition of another residue to the growing peptide chain. Several 
conditions for the synthesis were examined where peptides are constructed using both 
Fmoc and t-Boc methodologies and manual as well as automated solid-phase 
techniques. Furthermore, a range of coupling agents was examined using both 
strategies. To summarize, in the case of the coordination method, several different 
coupling reagents were used with similar success. These reagents include DCC/HOBt, 
DSC, TBTU, and TSTU. With the direct coupling method, Barton et al. observed that 
the presence of the metal centre makes the coupling reaction less efficient. The metal-
peptide complexes are more difficult to be cleaved off the resin than the peptide alone. 
Several linkages to the resins such as MBHA, PAM, and PEG-PAM were also 
examined, but variation in the linker does not affect the yield of the cleaved product. 
The presence of the metal complex, does, however, significantly decrease the overall 
yield; furthermore it tends to inhibit the coupling reaction since coordination on the 
resin is of lower efficiency than the coordination of the metal complex alone in solution. 
In conclusion, both strategies offer distinct advantages over solution phase methods, in 
that functionalization of side chains is precluded. Thus, selective attachment of the 
metal centre to a specific residue or to the N-terminus can be reliably accomplished. 
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Figure 6. Phenanthrenequinone diimine rhodium peptide conjugate. 
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4.3 Diphenylphosphineoserine (Pps) rhodium conjugate 
Gilbertson et al. reported over the last decade important examples of resin bound 
peptide based phosphine transition metal complexes.53 Rhodium was used to prepare the 
first peptide-phosphine-metal complexes. For the incorporation of a phosphine-
containing amino acid building block it was necessary to prevent the undesirable 
formation of phosphine oxide. To overcome this problem, a temporary conversion of 
the phosphine to the phosphine sulphide54 gave rise to an amino acid that could be used 
in standard coupling procedures. The best route to the required amino acid involved the 
use of Evans´chiral oxazolidinone chemistry (Scheme 21). Addition of 
diphenylphosphine to acrylic acid proceeded smoothly using tetramethylammonium 
hydroxide as a base. Treatment with sodium thiosulfate converted the phosphine to the 
phosphine sulphide 97. Acid 97 is then converted to the amino acid by formation of the 
oxazolidinone 98. Cleavage of the chiral auxiliary and reduction of the azide 98 with 
tin(II) chloride gives amino acid 99 which is finally converted to the Fmoc protected 
amino acid 100 ready for peptide synthesis.  
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Scheme 21. Synthesis of a phosphine-containing Fmoc protected amino acid building 
block for use in solid-phase peptide synthesis. 
Once the desired peptide was assembled, the phosphine was regenerated by 
desulfurization with Raney nickel.55 The phosphine-containing amino acids were 
incorporated in i, i + 4 position to stabilize helix formation and thus be able to chelate 
one metal ion between them (Scheme 22). The peptide conjugate was synthesized by 
standard Fmoc solid-phase peptide synthesis on Wang resin and the 
diphenylphosphineoserine (Pps) was incorporated as a dipeptide with alanine (Fmoc-
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Pps(sulphide)-Ala-OPfp).56 The resulting bis-phosphine ligand 101 was complexed with 
rhodium by stirring with RhCl(NBD)+ClO4- (NBD = norbonadiene). 
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Scheme 22. Complexation of the bis-phosphine ligand 101 with a rhodium-salt. 
4.4 Mixed bidentate Pps,Cps-based rhodium conjugate 
The diphenylphosphineoserine (Pps) group was later incorporated into a 12-residue 
peptide 103 along with a dicyclohexylphosphineoserine (Cps) (Scheme 23).57 The 
synthesis of the peptide conjugate, as well as the rhodium complexation, was done as 
described before, but on polystyrene resin. 
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Scheme 23. Mixed bidentate Pps,Cps-based rhodium conjugates. 
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5. Nickel, Palladium, Platinum (Group 10) Metal Complex – Peptide Conjugates 
5.1 Ethylenediamine platinum conjugate 
In 2000 Reedijk et al. reported the first synthesis of a trimeric arginine-containing 
peptide-dichloroplatinum(II) complex with potential antitumor activity by solid-phase 
synthesis.58 An ethylene diamine moiety, which serves as a platinum-chelating ligand 
was tethered to a resin-bound arginine-glycine dipeptide. The solid-phase peptide 
synthesis was performed on Rink amide resin with commercially available protected 
amino acids Fmoc-Arg(Pbf)-OH and Fmoc-Gly-OH following a standard Fmoc 
protocol.59 Fmoc-protected N-2-aminoethyl-glycine derivative 107 was then condensed 
to the dipeptide 106 followed by platination of the ethylenediamine moiety, subsequent 
deprotection and release from the solid support (Scheme 24). Preliminary resin-cleavage 
experiments with TFA/H2O/(TIS) led to metallic platinum and free ligand probably due 
to the reduction of the coordinated PtCl2 moiety by the scavenger TIS. However, nearly 
quantitative complexation was achieved by treatment with excess K2PtCl4 in DMF/H2O 
followed by a resin cleavage with TFA/H2O.  
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Scheme 24. Solid-phase synthesis of platinum complex 109. 
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Later, Reedijk and co-workers examined the scope and generality of the solid-phase 
platination approach preparing a six by six array of individual dichloroplatinum peptide 
analogues.60 The parallel solid-phase peptide synthesis of dichloroplatinum-peptide 
array was performed on Rink amide resin with six natural amino acids on an automated 
synthesizer. Unfortunately, these platinum peptide complexes showed no use as 
cytotoxic agents, but only demonstrated the utility of solid-phase peptide synthesis for 
the preparation of platinum drugs. However, in a subsequent publication,61 Reedijik et 
al. reported on cytotoxic platinum tripeptide complexes, although the highest activity, 
which was measured for the tripeptide conjugate containing the Gly-Gly dipeptide, was 
still lower than cisplatin. 
5.2 Dinuclear Nα,ε-L-lysine platinum conjugate 
As an extension of these studies, Reedijk et al. described the first solid-phase peptide 
synthesis of dinuclear lysine bridged platinum(II) complexes.62 Platination of the lysine 
was achieved with 5 fold excess of activated trans-platin to give the immobilized 
compound 111 (Scheme 25). To avoid strong acidic cleavage conditions considering the 
moderate stability of the immobilized platinum complex 111, Rink amide MBHA was 
used in combination with the 2-chlorotrityl linker, which allow mild cleavage 
conditions.  
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Scheme 25. Solid-phase synthesis of platinum complex 112 by metallation on solid 
support. 
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Both linkers were suitable for the solid-phase peptide synthesis of dinuclear trans-
platinum complexes. Biological testing of the platinum complexes showed their 
potential as anticancer agents. However, compared to cisplatin, compound 112 revealed 
a 60 fold decrease in activity. 
Metal complexes of suitable geometry and coordination properties are promising 
cross-linking agents.63 One application of metal complex cross-linking is to increase the 
affinity of an antisense oligonucleotide to its target.64 Lippert et al. used this strategy in 
a model cross-linking reaction of the monofunctional trans-Pt-modified PNA oligomer 
trans-[(NH3)2Pt(g-N7-attcgc)Cl]+ 113 with its complementary deoxyoligonucleotide 
5´d(GCGAATG) 114 (Scheme 26).65 The trans-Pt(II)-modified building block 116 was 
synthesized by the reaction of trans-[Pt(NH3)2Cl(DMF)]BF4 with Fmoc/Bhoc-PNA G.  
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Scheme 26. Cross-linking reaction of PNA 113 with DNA 114. 
Building block 116 was then coupled to the Rink amide-bound fully protected PNA 
oligomers using the coupling reagent HATU. Removal of the Bhoc protecting groups 
along with the release from the solid support was effected with TFA/m-cresol (Scheme 
27). In summary, this methodology allows the preparation of monofunctional trans-
Pt(II)-modified mixed pu/pym PNA oligomers, which have shown to cross-link 
sequence-specifically with a target oligonucleotide.  
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Scheme 27. Solid-phase synthesis of a monofunctional trans-PtII-modified PNA 
oligomere. 
5.3 Tetradentate monoanionic “pincer” NCN [C6H2(CH2NMe2)2-2,6-R-4)-] 
platinum conjugate 
Van Koten et al reported a robust organoplatinum(II) biomarker which can be 
incorporated in peptides using standard solid-phase coupling techniques.66 The 
biomarker-containing peptides can be identified by the addition of an aqueous KI3 
solution causing visually detectable coloured resin beads. For the almost instantaneous 
change of colour from colourless to deep purple, capping of only 6 % of the available 
amine termini of the resin bound peptide is sufficient. Furthermore, this colouration 
process is reversible by washing with DMF/Et3N or DMF/morpholine solutions. 
PEGA1900 resin (a copolymer of bis(2-aminopropyl)poly-(ethylene glycol)/acrylamide) 
was chosen as the solid support since it combines good characteristics for organic 
synthesis and screening in aqueous buffer solution, which is required for a biomarker-
function in solid-phase screening assays. First a lysine residue was coupled to the resin 
to double its loading capacity. The peptide sequence Gly-Pro-Pro-Phe-Pro-Phe was 
synthesized on a photolabile linker67, using syringe technology68 and Fmoc/OPfp-
derivatized amino acids, which were activated with Dhbt-OH. Finally, the N-protected 
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platinum(II) biomarker 122 was attached to the N-terminus of the resin-bound peptide 
121 using TBTU and NEM activation. 
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Scheme 28. Solid-phase synthesis of a platinum-biomarker-containing peptide using 
metal containing amino acid 122. 
5.4 Iminodiacetic acid (IDA) nickel conjugate 
Metallopeptides of the general form Ni(II)AA1-AA2-His69 are used in biochemical 
analysis of protein-nucleic acid and protein-protein interactions.70 Long and co-workers 
prepared two libraries derived from AA1-AA2-His sequence in which the first and the 
second positions of the peptide ligand were varied.71 Standard t-Boc protocols on 
methylbenzydryl amine (MBHA) resin were used including all possible combinations of 
18 natural α-amino acids excluding Cys and Trp to prevent disulfide formation and 
partial DNA intercalation72 of these residues. The optimized metallopeptide Ni(II)-Pro-
Lys-His was found to cleave DNA one order of magnitude better than Ni(II)-Gly-Gly-
His. 
Tampé and co-workers synthesized a metal-chelating amino acid building block for 
synthetic receptors.73 Such synthetic receptors bearing an IDA-chelate were employed 
as metal ion sensors and as receptors for histidine-tagged proteins. Standard solid-phase 
peptide synthesis was used to incorporate the SAAC 125 into a polypeptide (Scheme 
29). The peptide conjugate was further labeled with fluorescein at a cysteine residue74 to 
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signal metal-ion binding. After release of the IDA-peptide 127 from the resin, it was 
treated with Ni2+ and several experiments were performed which demonstrated a strong 
binding to imidazole.  
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Scheme 29. Solid-phase peptide synthesis of fluorescein-labeled IDA peptide 127 and 
subsequent metallation in solution to nickel complex 128. 
5.5 Bidentate phosphine palladium conjugates 
Palladium(II) allyl complexes were prepared by Meldal and co-workers from resin 
bound ligands to demonstrate their catalytic properties.75 The palladium complexes 133-
135 and 138 were synthesized on solid support using Fmoc protected amino acids and 
Fmoc protected amino aldehydes. Phosphine moieties were introduced by 
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phosphinomethylation of the free amines as the final solid-phase synthetic step, prior to 
complexation with palladium. PEGA1900 resin76 was selected due to its excellent 
swelling properties in organic solvents, as well as in water. After the PEGA1900 resin 
was functionalized with Fmoc-glycine by TBTU activation and subsequent Fmoc-
deprotection with piperidine, the HMBA linker was introduced by TBTU. The HMBA 
linker can be efficiently cleaved under mild conditions and is also suitable for on-bead 
NMR analysis, since it possesses no stereocenter making the analysis more difficult.  
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Scheme 30. Formation of palladium(II) allyl complexes on solid support. 
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The first amino acid Fmoc-phenylalanine was attached to the HMBA linker by MSNT 
activation in dichloromethane (Scheme 30). For all the other couplings TBTU was 
sufficient. The resulting peptide-based bidentate phosphine palladium conjugates 132 
and 137 were shown to be suitable for palladium catalyses of asymmetric allylic 
substitution reactions. 
5.6 Bidentate P,S-based palladium conjugates 
Recently, bidentate mixed heteroatom ligands have proven to be very successful for 
asymmetric organic synthesis.77 One class of such ligands are P,S-ligands,78 which have 
been successfully applied in palladium-catalyzed allylic substitution reaction.79 Meldal 
et al.80 expanded their above mentioned methodology for the solid-phase synthesis of 
peptide-based bidentate phosphine ligands to the solid-phase peptide synthesis of P,S-
bidentate chelating palladium(II) complexes exploiting the readily available chiral pool 
of cysteine derivatives. 
HMBAHO
1) Fmoc-Phe-OH, MSNT, Melm
2) Piperidine
3) Fmoc-Ala-OH, TBTU, NEM
4) Piperidine
5) Fmoc-Cys(tBu)-OH, TBTU, NEM
6) Piperidine
7) Fmoc-Phe-H, NaCNBH3, AcOH
8) Piperidine
9) C6H5COOH, TBTU, NEM
[PdCl(η3-C3H5)]2
MeCN
HMBAO
N
H
H
N
N
H
H
N
O
O
OO
PhS
Ph
HMBAO
N
H
H
N
N
O
O
O
PhS
Ph2P
Ph
Ph
O
Pd+
139
140
142
 
 37
Scheme 31. Palladium catalyst derived from a solid-phase synthesized peptide scaffold 
and metallation on solid support. 
6. Copper (Group 11) Metal Complex – Peptide Conjugates 
6.1 IDA copper conjugate 
Peptides with metal complexes in their side chains and peptide-metal complex 
conjugates have been used to enhance or control binding affinities and peptide 
conformations.81 To extend the scope of solid-phase synthesis of peptide – metal 
complex conjugates König et al.82 reported their preparation from modified amino acids 
bearing metal complex ligands or metal complexes in their side chains.  
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Scheme 32. Incorporation of CuII-IDA SAAC into a peptide sequence. 
The IDA motif, known for its ability to bind imidazole residues and N-terminal His was 
chosen and converted into its copper complex as a SAAC. This modified amino acid 
143 was incorporated into a peptide sequence using standard solid-phase peptide 
synthesis. The use of HMBA-AM resin allowed nucleophilic cleavage of the copper 
peptide conjugate from the resin without decomplexation. 
6.2 Bis(2-picolyl)amine (bpa) metal conjugate 
As discussed above, radioactive metals were successfully and extensively applied to 
radioimaging e.g. with 99mTc complexes. Thus control of cellular uptake and metal ion 
localization is a challenge for medicinal inorganic chemistry. However this concept is 
not widely applied to non-radioactive metals. Copper on the other hand plays an 
important role in cell regulating processes, but in certain cells there is not one single 
free copper ion.83 Any Cu2+ ion is sequestered by so-called Cu chaperones, proteins 
which also serve to deliver the metal to specific Cu enzymes.84 For such systems, 
Metzler-Nolte et al. proposed to use bioconjugates of metal-chelating ligands, linked to 
physiologically active peptides.85 The preparation of metal-bpa complexes linked to 
amino acids and a cellular localization signal peptide, namely, a nuclear localization 
signal86 (nls) was reported. The nls peptide Metzler-Nolte et al. used in their work is a 
heptapeptide with primary sequence H-Pro-Lys-Lys-Lys-Arg-Lys-Phe-OH and serves 
as a tag to proteins, indicating their destination in the nucleus of cells.87 The nls-bpa 
bioconjugate 148 (Figure 7) was prepared by Fmoc solid-phase peptide synthesis on 
Rink amide resin with an acid labile linker and acid labile side chain protecting groups 
for amino acids Lys (Boc) and Arg (Pbf) were used. The peptide synthesis cycle was 
composed of Fmoc deprotection by piperidine and TBTU coupling. Metal complexation 
was carried out in aqueous solution with Cu(NO3)2. The formation of the complex 148-
Cu was immediately apparent by the deep blue colour of the solution due to a blue shift 
of the Cu d-d transition in the Cu(bpa) complex. The metal-peptide conjugates were 
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suggested as artificial metallochaperones, because they have the potential to deliver 
metal ions to specific compartments in the cell as determined by the peptide moieties. 
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Figure 7. Structure of metal bioconjugates 148-M. M = Cu(II) or Zn(II). 
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7. Zinc (Group 12) Metal Complex – Peptide Conjugate 
7.1 Bpa zinc conjugate 
Metzler et al. showed that also Zn2+ binds to their nls peptide conjugate 148. The 
Cu(II) and Zn(II) complexes were characterized including X-ray structure analyses and 
the results indicated similar structural features of the transition metal complexes. 
Kraemer and co-workers prepared conjugates of peptide acids (PNA) and metal 
binding ligands using solid-phase synthesis.88 The ligands were attached to PNA via 
linkers of different length for optimization of metal complex–DNA interaction. 
Synthesis of conjugates was accomplished using sequential coupling/deprotection steps 
of the required number of Fmoc-Gly-OH building blocks to the terminal amino-group 
of Rink-resin bound PNA. Amination with bis-(2-picolyl)-amine, PNA deprotection and 
cleavage gave conjugates of 2-picolylamine. Equimolar concentrations of bioavailable 
metal ions, Ni2+, Zn2+ and Cu2+ were used in the complexation step and the affinity of 
the metal-bpa conjugates to DNA (Figure 8) was shown to be strongly dependent upon 
the sort of the metal, in the order Ni2+, Zn2+ > Cu2+. 
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Figure 8. A proposed approach for metal-dependent binding of PNA probes to 
oligonucleotide targets. 
König et al. reported solid-phase peptide synthesis protocols where position and 
number of SAAC and metal complexes thereof may vary.89 Peptide–metal complex 
conjugates were either obtained by incorporation of the metal coordinated SAAC 
followed by mild nucleophilic resin-cleavage or by complexation in metal salt solution 
after cleavage from the resin.  
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Figure 9. Bpa SAAC 150. 
A bpa containing peptide (Scheme 33) and a dinuclear peptide receptor (Scheme 34) 
based on the bpa-chelate were synthesized on Rink amide resin using solid-phase 
peptide synthesis. Fmoc protected aliphatic amino acids and SAAC 150 (Figure 9) were 
coupled with HBTU, HOBt and DIPEA in NMP/DMF using conventional frit-equipped 
syringe technique. After cleavage from the resin, the peptide conjugates were treated 
with Zn(NO3)2 in an aqueous solution.  
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Scheme 33. Solid-phase peptide synthesis of peptide conjugate 154 and subsequent 
metallation to peptide metal complex 155 in solution. 
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Scheme 34. Solid-phase peptide synthesis of bis-bps ligand 157 and subsequent 
metallation to dinuclear peptide metal complex 158 in solution. 
To expand the versatile solid-phase approach, an already metal coordinated bpa-
derived Fmoc-amino acid 159 (Figure 10) was incorporated into the peptide chain.  
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Figure 10. ZnII-bpa SAAC 159. 
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To avoid the loss of metal ions under acidic conditions, which are necessary to cleave 
from Rink amide resin, HMBA-AM was used as resin, as it allows nucleophilic 
cleavage of the peptide (Scheme 35). 
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Scheme 35. Direct solid-phase peptide synthesis of metal-peptide conjugate 163 on 
HMBA-AM resin using metal containing amino acid 159. 
7.2 Bis-bpa zinc conjugate 
Bis(ZnII-chloride)-SAAC 164 was also successfully used in solid-phase peptide 
synthesis. Cleavage with a solution of DIPEA/MeOH/DMF gave the metallated peptide 
bis-bpa-zinc complex 167.  
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Scheme 36. Incorporation of bis(ZnII-chloride)-SAAC 164 in a peptide sequence. 
7.3 Bis-(1,4,7,10-tetraazacyclododecane) (bis-cyclene) zinc conjugate 
The solid-phase synthesis of metal-complex containing peptides bearing a cyclene 
moiety has been performed.90 An amino acid complex 173 was prepared from the 
previously reported triazene-bis-cyclen91 168 by reaction with α-amino Z-protected L-
Lys-OBn (Scheme 37). Nucleophilic aromatic substitution gave compound 169 and the 
benzyl protecting groups were simultaneously removed by hydrogenation using 10% 
palladium on charcoal as catalyst. The complexation of the Fmoc protected cyclen 
ligand with Zn(II) required careful control of the reaction conditions.  
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Scheme 37. Preparation of Fmoc-protected amino acid 171 and the bis(ZnII-cyclen) 
SAAC 173. 
After Boc-deprotection with HCl saturated ether the complexation of the 
hydrochloride salt was achieved with Zn-salt in a buffered solution (Hepes buffer, pH 
8). Preliminary attempts to couple amino acid 171 to aliphatic amino acids using 
HBTU, TBTU and DIPEA as coupling reagents failed. The more efficient reagent 
HOAt92 was used instead of HOBt together with the onium salt HATU. DIPEA was 
exchanged by collidine,93 a more suitable base for the HOAt reagent. By using 
HOAt/HATU/collidine, the coupling of 171 using two coupling cycles gave dipeptide 
177 (Scheme 38).  
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Scheme 38. Solid-phase synthesis of dipeptide conjugate 177. 
A more extended peptide 180 was obtained on an Fmoc–Ala loaded SASRIN resin 
178 using the same coupling conditions (Scheme 39). In the following steps, the Boc 
groups were cleaved with HCl saturated ether and the neutralized compound 181 was 
subsequently treated with Zn(ClO4)2 salt to obtain the peptide complex 182. 
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Scheme 39. Solid-phase synthesis of peptide 180 and peptide complex 182. 
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8. Samarium, Europium, Terbium and Gadolinium (Lanthanides) Metal Complex 
– Peptide Conjugates 
8.1 N-Isothiocyanatobenzyl)diethylenetriamine-N,N´,N´´,N´´´-tetrakis acetic acid 
metal conjugate  
The chelates of certain lanthanides, such as Eu3+, Tb3+, Sm3+ and Dy3+, have unique 
fluorescence properties, e.g. large Stoke´s shift, sharp emission peaks and exceptionally 
long decay times.94 These properties are exploited in time-resolved fluorometry95 
(TRF). Oligopeptide conjugates were synthesized and used in a TRF-quenching assay 
(based on caspase-3, an enzyme that plays a key role in programmed cell death, or 
apoptosis.) and in a receptor binding assay (based on motilin, a polypeptide hormone 
secreted by Mo cells of the small intestine that increases the migrating myoelectric 
complex component of gastrointestinal motility and stimulates the production of 
pepsin).96 Hovinen et al. described the synthesis of oligopeptide building blocks that 
allow for the introduction of lanthanide(III) chelates to synthetic oligopeptides using 
standard automated solid-phase peptide synthesis. The applicability of building block 
18397 for oligopeptide derivatization was demonstrated with peptide sequences of 
motilin, substance-P, neurokinin-A and caspase-3 synthesized using Fmoc solid-phase 
peptide synthesis (Scheme 40). After the building block 183 was coupled to the amino 
terminus of the coding sequence using prolonged reaction time, but otherwise standard 
HBTU/HOBt conditions, the oligopeptide was released from the resin. Treatment of the 
deblocked oligomer with europium(III) citrate converted the conjugate to the 
corresponding europium peptide chelate 185. 
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Scheme 40. Introduction of a luminescent europium(III) chelate by solid phase 
oligopeptide synthesis with N-terminal 183 and subsequent complex formation in 
solution.  
Karvinen et al. have paved the way to a multiparametric caspase assay by 
characterizing fluorescence properties of a series of lanthanide (Ln3+) chelates (Scheme 
41) incorporated into peptides and testing their functionality in a caspase-3 assay.98 
Caspases are a group of cysteine proteases involved in apoptosis99 and inflammatory 
reactions[100. As the caspases and their substrates are a well-characterized101 and an 
interesting group of enzymes as potential drug targets102, Karvinen et al. have chosen 
them as a model system for the development of a multiparametric homogeneous time-
resolved fluorescence quenching assay (TR-FQA). The principle of the enzymatic assay 
is shown in Figure 11.  
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Figure 11. Principle of the TR-FQA caspase assay. The assay is based on recovery of 
the Ln3+ fluorescence after removal of the quencher by protease activity. QSY-7 ε-
amino labeled lysine, inserted into a caspace recognition sequence, was used as 
quencher for all lanthanide chelates. 
The homogeneous multiparametric assay was capable to measure the activity of three 
different caspases from one well using specific substrates labeled with europium, 
samarium, and terbium chelates. Although the quenching efficiencies were significantly 
lower than those observed earlier,103 some of the chelates tested during this work proved 
to be extremely functional in TR-FQ assays and the technique might be adaptable to 
DNA assays. 
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Scheme 41. Simplified structures of the tested lanthanide chelates. 
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Hovinen et al. modified the synthesis of the building block 187, that allows the 
introduction of photoluminescent europium(III) and samarium(III) chelates to synthetic 
oligopeptides on solid-phase using Fmoc chemistry. Oligopeptide synthesis and 
introduction of the Fmoc protected building block 191 to the growing peptide chain was 
performed as reported earlier.104 Upon completion of the oligopeptide synthesis, the 
conjugates were converted to the corresponding lanthanide(III) chelates by treatment 
with the appropriate lanthanide(III) salt (Scheme 42). 
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Scheme 42. Introduction of luminescent lanthanide(III)-chelates to oligopeptides using 
building block 191. 
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8.2 1,4,7,10-Tetraazacyclododecane (cyclene) europium conjugate 
The metal coordinating ligand cyclene was attached to the arginine-rich region of the 
TAT-protein, (a transactivator of the HIV-1 infection, which is responsible for the 
replication and expression of HIV-1) and the lanthanide-complexes of the ligand-
peptide conjugate were investigated in hydrolysis-cleavage experiments.105 TAR-RNA 
of HIV-1 was chosen as the target for the hydrolysis studies, as it is recognized by the 
HIV-1 regulatory TAT.106 The peptide-cyclene conjugate nonamer 196 with the 
attached cyclene moiety was synthesized by standard solid-phase peptide synthesis. In 
the last coupling step, the Boc-protected cyclene acetic acid 195[107 was coupled to the 
N-terminus of the nonapeptide 194. After subsequent cleavage from the resin by 
standard TFA conditions, the peptide 196 was incubated with Eu(III)-salt (Scheme 43). 
Surprisingly, the nonamer-cyclene conjugate without Eu(III) 196 gave selective and 
efficient cleavage at neutral pH and room temperature and the authors report those 
cleavage reactions are more efficient in the absence than in the presence of Eu(III). 
FmocHN-Arg-Arg-Gln-Arg-Arg-Arg
N N
NN
Boc Boc
Boc OH
O
1) SPPS-coupling:
2) Deprotection with TFA
N N
NN
H H
H NH-Arg-Arg-Gln-Arg-Arg-Arg
O Eu3+
N N
NN
H H
H NH-Arg-Arg-Gln-Arg-Arg-Arg
O
Eu(III)salt
194
195
196 197  
Scheme 43. Synthesis of peptide-cyclen conjugates by solid-phase synthesis and 
europium complex formation in solution. 
8.3 1,4,7,10-Tetraazacyclododecane-N,N´,N´´,N´´´-tetraacetic acid (DOTA) 
gadolinium conjugate 
Several types of ligands including DOTA, DTPA, NOTA and TETA,108 have been 
attached to peptides. DOTA is of particular interest, since this macrocyclic ligand forms 
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complexes with a variety of metal ions with exceptionally high binding affinities and 
kinetic stabilities.109 Sherry et al. prepared Gd3+-G80BP (Binding Peptide) using solid-
phase peptide synthesis (Scheme 44) and demonstrated that magnetic resonance 
imaging (MRI) can detect the binding event of a Gd3+-DOTA-labeled peptide (Gd3+-
G80BP) to its target protein Gal-80110 (Gal-80 is a protein involved in regulation of 
galactose metabolism).111 In a later work, Sherry et al. modified the Gal-80 binding 
peptide TFDDLFWKEGHR by introducing a DOTA-chelating group at three different 
residues (Scheme 45).112 Conjugation of DOTA to the N-terminus of the resin bound 
peptide was accomplished using DOTA-tris(tBu) ester and standard Fmoc solid-phase 
peptide synthesis. Attempts to add subsequent amino acids beyond DOTA using even 
either HATU or TFFH as coupling agents were not successful. These coupling agents 
are reported to have superior coupling capabilities over HBTU. A report by Lewis et al. 
showed that Fmoc-DOTA-lysine can be introduced into a peptide sequence using a 
XAL-PEG-PS resin.113 XAL-PEG-PS solid supports are prepared by grafting soluble 
polar PEG chains onto microporous polystyrene-co-divinylbenzene and have been 
shown to be superior to conventional resins for the synthesis of hydrophobic peptides.114  
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Scheme 44. Solid-phase peptide synthesis of Gd3+-G80BP 200. 
However, Sherry et al. used in their work the more reactive activated amino acid Fmoc-
pentafluorophenyl ester to couple successfully the remaining amino acids to the endo-
DOTA peptides. After addition of Gd3+ to each peptide-DOTA conjugate, competitive 
binding experiments showed that the exo-peptide labeled with Gd3+-DOTA at the  
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N-terminal had a reasonable affinity for Gal-80, while those peptides labelled with 
Gd3+-DOTA at endo-positions within the peptide sequence had no detectable binding 
affinity for Gal-80.  
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Scheme 45. Solid-phase peptide synthesis of three pentapeptides with variable DOTA 
position. 
8.4 Diethylenetriamine pentaacetic acid (DTPA) gadolinium conjugate 
Gadolinium complexes of DTPA are widely employed as contrast agents in medicinal 
imaging.115 The effectiveness of GdIIIDTPA-based contrast agents can be improved by 
incorporating target-specific oligopeptides to induce accumulation of MRI probes in the tissue 
of interest.116 A cyclic peptide containing the Cys–Asn–Gly–Arg–Cys (CNGRC) sequence 
(cNGR) was identified as a targeting unit for the aminopeptidase CD13 that is overexpressed on 
endothelial cells during angiogenesis.117 Hackeng and Meijer et al.118 designed a cNGR-
GdIIIDTPA complex 215 composed of the cNGR targeting domain and a GdIIIDTPA complex 
for imaging of angiogenesis (Scheme 46). The gadolinium chelate was introduced at the ε-
amine of the lysine side chain of the peptide 210. For this purpose, an isocyanate-functionalized 
lysine-based DTPA pentaester 211 was coupled to the resin bound peptide 210. Solid-phase 
peptide synthesis and HBTU activation procedure for Boc chemistry on a MBHA resin119 was 
applied to synthesize side chain protected BocCNGRCGGK(Fmoc)-MBHA 209 containing the 
target-specific NGR sequence. The conversion of the amine functionalized DTPA120 into the 
corresponding isocyanate 211 was achieved with di-tert-butyl tricarbonate, which is a versatile 
reagent for the quantitative conversion of primary amines into isocyanates under mild reaction 
conditions.121 The DTPA-functionalized oligopeptide 212 was obtained by reaction of the lysine 
side-chain ε-amine group with an excess of isocyanate-functionalized DTPA analogue 211. 
After quantitative formation of the disulfide bridge by oxidation, the gadolinium complex 215 
was prepared by adding gadolinium chloride to a solution of peptide conjugate 214 in water. 
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Scheme 46. Synthesis of cNGR-GdIIIDTPA complex 215 by solid phase synthesis of the 
ligand and subsequent gadolinium comple formation in solution. 
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9. Conclusions 
The discussed examples of metal complex – peptide conjugates synthesized on solid 
phase show that a wide variety of different structures is already accessible by the 
developed methods. Procedures are in many cases different compared to standard SPPS 
protocols to address the special requirements of ligand and complex stability. Both 
general strategies, the synthesis of peptide – ligand conjugates and complexation with 
excess metal ions on solid support or the incorporation of an amino acid complex in the 
growing immobilized peptide chain have their specific advantages and limitations. 
While complexation of peptide – ligand conjugates is synthetically more facile in many 
cases, it does not allow the specific preparation of bi- or oligonuclear complexes with 
different metal ions. This is in principle possible with artificial metal complex amino 
acids, if they are kinetically and thermodynamically sufficiently stable and introduced 
in the right order. However, all reaction conditions of the subsequent peptide synthesis 
including deprotection and cleavage steps must be compatible with the stability of the 
complexes. With further advancements of the methodology the preparation of peptide 
metal complex conjugates by automated solid phase synthesis will surely become more 
common. However, the special conditions which are necessary for the formation of 
various metal complex types and their individual stability profile will always call for 
specific protocols. 
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10. Abbreviations 
Bhoc  N-Benzhydryloxycarbonyl  
Boc  tert-Butoxy carbonyl 
BOP Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate 
ByPOP  Benzotriazole-1-yl-oxy-tris-pyrralidino-phosponiumhexafluorophosphate 
DCC  N,N‘-Dicyclohhexylcarbodiimide 
Dde  1-(4,4-Dimethyl-2,6 dioxocyclohexyldiene)ethyl 
Dhbt-OH 3,4-Dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazine 
DIC  N,N‘-Diisopropylcarbodiimide 
DIPEA N,N-Diisopropylethylamine 
DMAP 4-(N,N-Dimethylamino)-pyridine 
DMF  Dimethylformamide 
DNA  Deoxyribonucleic acid 
DSC  N,N-Disuccinimidyl carbonate 
EDTA  Ethylenediamine tetraacetic acid 
FITC   Fluorescein isothiocyanate 
HATU 2-(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium 
hexafluorophosphate methanaminium 
HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronoium 
hexafluorphosphate 
HMBA Hydroymethylbenzoic acid 
HMBA-AM 4-Hydroxymethylbenzoic acid AM 
HOAt  1-Hydroxy-7-azabenzotriazole 
HOBt  1-Hydroxybenzotriazole 
MBHA 4-Methylbenzhydrylamine 
MeOH  Methanol 
MSNT  1-(Mesitylene-2-sulfonyl)-3-nitro-1,2,4-triazole 
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Mtt   4-Methyl trityl  
NBD  4-Halo-7-nitrobenzo-2-oxa-1,3-diazole 
NEM  N-Ethylmorpholine 
NHS  N-Hydroxysuccinimide 
NMP  N-Methyl pyrrolidone 
OPfp  (Acetic acid) pentafluorophenyl ester 
PAL linker  5-(Aminomethyl-3,5-dimethoxyphenoxy)-pentanoic acid 
PAM resin para-Hydroxymethylphenylacetamidomethyl polystyrene 
Pbf  2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl 
PEG  Polyethylene glycol 
PNA  Peptide nucleic acid 
Pu  Purine 
Pym  Pyrimidine 
SAAC  Single Amino Acid Chelate 
SASRIN Super Acid Sensitive Resin 
SPPS  Solid-phase peptide synthesis 
TBTU  2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate 
TFA  Trifluoroacetic acid 
TFFH  N,N,N‘,N‘-Tetramethylfluoroformamidinium hexafluorophosphate 
TIS  Triisopropylsilane 
TMS  Trimethylsilane 
TSTU  N,N,N’,N’-Tetramethyl-O-(succinimidyl)uronium tetrafluoroborate 
XAL  Xanthenyloxyalkylamide 
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B. Main Part 
 
 
 
 
1. Solid Phase Synthesis of Metal-Complex containing Peptides* 
 
 
 
Graphical Abstract 
 
In this chapter is reported the synthesis of Fmoc protected single amino acid chelates 
(SAAC) and their metal complexes. The modified amino acids are suitable for solid 
phase peptide synthesis. The use of 4-hydroxymethylbenzoic acid AM (HMBA-AM) 
resin allows the nucleophilic cleavage of the peptide – metal complexes from the resin 
without decomplexation.  
                                                 
* G. Dirscherl, R. Knape, P. Hanson, B. Koenig Tetrahedron 2007, 63, 4918-4928. 
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1.1 Introduction 
 
Peptides with metal complexes in their side chains and peptide-metal complex 
conjugates have been used to enhance or control binding affinities and peptide 
conformations. Banjerjee and Stephenson et al. have reported the solid-phase synthesis 
of peptides bearing 2,2´-dipicolylamine single amino acid chelate (dpa-SAAC) for 
peptide based technetium and rhenium radiopharmaceuticals.1 Metzler-Nolte and co-
workers prepared N-terminally modified bioconjugates by a series of dpa based copper 
or zinc complexes for potential applications as artificial metallochaperones.2 Recent 
reports on dpa-SAAC describe a more flexible preparation of peptide–Re and peptide–
Tc ligand conjugates with non-terminal SAAC.3 However, the reported syntheses of 
peptide – metal complex conjugates on solid phase are either limited to conjugation of 
the metal complex to the N-terminus of the resin-bound peptide or focus on the 
coordination of Tc(CO)3 and Re(CO)3.4 To extend the scope of solid phase synthesis of 
peptide – metal complex conjugates, we report here their preparation from modified 
amino acids bearing metal complex ligands or metal complexes in their side chains. The 
modified amino acids can be incorporated at any position into the peptide during 
synthesis and the use of 4-hydroxymethylbenzoic acid AM (HMBA-AM) resin allows 
nucleophilic cleavage of the peptide from the resin avoiding decomplexation. 
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1.2 Results and discussion 
 
1.2.1 Metal chelates 
 
We have selected the iminodiacetic acid (IDA) motif as metal complex binding sites, 
known for its ability to bind imidazole residues and N-terminal His, and triazen-bis-
zinc-cyclen, dipyridylmethyl amine (dpa) and bis-diypridylmethyl amine (bis-dpa) zinc 
complexes, which show affinity to phosphate groups. First we discuss the synthesis of 
the modified amino acids bearing the respective ligand or complex, and describe then 
their use in solid phase peptide synthesis. 
 
1.2.2 Synthesis of Fmoc-amino acids with ligand or metal complex side chain 
 
The synthesis of Fmoc protected IDA amino acid 1 (Figure 1) has been described by 
reductive amination of tert-butyl 2-oxoacetate,5 or the nucleophilic substitution of the 
lysine side chain as reported by Tampé.6 After optimization of the reaction conditions of 
hydrogenolytic cleavage of the Z-protecting group and Fmoc-protection using the more 
reactive Fmoc-OSu instead of Fmoc-Cl, 1 was obtained in good yield from the latter 
method. The ligand was converted into its copper complex using either two equivalents 
of Cu2(OH)2CO3 or a stoichiometric amount of CuCl2 with one equivalent of base. In 
both cases, mass spectrometric analysis (ESMS) confirmed the complete formation of 
complex 2. 
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Figure 1.  Fmoc-protected IDA-amino acid 1 and its copper(II) complex 2. 
 
Amino acid complex 8 was prepared from the previously reported triazene-bis-cyclen 37 
by reaction with α-amino Z-protected L-Lys-OBn (Scheme 1). The nucleophilic 
aromatic substitution gave compound 4 in 86 % yield and Z and benzyl protecting 
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groups were simultaneously removed by hydrogenation using 10% palladium on 
charcoal as catalyst. Fmoc protection gave compound 6. The complexation of the cyclen 
ligands with Zn(II) requires careful control of the reaction conditions. After Boc-
deprotection with HCl saturated ether the hydrochloride salt 7 must be neutralized by 
base for metal ion complexation and the complexation step typically requires elevated 
temperatures,8 conditions which may cleave the Fmoc group. Ion exchange 
chromatography for deprotonation of the hydrochloride salt was therefore not applicable 
and a buffered solution was used for complexation. A clean twofold Zn(II)-
complexation was achieved in Hepes buffer (pH 8) with Zn(ClO4)2 • 6 H2O yielding the 
protected amino acid 8.  
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Scheme 1. Preparation of Fmoc-protected amino acid 6 and the bis(ZnII-cyclen) 
compound 8. 
 
Amino acid 9 with a tridentate donor side chain was prepared according to a literature 
procedure9 from Fmoc-lysine hydrochloride pyridine-2-carboxyaldehyde by reductive 
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amination with NaBH(OAc)3.10 The dpa complexes 10 are obtained quantitatively using 
stoichiometric amounts of the appropriate metal salts in a water/methanol solution.  
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Figure 2. Dpa amino acid 9 and dpa metal complexes 10 (M = Zn, Cu, Ni). 
 
The synthesis of amino acids 15 with binuclear Zn(II) dpa complex starts from Boc-L-
tyrosine methyl ester (Scheme 2). The Mannich reaction with dpa and 
paraformaldehyde afforded ligand 11.11 Saponification and subsequent reprotection 
resulted in the desired amino acid 14. The complexation of 14 with 2 equivalents of 
either Zn(NO)3 • 6 H2O or ZnCl2 gave dpa metal complexes 15†.  
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Scheme 2. Synthesis of bis-dpa amino acid 14 and bis-dpa metal complexes 15. 
 
 
 
 
                                                 
† Bis-dpa metal complex 15b was synthesized by Knape Robert, University of Regensburg. 
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1.2.3 Solid Phase Peptide Synthesis 
 
1.2.3.1 Synthesis of dpa-containing peptides 
 
As a first peptide compound 16 was prepared (Scheme 3). After complete 
characterization by 2-dimensional NMR, peptide 16 was complexed in solution. This 
approach allowed the use of the versatile Rink amide MBHA resin, a resin based on 
MBHA with a modified Rink amide linker as an ideal tool for Fmoc SPPS, providing 
peptide amides in high yields and purities.12 After Fmoc deprotection, the Fmoc 
protected aliphatic amino acids glycine and alanine were coupled by HBTU, HOBt and 
DIPEA in NMP/DMF using the conventional frit-equipped syringe technique. All 
coupling steps where carried out only once. Standard deprotection and washing cycles 
as outlined in Scheme 3 were performed after each coupling step. The SAAC 9 was 
then coupled using the same coupling reagents and equivalents of reagents. The reaction 
was completed after 3 hours indicated by a negative Kaiser test13 and the deprotected N-
terminus was subsequently coupled to Fmoc protected amino acids glycine, leucine and 
valine. Final Fmoc deprotection completes the solid-phase synthesis and gave peptide 
16 after cleavage from the resin with 90% TFA, 5% TIS, 5% H2O. After subsequent 
precipitation using cold diethyl ether and centrifugation (see experimental part for 
details), the peptide conjugate was dissolved in water, lyophilized and characterized by 
ESI-MS and 2-dimensional NMR. 26 mg of the target peptide sequence 16 were 
obtained analytically pure. Thus, peptide 16 was treated with Zn(NO3)2 • 6 H2O (1 
equiv) to obtain exclusively metal bound peptide conjugate 17 exclusively. 
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Scheme 3. Solid-Phase Synthesis of peptide conjugate 16 and peptide metal complex 
17. 
 
 
The same approach was used to prepare the dinuclear peptide receptor 19 (Scheme 4). 
Peptide 18 was first synthesised on Rink amide MBHA resin. After cleavage from the 
resin, 16 mg of the target peptide sequence 18 were obtained in > 95% purity as verified 
by NMR. 2-Dimensional NMR allowed the complete assignment of all resonances. 
Thus, peptide 18 was treated with Zn(NO3)2 • 6 H2O (1 equiv) to obtain metal bound 
dinuclear peptide receptor 19. 
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Scheme 4. SPRS of dinuclear peptide metal complex 19. 
 
In the synthesis of peptide 20, the already metal coordinated Fmoc-Dpa complex 10a 
was incorporated into the peptide chain (Scheme 5). To avoid the loss of metal ions 
under acidic conditions, which are necessary to cleave from Rink amide resin, HMBA-
AM was used as the resin as it allows nucleophilic cleavage of the peptide from the 
resin. Otherwise the same procedure as above was used yielding peptide 20 in > 95% 
purity as verified via NMR. 
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Scheme 5. Direct SPRS of 20 on HMBA-AM resin 
 
1.2.3.2 Synthesis of peptides containing bis-zinc-cyclen amino acid 8 
 
First attempts to couple amino acids 8 or 6 in solid phase protocols to aliphatic amino 
acids using HBTU,14 TBTU and DIPEA as coupling reagents failed. Therefore the more 
efficient reagent HOAt was used instead of HOBt together with the onium salt HATU. 
DIPEA was exchanged by collidine,15 a more suitable base for the HOAt reagent. Using 
HOAt (2.5 eq.), HATU (2.5 eq.) and collidine (5 eq.) the coupling of 6 (2 x 2.5 eq.) 
using two coupling cycles gave dipeptide 21 (Scheme 6). A more extended peptide 22 
was obtained on an Fmoc-Ala loaded SASRIN resin using the same coupling conditions 
(Scheme 7). In both cases the solely observed molecular ions in electro-spray mass 
spectrometry were only consistent with the mass of the desired compounds. In the 
following step, the Boc groups were cleaved with HCl saturated ether and the 
neutralized compound 23 was subsequently treated with Zn(ClO4)2 salt to obtain the 
peptide complex 24. 
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Scheme 6. Solid-phase synthesis of dipeptide conjugate 21. 
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Scheme 7. Solid-phase synthesis of peptide 22 and peptide complex 24. 
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1.2.3.3 Synthesis of peptides containing IDA amino acid 2 
 
To illustrate the incorporation of the IDA amino acid metal complex 2 into a short 
peptide sequence by a solid phase protocol peptide 25 was prepared on HMBA-AM 
resin using the standard coupling conditions as outlined in examples of the dpa-chelate 
(Scheme 8). Electro-spray mass analysis confirmed the formation of the desired 
compound.  
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Scheme 8. SPRS of peptide metal complex 25. 
 
1.2.3.4 Synthesis of peptides containing bis-dpa-zinc amino acid 15 
 
The first attempt at incorporating 15 into a peptide backbone was as the bis(ZnII-
nitrate)-SAAR 15a derived from complexation of 14 with Zn(NO)3 • 6 H2O. Due to the 
poor solubility of the metal complexes in NMP or DMF, the coupling was not efficient 
enough to give pure products.  Fortunately, bis-ZnII-SAAR 15b, having chloride counter 
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ions, was more soluble in NMP and the synthesis of 26‡ on HMBA-AM resin was 
successful using standard HOBt/TBTU conditions. Electro-spray mass analysis 
confirmed the clean formation of the desired compound. 
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Scheme 9. SPRS of peptide metal complex 26. 
                                                 
‡ Peptide metal complex 26 was synthesized by Knape Robert. 
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1.3 Conclusion 
 
In conclusion, we have reported the synthesis of Fmoc protected SAAC and their use in 
solid-phase synthesis. Peptide – metal complex conjugates were either obtained by 
incorporation of the metal coordinated SAAC followed by mild nucleophilic resin-
cleavage or by complexation in metal salt solution after cleavage from the resin. Our 
reported solid phase peptide synthesis protocols are suitable for automation and the 
position and number of the modified amino acid within the peptide chain may vary. 
This allows the synthesis of libraries of modified peptides with metal complexes as 
binding sites in synthetic receptors or as paramagnetic labels. 
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1.4 Experimental 
 
1.4.1 General procedure of solid phase peptide synthesis 
 
Loading of the HMBA-AM resin: 
HMBA-AM resin was added to a syringe with filter suited for SPPS, suspended in DMF 
and shaken for 30 min. After the DMF was drained off by vacuum, a solution of the 
appropriate Fmoc-AA (4 eq) in a 0.5 M HOBt-solution and 4 eq of N, N´-
diisopropylcarbodiimide (DIPCI) were added. After 1 hour DIPEA (5 eq) was added 
and the so equipped syringe was shaken over night. The resin was washed 3 times each 
with DMF, DCM and Et2O and dried under vacuum.  
Photometric determination of the loading of the HBBA-AM resin with the first 
AA: 
To a weighed sample of the resin was added a 20 % solution of piperidine in DMF (v/v) 
and the mixture was shaken for 30 min. A diluted sample of the filtrate was used to 
record the absorbance of the corresponding 9-methylene-9-fluorene at 266, 289 and 300 
nm. With the appropriate extinction coefficients ε(266) = 17500 M-1cm-1, ε(289) = 5800 
M-1cm-1 and ε(300) = 7800 M-1cm-1 the loading was determined using the Lambert-Beer 
equation. 
Capping: 
Prior to acetylation the resin was swollen in DMF for 30 min. The solvent was filtered 
of and acetic anhydride (10 eq based on the difference in substitution-loading) and 
DIPEA (10 eq) were added. After 40 min the solution was drained off and the resin was 
washed 3 times each with DMF, DCM and Et2O and dried under vacuum.  
General coupling procedure for aliphatic amino acids: 
All peptides were synthesised using 2 / 5 mL frit syringes filled with 50 / 100 mg of 
resin. Fmoc-AA-loaded HMBA-AM resin, Rink Amide MBHA resin or Fmoc-AA-
loaded SASRIN resin was added to a frit-syringe, suspended in DMF and allowed to 
swell for 30 min. Prior to the amino acid coupling the Fmoc protecting group of the 
growing peptide chain was cleaved using the procedure described beneath.  Fmoc 
protected aliphatic amino acids (5 eq) in 0.45 M HOBt-solution, 5 equivalents of a 0.44 
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M HBTU§ or TBTU solution in DMF and 10-fold excess of DIEA as a 1.2 M solution 
in DMF were added in succession. The syringe was subsequently shaken for 40 min. 
Following filtration, the resin was washed 4 times with DMF. Fmoc cleavage was 
brought about through the addition of 40 % (v/v) piperidine-DMF solution and shaking 
for 3 min followed by the addition of a 20 % (v/v) piperidine-DMF solution and shaking 
for 10 min. The solution was drained of, the deprotected resin bound peptide was 
washed 6 times with DMF and subsequently coupled to the next Fmoc protected amino 
acid or Fmoc protected SAAC.  
General coupling procedure for SAAC and receptor units: 
SAAC 9, SAAR 10a, SAAR 2 and SAAR 15b were coupled using the same conditions 
as for the aliphatic amino acids.  
The coupling procedure of BC-SAAC 6 was performed twice. Two times 2.5-fold 
excess of BC-SAAC 6 was dissolved in NMP and activated by sequential addition of 1 
eq HOAT (0.5 M in NMP) and 1 eq HATU (0.5 M in NMP) and 2.5 eq collidine. 
Cleavage from the solid support (Rink Amid): 
Cleavage from the solid support was performed using a TFA cocktail containing 
TFA/TIS/H2O (90:5:5 v/v/v) for 3 hours. In order to precipitate the peptide, cold Et2O 
was added and the resulting heterogeneous solution centrifuged for 10 min at -4°C. The 
supernatant was decanted and the resulting pellet was washed with colt Et2O. This 
procedure was repeated several times before the precipitate was dissolved in water and 
lyophilized. 
Cleavage from the solid support (HMBA-AM): 
Best results were achieved when adding DIEA/MeOH/DMF (1:5:5 v/v/v) to the 
preswollen resin and cleaving over night. If the peptide precipitates by adding cold 
Et2O, resulting heterogeneous solution was centrifuged for 10 min at -4°C. The 
supernatant was decanted and the resulting pellet was washed with colt Et2O. This 
procedure was repeated several times before the precipitate was dissolved in water and 
lyophilized. 
                                                 
§ Abbreviations not defined in the text: HBTU = N-[(1H-benzoltriazol-1-
yl)(dimethylamino)methylene]N-methylmethanaminium hexafluorophosphate N-oxide, HOBt = 1-
Hydroxybenzotriazole; DIPEA = diisopropylethylamine; TBTU = Benzotriazol-1-yl-tetramethyluronium 
tetrafluoroborate, HOAt = 4-Hyddroxypyrazolo[3,4-d]pyrimidine, HATU = O-(7-Azabenzotriazole-1-yl)-
N, N,N’N’-tetramethyluronium hexafluorophosphate, DIC = 1,3 – Diisopropylcarbodiimide. 
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If the precipitation fails, the filtrate is evaporated to dryness on a rotary evaporator, 
dissolved in water and lyophilized. 
Cleavage from the solid support (SASRIN): 
The preswollen peptide resin was treated with 1% TFA/DCM (15 mL/g) for 3 min. The 
cleavage solution was sucked into a vessel containing 2 eq of pyridine (per eq of TFA) 
and a little methanol (1 mL/10 mL solution). The treatment was repeated with further 
portions of 1% TFA/DCM. Volatile compounds of the collected filtrates were removed 
in vacuum and the residue was redissolved in Et20 and removed under reduced pressure. 
This procedure was repeated several times before the precipitate was dissolved in little 
methanol and precipitated with cold Et2O. 
 
 
1.4.2 Synthesis and characterisation of compounds 
 
Cu-IDA-complex 2 
Compound 1 was first treated with HCl saturated ether to obtain the free iminodiacetic 
acid functionality: Compound 1 (1.62 g, 2.72 mmol) was dissolved in DCM and cooled 
to 0 °C using an ice bath. To this mixture 30 mL of HCl saturated ether was added. The 
mixture was allowed to warm to room temperature and stirred over night. The reaction 
progress was controlled by 1H-NMR. The mixture was concentrated under reduced 
pressure and dried under high vacuum to obtain product 1a as colorless solid in 
quantitative yield and was subsequently used for complexation. mp: 135 °C; [a]20D = -
13.9 ° (c = 0.13 in MeOH); IR (KBr disk): ν~  [cm-1] = 3419, 2953, 2619, 1735, 1528, 
1250, 740; MS (ESI, MeOH + 10 mmol/L NH4OAc): e/z (%) = 485 (100) [MH+], 619.4 
(7) [MNa+]. EA (C25H28N2O8 + 3 H2O) calculated (%): C 55.74, H 6.37, N 5.20. Found: 
C 55.18, H 6.21, N 4.96. 
Fmoc-IDA-OH 1a (930 g, 1.79 mmol) and Cu2(OH)2CO3 (395 mg, 1.79 mmol) were 
suspended in H20/MeOH solution (30 mL, 1:1). The mixture was stirred for 3 h at 70 °C 
and the resulting blue solution was decanted from the residual Cu2(OH)2CO3. MeOH 
was removed under vacuum and the remaining aqueous solution was lyophilized 
yielding 2 as a blue solid in quantitative yield. mp: decompostition at 135 °C; IR (KBr 
disk): ν~  [cm-1] = 3414, 2945, 1707, 1622, 1583, 1400, 740; MS (ESI, 
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H2O/MeCN/MeOH + 10 mmol/L NH4Ac): m/z (%) = 544 (100) [M - H+]-, 580 (35) [M 
+ Cl-]-, 1091 (8) [2M - H+]-. 
 
1,4,7-Tri-tert-butyl 10,10'-(6-(6-(benzyloxy)-5-(benzyloxycarbonylamino)-6 oxo-
hexylamino)-1,3,5-triazine-2,4-diyl)-bis-(1,4,7,10-tetraazacyclododecane-1,4,7 
tricarboxylate) 4 
To a solution of Z-Lys-OBzl benzenesulfate (1.96 g, 371 mmol) and K2CO3 (1.03 g, 
7.42 mmol) was added bis-Boc-cyclen triazin 316 (3.73 g, 3.53 mmol) and the reaction 
mixture was refluxed for 3 d. The filtrate was concentrated under reduced pressure and 
the crude compound was purified by silica gel column (eluent: CHCl3/MeOH = 95:5; Rf 
= 0.73) to give 4 as a white solid (4.19 g, 3.01 mmol, 85 %). mp: 140 °C; [a]20D = -3.4 
(c = 0.01 in CHCl3); 1H-NMR (600 MHz, d-DMSO): δ = 1.13-1.55 (m, 58 H, Boc-CH3, 
Lys-CHCH2CH2, CHCH2CH2CH2), 1.57-1.74 (m, 2 H, Lys-CHCH2), 3.06-3.78 (m, 34 
H, Cyclen-CH2, CHCH2CH2CH2CH2), 4.00-4.08 (m, 1 H, CH), 4.98-5.07 (m, 2 H, H-
Bzl), 5.10 (s, 2 H, H-Z) 6.64 (bs, 1 H, NH), 7.27-7.38 (m, 10 H, H-Aryl), 7.73 (d, 1 H, 
NH); 13C-NMR (150 MHz, d-DMSO, HSQC, HMBC): δ = 22.9 (−, C-3), 27.9 (+, 12 C, 
Boc), 28.0 (+, 6 C, Boc), 28.9 (−, C-4), 30.5 (−, C-2), 40.0 (−, C-5), 49.4 (−, 16 C, 
Cyclen), 54.0 (+, CH), 65.5 (−, CH2Bzl), 66.8 (−, CH2Z), 78.9 (Cquat, Boc), 79.0 (Cquat,  
Boc), 79.1 (Cquat, 2 C, Boc), 79.3 (Cquat, Boc), 79.4 (Cquat, Boc), 127.7 (Cquat, 2 C, Aryl), 
127.7 (Cquat, 2 C, Aryl), 127.8 (Cquat, Aryl), 127.9 (Cquat, Aryl), 128.3 (Cquat, 2 C, Aryl), 
128.3 (Cquat, 2 C, Aryl), 155.5 (Cquat, 3 C, triazin), 156.1 (Cquat, ester), 172.2 (Cquat, 
carbamate); IR (KBr disk): ν~  [cm-1] = 3441, 2974, 2932, 2360, 2342, 1560, 1542, 
1410, 1366, 1250, 1166; MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc) : e/z (%) = 
1391.2 (100) [MH+], 646.1 (26) [M + 2H+ - Boc]2+, 704.7 (7) [MH+ + NH4+]2+. 
 
2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-6-(4,6-bis(4,7,10-tris(tert-butoxy-
carbonyl)-1,4,7,10-tetraazacyclododecan-1-yl)-1,3,5-triazin-2-ylamino)hexanoic 
acid 6 
Fmoc-OSuc (405 mg, 1.20 mmol) and DIPEA (155 µL, 1.20 mmol) were added in 
succession to a suspension of 5 (1.54 g, 1.10 mmol) in DCM (100 mL). The reaction 
mixture was stirred at room temperature for 12 h. It was extracted with an aqueous 
solution of NaH2PO4 (100 mM, 3 x 40 mL, pH 5.0) and the organic phase was washed 
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with water, then dried over anhydrous magnesium sulphate and the solvent was 
removed under vacuum. The crude product was purified by silica column 
chromatography (eluent: CHCl3/MeOH = 95:5; Rf = 0.38) to give 6 (1052 mg, 0.76 
mmol, 68 %) as a white solid solid. mp: 102 °C; [a]20D = +25.0 (c 0.008 in CDCl3); 1H-
NMR (400 MHz, CDCl3, COSY, HSQC, HMBC): δ = 1.35-1.48 (m, 54 H, Boc), 1.49-
165 (m, 4 H, H-3, H-4), 1.76-1.98 (m, 2 H, H-2), 2.99-3.95 (m, 34 H, H-cylen, H-5), 
4.13-4.23 (m, 1 H, H-10), 4.26-4.44 (m, 3 H, H-1, H-9), 6.07 (bs, 1 H, NH), 7.21-7.28 
(m, 2 H, H-B), 7.31-7.38 (m, 2 H, H-C), 7.54-7.63 (m, 2 H, H-A), 7.71 (d, 2 H, 3J = 7.3 
Hz, H-D); 13C-NMR (100 MHz, CDCl3, HSQC, HMBC): δ = 22.0 (−, C-3/4), 28.5 (+, 
12 C, Boc), 28.5 (+, 6 C, Boc), 30.9 (−, C-3/4), 31.9 (−, C-2), 40.1 (−, C-5), 47.2 (+, C-
10), 50.2 (−, 16 C, Cyclen), 54.3 (+, C-1), 66.9 (−, C-9), 80.0 (Cquat, 6 C, Boc), 119.9 
(Cquat, 2 C, C-D), 125.3 (Cquat, 2 C, C-A), 127.0 (Cquat, 2 C, C-B), 127.6 (Cquat, 2 C, C-
C), 141.2 (Cquat, 4 C, Fmoc), 143.9 (Cquat, 2 C, Fmoc), 144.1 (Cquat, 2 C, Fmoc), 156.1 
(Cquat, triazin), 156.8 (Cquat, 2 C, triazin), 156.8 (Cquat, ester), 175.2 (Cquat, acid); IR (KBr 
disk): ν~  [cm-1] = 3433, 2974, 2932, 1693, 1542, 1411, 1366, 1250, 1165; MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc) : e/z (%) = 703.7 (100) [MH+ + NH4+]2+, 1389.1 
(33) [MH+], 645.2 (21) [M + 2H+ - Boc]2+, 617.1 (21) [MH+ + 2H+ - Boc - ∆C4H8]2+, 695 
(10) [(MH+ + 2H+)]2+. EA (C70H109N13O16 + 5 H2O) calculated (%): C 56.84, H 8.12, N 
12.32: Found: C 56.80, H 7.86, N 12.03. 
 
Bis-Zn-cyclen-complex 8 
Hepes buffer (10 mM, pH 8) was prepared and 10 mL where heated to 80 °C in a round-
bottom flask. L-Tyr(tri-Boc-bis-Cyc)-OH 7 (500 mg, 0.54 mmo) and Zn(ClO4)2 (402 
mg, 1.08 mmol) where each dissolved in 10 mL of Hepes-buffer and added dropwise 
and simultaneously under stirring. The reaction mixture was stirred for further 3 h at 
80°C and at room temperature over night. Compound 8 was obtained as a white solid 
after lyophilization.  
MS (ESI, H2O/MeCN/MeOH + 10 mmol/L NH4OAc): e/z (%) = 456.8 (100) [K4+ - 
2H+]2+, 476.4 (24) [K4+ + Cl- - H+]2+. 
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Fmoc-bpa-Zn(NO3)2 10a 
To the SAAC 9 (850 mg, 1.54 mmol) in 80 mL MeOH was added a solution of 
Zn(NO3)2 · 6 H2O (458 mg, 1.54 mmol) in 20 ml H20 and the resulting solution was 
stirred for 1 h. The MeOH was removed under vacuum and the remaining aqueous 
solution was lyophilized yielding 10a as a white solid in quantitative yield. mp: 
decomposition at 150 °C; [a]20D = -27.2 ° (c = 0.007 in MeOH); IR (KBr disk): ν~  [cm-
1] = 3416, 3066, 2944, 1711, 1609, 1415, 1383, 1312, 1026, 763; MS (ESI, 
H2O/MeCN): m/z (%) = 613 (100) [Fmoc-BPA-Zn2+ - H+]+, 1229 (10) [2(Fmoc-BPA-
Zn2+) - 3H+]+; 
 
2-{[(9H-Fluoren-9-yl)methoxy]carbonylamino}-3-{3,5-bis[(bis-pyridin-2-ylmethyl-
amino)methyl]-4-hydroxyphenyl}propanoic acid 14 
DIPEA (0.68 mL, 4.0 mmol) and Fmoc-OSuc (236 mg, 0.70 mmol) were added 
successively to a suspension of 13 (520 mg, 0.48 mmol) in DCM (50 mL). The reaction 
mixture was stirred at room temperature for 12 h. The mixture was extracted with an 
aqueous solution of NaH2PO4 (100 mM, 3 x 20 mL, pH 5.0) and the organic phase was 
washed with water, then dried over anhydrous magnesium sulphate and the solvent 
removed under vacuum. The crude product was purified by silica column 
chromatography (eluent: CHCl3/MeOH = 95:5; Rf = 0.05) to give 14 (309 mg, 0.37 
mmol, 78 %) as a pale yellow solid. mp: decomposition 88°C; [a]20D = +41.5 ° (c = 0.02 
in CHCl3); IR (KBr disk): ν~  [cm-1] = 3414, 3252, 3057, 3057, 2924, 2822, 2362, 1714, 
1592. 1H-NMR (600 MHz, CDCl3, COSY, HSQC, HMBC): δ = 2.97 (dd, 1 H, 2J = 13.2 
Hz, 3J = 5.0 Hz, TyrCHCH2), 3.11 (dd, 1 H, 2J = 12.7 Hz, 3J = 2.5 Hz, TyrCHCH2), 
3.48- 3.50 (m, 2 H, TyrCH2N), 3.76-3.86 (m, 10 H, Pyr-CH2-N, TyrCH2N), 4.11-4.16 
(m, 1 H, Fmoc-CH), 4.17-4.22 (m, 1 H, Fmoc-CH2), 4.26-4.31 (m, 1 H, TyrCH), 4.32-
4.37 (m, 1 H, Fmoc-CH2), 5.95 (d, 1 H, 3J = 5.1 Hz, NH), 6.90 (bs, 2 H, CH-phenol), 
7.10-7.14 (m, 4 H, pyr), 7.19-7.27 (m, 6 H, pyr, aryl), 7.34-7.39 (m, 2 H, aryl) 7.52-7.60 
(m, 6 H, pyr, aryl), 7.74 (d, 2 H, 3J = 7.5 Hz, aryl), 8.61-8.70 (m, 4 H, pyr), 10.96 (bs, 1 
H, Tyr-OH); 13C-NMR (151 MHz, CDCl3, HSQC, HMBC): δ = 37.6 (−, CH2), 47.4 (+, 
CH), 54.8 (−,2 C, CH2), 57.4 (+, CH), 59.6 (−, 4 C, CH2), 66.2 (−, CH2), 119.8 (+, 2 C, 
CH), 122.3 (+, 4 C, CH), 122.9 (Cquat, 2 C), 123.5 (+, 4 C, CH), 125.3 (+, 2 C, CH), 
127.0 (+, 2 C, CH), 127.5 (+, 2 C, CH), 129.2 (Cquat, 1 C), 131.3 (+, 2 C, CH), 136.7 (+, 
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4 C, CH), 141.2 (Cquat, 2 C), 144.3 (Cquat, 1 C), 149.8 (+, 4 C, CH), 154.2 (Cquat, 1 C), 
155.3 (Cquat, carbamate), 158.3 (Cquat, 4 C), 176.6 (Cquat, acid); MS (ESI, 
DCM/MeCN/H2O + 10 mmol/L TFA) : m/z (%) = 413 (100) [M + 2H+], 826.4 (30) 
[MH+]. HRMS calculated for C50H48N7O5 [MH+]: 826.3765; found: 826.3765 ± 5.8 
ppm. 
 
Bis-bpa-Zn(Cl)-complex 15b 
The free ligand 14 (320 mg, 0.39 mmol) was dissolved in methanol (25 mL). To this 
solution, ZnCl2 (52.8 mg, 0.39 mmol) in 5 mL H2O was added and the mixture was 
stirred at room temperature for 3 h. Methanol was then removed under reduced pressure 
and the remaining aqueous solution was lyophilized to give the desired zinc coordinated 
complex as a white solid in quantitative yield. mp: decomposition > 170 °C; [a]20D = 
+45.0 ° (c = 0.01 in CHCl3);  IR (KBr disk): ν~  [cm-1] = 3422, 3055, 2921, 1713, 1606, 
1526; MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): e/z (%) =1070.4 (100) [K3+ + 
2CH3COO-]+, 1010.3 (45) [K3+ - H+ + CH3COO-]+, 505.4 (6) [K3+ - H+]2+. 
 
Peptide 16 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using Fmoc protected Rink amide resin (100 mg, subst.: 0.7 mmol/g). SPPS of Fmoc 
protected aliphatic amino acids and SAAC 9 according to the specific stated procedure 
provided peptide 16 as a white solid. 1H-NMR (600 MHz, DMSO-d6, COSY, HSQC, 
HMBC): δ = 0.85 (d, 3 H, 3J = 6.7 Hz, H-29a), 0.83 (d, 3 H, 3J = 6.9 Hz, H-24a), 0.81 
(d, 3 H, 3J = 6.7 Hz, H-29b), 0.80 (d, 3 H, 3J = 6.9 Hz, H-24b), 1.22 (d, 3 H, 3J = 7.06 
Hz, H-11), 1.23-1.32 (m, 2 H, H-3), 1.42-1.46 (m, 2 H, H-22), 1.47-1.52 (m, 1 H, H-2a), 
1.54-1.59 (m, 1 H, H-23), 1.60 – 1.67 (m, 1 H, H-2b), 1.69-1.76 (m, 2 H, H-4), 1.90-1-
96 (m, 1 H, H-28), 3.06-3.13 (m, 2 H, H-5), 3.52-3.62 (m, 2 H, H-14), 3.68 (dd, 1 H, 3J 
= 5.8 Hz, 2J = 16.7 Hz, H-18a), 3.74 (dd, 1 H, 3J = 5.6 Hz, 2J = 16.7 Hz, H-18a), 4.06 
(dd, 1 H, 3J1 = 6.9 Hz, 3J2 = 8.9 Hz, H-27), 4.18-4.22 (m, 1 H, H-1), 4.31-4.40 (m, 2 H, 
H-21, H-10), 4.50 (bs, 7 H, H-7), 7.00 (s, 1 H, H-31a), 7.33 (s, 1 H, H-31b), 7.41-7.45 
(m, 2 H, H-B), 7.51 (d, 2 H, 3J = 7.9 Hz, H-D), 7.67 (d, 1 H, NH-30), 7.87 (dd, 1 H, 3J1 
= 7.7 Hz, 3J2 = 7.7 Hz, H-Ca), 7.87 (dd, 1 H, 3J1 = 7.7 Hz, 3J2 = 7.7 Hz, H-Cb), 7.96 (d, 
1 H, NH-25), 8.00-8.08 (m, 2 H, NH-13, NH-19), 8.19 (d, 1 H, 3J = 7.7 Hz, NH-16), 
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8.55 (d, 1 H, 3J = 7.3 Hz), 8.61-8.63 (m, 2 H, H-A); 13C-NMR (150 MHz, DMSO-d6, 
HSQC, HMBC): δ = 18.0 (+, C-29a), 18.4 (+, C-11), 19.2 (+, C-29b), 21.5 (+, C-24a), 
22.4 (−, C-3), 23.1 (+, C-24b), 23.1 (−, C-4), 24.1 (+, C-23), 30.4 (+, C-28), 31.2 (−, C-
2), 40.0 (−, C-14), 40.1 (−, C-22), 41.8 (−, C-18), 48.3 (+, C-10), 51.1 (+, C-21), 52.5 
(+, C-1), 53.8 (−, C-5), 56.9 (−, 4 C, C-7), 57.5 (+, C-27), 123.9 (+, 2 C, C-B), 124.7 (+, 
2 C, C-D), 137.6 (+, 2 C, C-C), 149.1 (+, 2 C, C-A), 150.1 (Cquat, 2 C, C-E), 165.5 
(Cquat, C-8), 168.4 (Cquat, C-20), 171.4 (Cquat, C-17), 171.7 (Cquat, C-26), 171.8 (Cquat, C-
12), 172.8 (Cquat, C-15); MS (ESI, DCM/MeOH + NH4OAc): e/z (%) = 363.2  (100) [M 
+ 2H+]2+, 725.6 (71) [MH+]. 
 
Peptide complex 17 
To a solution of peptide 16 (20 mg, 0.03 mmol) in 10 mL H2O was added Zn(NO3)2 · 
6H2O (8.4 mg, 0.03 mmol). After the mixture was stirred over night a white solid was 
obtained after lyophilization. 1H-NMR (600 MHz, DMSO-d6, COSY, HSQC, HMBC): 
δ = 0.80-0.86 (m, 12 H, H-29, H-24), 1.08-1.19 (m, 2 H, H-4), 1.12 (d, 3J = 7.0 Hz, 3 H, 
H-11), 1,42-1.48 (m, 5 H, H-22, H-2a, H-3), 1.53-1.61 (m, 2 H, H-2b, H-23), 1.91-1.97 
(m, 1 H, H-28), 2.56-2.62 (m, 2 H, H-5), 3.53-3.75 (m, 4 H, H-14, H-18), 4.00 (d, 2 H, 
2J = 16.0 Hz, H-7a), 4.07 (dd, 3J = 9.0, 3J = 6.8, 1 H, H-27), 4.17 (m, 1 H, H-1), 4.24 
(dd, 2J = 16.0, 4J = 2.3, 2 H, H-7b), 4.30-4.40 (m, 2 H, H-10, H-21), 7.02 (s, 1 H, N-H), 
7.34 (s, 1 H, N-H), 7.59-7.66 (m, 2 H, H-B, H-D), 7.93-7.99 (m, 1H, N-H), 8.05 (t, 3J = 
5.5, 1 H, N-H), 8.08-8.12 (m, 2 H, H-C), 8.15 (d, 1 H, 3J = 7.7 Hz, N-H), 8.50 (d, 3J = 
7.2 Hz, 1 H, NH), 8.71 (d, 3J = 4.8 Hz, 2 H, H-A); 13C-NMR (150 MHz, DMSO-d6, 
HSQC, HMBC): δ = 18.0 (+, C-29a), 18.5 (+, C-11), 19.2 (+, C-29b), 21.5 (+, C-24a), 
22.8 (−, C-3), 23.1 (+, C-24b), 23.1 (−, C-4), 24.1 (+, C-23), 30.4 (+, C-28), 31.5 (−, C-
2), 40.1 (−, C-14), 40.8 (−, C-22), 41.8 (−, C-18), 48.3 (+, C-10), 51.1 (+, C-21), 52.6 
(+, C-1), 54.9 (−, C-5), 56.7 (−, C-7), 57.4 (+, C-27), 124.2 (+, 2 C, C-B), 124.6 (+, 2 C, 
C-D), 140.7 (+, 2 C, C-C), 147.8 (+, 2 C, C-A), 155.1 (Cquat, 2 C, C-E), 165.4 (Cquat, C-
8), 168.4 (Cquat, C-20), 171.4 (Cquat, C-17), 171.7 (Cquat, C-26), 171.7 (Cquat, C-12), 
172.7 (Cquat, C-15); MS (ESI, H2O/NH4OAc): e/z (%) = 394.3 (100) [M]2+, 901.4 (14) 
[M2+ + TFA]+, 787.4  (8) [M2+ - H+]+, 850.4 (3)[M2+ + NO3-]+. 
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Peptide 18 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using Fmoc protected Rink amide resin (50 mg, subst.: 0.7 mmol/g). SPPS of Fmoc 
protected amino acid monomers and SAAC 9 according to the specific stated procedure 
provided compound 18 as a white solid. 1H-NMR (600 MHz, DMSO-d6, COSY, HSQC, 
HMBC): δ = 0.75-0.83 (dd, 6 H, 3J1 = 6.7 Hz, 3J2 = 6.9 Hz, H-21, H-21’), 0.94 (d, 6 H, 
3J = 6.7 Hz, H-35, H-35’), 1.17 (d, 3 H, 3J = 7.2 Hz, H-11), 1.20 (d, 3 H, 3J = 7.2 Hz, H-
25), 1.20-1.32 (m, 4 H, H-3), 1.55-1.42 (m, 2 H, H-2´a, H-2’b), 1.55-1.67 (m, 2 H, H-
2a, H-2’a), 1.69-1.78 (m, 4 H, H-4), 1.82 (s, 1 H, H-36), 1.85 (s, 1 H, H-36), 1.92-1.99 
(m, 1 H, H-20), 2.01-2.07 (m, 1 H, H-34), 3.04-3.12 (m, 4 H, H-5), 3.62-3.66 (m, 1 H, 
H-30b), 3.67-3.76 (m, 2 H, H-14b, H-30a), 3.94 (dd, 1 H, 3J = 16.6 Hz, 2J = 6.1 Hz, H-
14a), 4.11-4.23 (m, 3 H, H-33, H-10, H-19), 4.28-4.34 (m, 2 H, H-24, H-1), 4.49 (m, 8 
H, H-7), 7.00 (s, 1 H, H-8), 7.29-7.33 (m, 1 H, H-8), 7.42-7.45 (m, 4 H, H-B), 7.53 (d, 4 
H, 3J = 7.9 Hz, H-D), 7.67 (dd, 1 H, 3J = 27.7 Hz, 4J = 8.7 Hz, H-22), 7.86-7.90 (m, 4 
H, H-C), 7.91 (d, 1 H, 3J = 7.4 Hz, H-12), 8.08-8.21 (m, 4 H, H-15, H-26, H-28, H-31), 
8.61-8.66 (m, 4 H, H-A); 13C-NMR (150 MHz, DMSO-d6, HSQC, HMBC): δ = 17.7 (+, 
iPr), 17.7 (+, C-11), 18.2 (+, iPr), 18.2 (+, C-25), 19.1 (+, iPr), 22.3 (−, 2 C, C-3), 23.1 
(−, C-4), 29.7 (+, C-34), 30.5 (+, C-20), 31.3 (−, C-2), 31.7 (−, C-2’), 41.6 (−, C-14), 
41.9 (−, C-30), 48.0 (+, C-10), 48.2 (+, C-24), 52.0 (+, C-1), 52.5 (+, C-33), 53.7 (−, C-
5), 56.9 (−, C-7), 57.3 (+, C-19), 123.9 (+, C-B), 124.7 (+, C-D), 137.6 (+, C-C), 149.1 
(+, C-A), 151.4 (Cquat, C-E), 174.1 (Cquat, C-9), 167.9 (Cquat, C-16), 168.1 (Cquat, C-13), 
168.1 (Cquat, C-29), 170.8 (Cquat, C-18), 171.0 (Cquat, C-27), 171.5 (Cquat, C-32), 171.7 
(Cquat, C-23), 174.1 (Cquat, C-9); MS (ESI, H2O/NH4OAc): e/z (%) = 365 (100) [M + 3 
H+]3+, 547 (24) [M + 2 H+]2+, 1092.7 (0.3) [MH+].  
 
Peptide complex 19 
To a solution of peptide 18 (10 mg, 0.01 mmol) in 10 mL H2O was added Zn(NO3)2 · 
6H2O (5.6 mg, 0.02 mmol). After the mixture was stirred over night a white solid was 
obtained after lyophilization. MS (ESI, H2O/MeOH + NH4OAc): e/z (%) = 407.3 (100) 
[M4+ - H+]3+, 608.9 (74) [M4+ - 2H+]2+, 365.8 (40) [(M4+ - 2Zn2+ + 3H+)]3+. 
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Peptide complex 20 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using HMBA-AM resin (100 mg, subst.: 0.83 mmol/g). SPPS of Fmoc protected amino 
acids and SAAR 10a according to the specific stated procedure provided compound 20 
as a white solid. 1H-NMR (600 MHz, DMSO-d6, COSY, HSQC, HMBC): δ = 0.80 (d, 
3 H, 3J = 6.7 Hz, H-18´), 0.85 (d, 3 H, 3J = 6.5 Hz, H-18), 1.08 (d, 3 H, 3J = 6.9 Hz, H-
11), 1.15-1.28 (m, 2 H, H-3), 1.25 (d, 3 H, 3J = 7.3 Hz, H-25), 1.38-1.50 (m, 5 H, H-2a, 
H-4, H-21), 1.52-1.62 (m, 2 H, H-2b, H-17), 2.39 (t, 2 H, 3J = 7.2 Hz, H-5), 3.21-3.40 
(m, 1 H, H-10), 3.60 (s, 3 H, OMe), 3.66-3.71 (m, 4 H, H-7, H-16), 4.18-4.29 (m, 3 H, 
H-24, H-15, H-1), 7.20-7.23 (m, 2 H, H-B), 7.50 (d, 2 H, 3J = 7.7 Hz, H-D), 7.74 (dd, 1 
H, 3J1 = 6.7 Hz, 3J2 = 7.7 Hz, H-Ca), 7.74 (dd, 1 H,  3J1 = 7.7 Hz, 3J2 = 7.7 Hz, H-Cb), 
7.81-7.96 (m, 1 H, C-14), 8.05 (d, 1 H, 3J = 7.1 Hz, NH-8), 8.11 (d, 1 H, 3J1 = 6.9, H-
23), 8.16 (t, 1 H, 3J = 5.9, H-20), 8.43-8.47 (m, 2 H, H-A); 13C-NMR (150 MHz, 
DMSO-d6, HSQC, HMBC): δ 17.0 (+, C-25), 21.5 =  (+, H-11), 21.6 (+, C-18´), 22.9 
(+, C-18), 24.1 (−, C-17), 26.3 (−, C-4), 32.3 (−, C-2), 40.4 (−, C-21), 41.6 (−, C-16), 
47.5 (+, C-24), 50.1 (+, C-10), 51.3 (+, C-1), 51.8 (+, C-15), 51.8 (+, OMe), 53.5 (−, 4 
C, C-7), 122.0 (+, 2 C, C-B), 122.4 (+, 2 C, C-D), 136.4 (+, 2 C, C-C), 148.7 (+, 2 C, 
C-A), 159.5 (Cquat, 2 C, C-E), 168.5 (Cquat, C-22), 171.8 (Cquat, C-13), 172.1 (Cquat, C-
19), 172.9 (Cquat, C-26), 175.5 (Cquat, C-9); MS (ESI, H2O/MeOH + NH4OAc): e/z (%) 
= 359.1 (100) [M]2+, 717.3 (14) [M2+ - H+]+, 352.1 (30) [M -  OMe + OH]2+, 703.3 (20) 
[(M -  OMe + OH) - H+]+. 
 
Dipeptide 21 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using HMBA-AM resin (100 mg, subst.: 1.1 mmol/g). SPPS of Fmoc protected amino 
acids and SAAC 6 along with HOAt and HATU as coupling reagents according to the 
specific stated procedure provided compound 21 as a white solid. MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): e/z (%) = 626.6 (100) [M + 2H+]2+, 1252.1 (29) 
[MH+], 1220.1 (4) [MH+ - CH3OH]. 
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Peptide 22 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using SASRIN resin (100 mg). SPPS of Fmoc protected amino acids and SAAC 6 
along with HOAt and HATU as coupling reagents according to the specific stated 
procedure provided compound 22 as a white solid. MS (ESI, DCM/MeOH + 10 
mmol/L NH4OAc): e/z (%) = 726.1 (100) [M + 2H+]2+, 1451.4 (20) [MH+], 1463.2 (4) 
[M + Na+]. 
 
Peptide complex 25 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using HMBA-AM resin (100 mg, subst.: 0.83 mmol/g). SPPS of Fmoc protected amino 
acids and SAAR 2 according to the specific stated procedure provided compound 25 as 
a white solid. MS (ESI, H2O/MeOH + NH4OAc): e/z (%) = 441 (8) [(M + 2H+)]2+, 882 
(8) [MH+], 904 (6) [M + Na+]. 
 
Peptide complex 26 
The synthesis was performed manually in a 5 mL syringe equipped with porous filter 
using HMBA-AM resin (100 mg, subst.: 1.1 mmol/g). SPPS of Fmoc protected amino 
acids and SAAR 15b according to the specific stated procedure provided compound 26 
as a white solid. MS (ESI, H2O/MeOH + NH4OAc): e/z (%) = 543.4 (100) [K3+ + 
CH3COO-]2+, 1145.6 (50) [K3+ + 2CH3COO-]+. 
 
2-{[(9H-Fluoren-9-yl)methoxy]carbonylamino}-6-[bis(2-tert-butoxy-2 
oxoethyl)amino] hexanoic  acid 1 
Improved synthesis according to ChemBioChem 2003, 4, 1340-1344: Fmoc-OSuc (1.96 
g, 5.80 mmol) and DIPEA (1.00 mL, 5.80 mmol) were added to a solution of N,N-
bis(tert-butyloxycarbonylmethyl)-L-lysine (2.13 g, 5.69 mmol) in dry CH2Cl2 (50 mL) 
and the reaction mixture was stirred over night at room temperature under a nitrogen 
atmosphere. The volatile compounds were removed under reduced pressure and the 
crude product was redissolved in CH2Cl2 (50 mL) and washed with an aqueous solution 
of NaH2PO4 (100 mM, 3 x 20 mL, pH 5.0). The organic phase was dried over 
anhydrous magnesium sulphate and the solvent was removed under vacuum. The crude 
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product was purified by silica column chromatography with CHCl3/MeOH (3:1) as 
eluent. Yield: 2.44 g (72 %). mp: 50 °C; [a]20D = 12.5° (c = 0.01 in CHCl3); 1H-NMR 
(300 MHz, CDCl3): δ = 1.24-1.55 (m, 4 H, CHCH2CH2, CHCH2CH2), 1.44 (s, 18 H, 
Boc), 1.68-1.99 (m 2 H), 2.57-2.87 (m, 2 H), 3.51 (bs, 4 H, N-(CH2)2), 4.20 (t, 1 H, 3J = 
7.0 Hz, CH-Fmoc), 4.29-4.50 (m, 3 H, CH2-Fmoc, Lys-CH), 5.73 (bs, 1 H, NH), 7.27-
7.33 (m, 4 H, Fmoc), 7.38 (t, 2 H, Fmoc), 7.52-7.63 (m, 2 H, Fmoc), 7.74 (d, 2 H, 
Fmoc); MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): e/z (%) = 597.4 (100) [MH+], 
619.4 (5) [MNa+]. 
 
2-Amino-6-(4,6-bis(4,7,10-tris(tert-butoxycarbonyl)-1,4,7,10-tetraazacyclododecan-
1-yl)-1,3,5-triazin-2-ylamino)hexanoic acid 5 
Z-L-Tyr(tri-Boc-Cyc)-OBzl 4 (4.17 g, 3.0 mmol) was dissolved in EtOH (100 mL) and 
a spatula Tipp of 10% Pd/C was added. The reaction mixture was stirred in an autoclave 
under a hydrogen atmosphere at 10 bar pressure for 18 h. The catalyst was filtered off 
using celite and the filtrate was concentrated under vacuum. 5 (2.98 g, 2.56 mmol, 85 
%) was obtained as a colourless solid and was subsequently used in the next step 
without further purification. 
 1H-NMR (300 MHz): δ = 1.41 (s, 36 H, Boc), 1.45 (s, 18 H, Boc), 1.54-1.72 (m, 4 H, 
LysCHCH2CH2CH2, LysCHCH2CH2CH2), 1.94-2.10 (m, 2 H, CH2-N), 3.17-3.91 (35 H, 
cylen, CH), 8.43 (bs, 2 H, NH2) 8.82-9.75 (bs, 1 H, OH); MS (ESI, DCM/MeOH): m/z 
(%) = 1157.1 (21) [MH+], 584.1 (100) [M+2H+]2+. 
 
10,10'-(6-(5-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-5-carboxypentylamino)-
1,3,5-triazine-2,4-diyl)diaza-1,4,7-triazoniacyclododecane-1,4,7-triium 7 
Fmoc-L-Tyr(tri-Boc-bis-Cyc)-OH 6 (620 mg, 0.45 mmol) was dissolved in MeOH, 
treated with trifluoroacetic acid (38 mmol) and stirred at room temperature for 24 h. The 
volatile compounds were removed under vacuum affording the fully deprotected 
compound as a white solid in sufficient purity for use in subsequent step. 1H-NMR (300 
MHz, MeOD): δ = 1.24-1.38 (m, 1 H), 1.44-1.82  (m, 3 H), 1.86-2.04 (m, 1 H), 2.95-
3.43 (m, 35 H), 4.12-4.25 (m, 3 H), 4.29-4.40 (m, 1 H), 7.25-7.34 (m, 2 H), 7.35-7.44 
(m, 2 H), 7.59-7.70 (m, 2 H), 7.80 (d, 2 H, 3J = 7.7 Hz) 
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2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-6-(bis(pyridin-2-
ylmethyl)amino)hexanoic acid 9** 
DIPEA (131 mg, 1.02 mmol) was added to a suspension of Fmoc-L-Lys(HCl)-OH (405 
mg, 1.00 mol) in 15 mL DCM. 2-Pyridinecarboxaldehyde (307 mg, 2.87 mmol) was 
added and the resulting mixture was stirred for 15 min. Sodium triacetoxyborohydride 
(890 mg, 4.20 mmol) was added and the resulting cloudy yellow solution was stirred 
for 90 h at ambient temperature under a nitrogen atmosphere. The organic phase was 
separated and the aqueous phase was extracted 3 times with chloroform/isopropanol 
3:1. The organic phases were combined and washed with brine then dried with MgSO4. 
The solvent was removed under reduced pressure to give brown oil which was purified 
by column chromatography on silica gel (7:3 chloroform/methanol). Concentration of 
the appropriate fractions gave the dipyridylmethyl derivative of Fmoc-L-lysine 9 as a 
colourless solid (465 mg, 85%). mp: 79 °C; 1H NMR (300 MHz, d6-DMSO): δ = 8.45 
(d, 3J = 4.1, 2 H, aryl), 7.90-7.83 (m, 2 H, aryl), 7.74-7.64 (m, 4 H, aryl), 7.51-7.46 (m, 
2 H, aryl), 7.42-7.35 (m, 2 H, aryl), 7.30-7.17 (m, 4 H, aryl), 6.93 (bs, 1 H, OH), 6.40 
(bs, 1 H, N-H), 4.33-4.16 (m, 3 H, CH, CH2), 3.83-3.65 (m, 4 H, 2x CH2), 2.43-2.36 
(m, 2 H, CH2), 1.70-1.16 (m, 6 H, 3x CH2); MS (ESI, CH2Cl2/MeOH + NH4Ac): e/z 
(%) = 551.5 (100) [MH+]; HRMS (C33H34N4O4) calculated 551.2658 found 551.2653 ± 
0.96 ppm. 
 
Fmoc-bpa-CuCl2 10b 
To the SAAC 9 (466 mg, 0.85 mmol) in 50 mL MeOH was added a solution of 
NiC4H6O4 · 4 H2O (210 mg, 0.85 mmol) in 20 ml H20 and the resulting solution was 
stirred over night. The MeOH was removed under vacuum and the remaining aqueous 
solution was lyophilized yielding 10b as a green solid in quantitative yield.  mp: 
decomposition > 200 °C; [a]20D =  -26.0° (c = 0.008 in MeOH); IR (KBr disk): ν~  [cm-
1] = 3423, 3080, 2939, 1713, 1603, 1442, 1410, 762; MS (ESI, H2O/MeOH): m/z (%) = 
612.1 (100) [Fmoc-BPA-Cu2+ - H+]+, 648.1 (30) [Fmoc-BPA-Cu2+ + Cl-]+, 1261.5 (10) 
[2Fmoc-BPA-Cu2+ + Cl- - 2H+]+, 1223.5 (6) [2Fmoc-BPA-Cu2+ - 3H+]+. 
 
                                                 
** The compound was synthesized according to a similar, at that time unpublished procedure of Dr. Kate 
Jolliffe from the University of Sydney, Australia and was later published: Levada, M. K.; Banerjee, S. R.; 
Maresca, K. P.; Babich, J. W.; Zubieta, J.  Synthesis 2004, 11, 1759-1766. 
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Fmoc-bpa-Ni(ac)2 10c 
To the SAAC 9 (466 mg, 0.85 mmol) in 50 mL MeOH was added a solution of 
NiC4H6O4 · 4H2O (210 mg, 0.85 mmol) in 20 ml H20 and the resulting solution was 
stirred over night. The MeOH was removed under vacuum and the remaining aqueous 
solution was lyophilized yielding 10c as a green solid in quantitative yield. mp: 
decomposition > 200 °C; [a]20D =  -26.0° (c = 0.008 in MeOH); IR (KBr disk): ν~  [cm-
1] = 3423, 3080, 2939, 1713, 1603, 1442, 1410, 762; MS (ESI, H2O/MeOH): m/z (%) = 
607 (100) [Fmoc-BPA-Ni2+ - H+]+. 
 
3-{3,5-Bis[(bis-pyridin-2-ylmethyl-amino)methyl]-4-hydroxyphenyl}-2-(tert-
butoxycarbonylamino)propionic acid methyl ester 11†† 
Boc-L-Tyr-OMe (300 mg, 1.02 mmol) and 1 M HCl (0.25 mL) were added to a 
suspension of paraformaldehyde (100 mg, 3.35 mmol) and 2, 2´-dipicolylamine (508 
mg, 2.55 mmol) in ethanol (2.0 mL) and water (6.0 mL). The solution was refluxed for 
36 hours, then cooled to room temperature and neutralized with Na2CO3. The neutral 
product was extracted into chloroform, dried with magnesium sulphate, and the solvent 
was evaporated to yield a yellow oil. The crude compound was purified by silica gel 
column (eluent: EtOH/EtOAc = 1:1, Rf = 0.41) to give 11 as a yellow solid (377 mg, 
0.53 mmol, 52 %). 1H-NMR (300 MHz, CDCl3): δ = 1.32 (s, 9 H, H-Boc), 2.86-3.02 
(m, 2 H, CH2Tyr), 3.61 (s, 3 H, OCH3), 3.79 (s, 4 H, Tyr-CH2N), 3.88 (s, 8 H, Pyr-CH2-
N), 5.23 (m, 1 H, CHCH2Tyr), 7.01 (s, 2 H, Tyr-aryl), 7.09-7.16 (m, 4 H, pyr), 7.48 (d, 
4 H, J = 8.0), 7.56-7.64 (m, 4 H, Pyr), 8.46-8.64 (m, 4 H, Pyr); MS (ESI, 
DCM/MeCN/H2O + 10 mmol/L TFA) : m/z (%) = 718.4 (100) [M+2H+]2+, 359.8 (31) 
[MH+], 331.8 (23) [M+2H+-C4H8]2+. 
 
3-{3,5-Bis[(bis-pyridin-2-ylmethyl-amino)methyl]-4-hydroxyphenyl}-2-(tert-
butoxycarbonylamino)propanoic acid 12 
Lithium hydroxide (25.2 mg, 1.05 mmol) was dissolved in water (5 mL) and added 
dropwise to a solution of 11 (0.50 g, 0.70 mmol) in water/methanol (25 %, 50 mL). The 
                                                 
†† Sun, L.; Burkitt, M.; Tamm, M.; Raymond, M. K.; Abrahamsson, M.; LeGourrierec, D.; Frapart, Y.; 
Magnuson, A.; Kenez, P. H.; Brandt, P.; Tran, A.; Hammarstroem, L.; Styring, S.; Aakermark, B. J. Am. 
Chem. Soc. 1999, 121, 6834-6842. Jiang, H.; O'Neil, E. J.; DiVittorio, K. M.; Smith, B. D. Org. Lett. 
2005, 7, 3013-3016. 
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mixture was stirred at room temperature for 12 h. The solvent was removed under 
reduced pressure and the residue was redissolved in water. The pH value was adjusted 
to 5 by NaH2PO4 · H2O and the product was extracted in DCM. The organic layer was 
washed with brine, dried over anhydrous magnesium sulphate and concentrated under 
reduced pressure to obtain 12 as white solid (471 mg, 0.67 mmoL, 95 %). 1H-NMR 
(600 MHz, d6-DMSO, HSQC, HMBC): δ = 1.18 (bs, 9 H, Boc), 2.73 (dd, 2J = 13.8 Hz, 
3J = 10.0 Hz, 1 H, TyrCHCH2), 2.91 (dd, 2J = 14.0 Hz3J = 4.5 Hz, 1, H, TyrCHCH2), 
3.66 (s, 4 H, TyrCH2N), 3.76 (s, 8 H ,Pyr-CH2-N), 4.08-4.11 (m, 1 H, TyrCH), 6.96 (d, 
3J = 8.6 Hz, 1 H, NH), 7.07 (s, 2 H, CH-phenol), 7.21-7.24 (4 H, pyr), 7.44 (d, 4 H, 3J = 
7.8 Hz, pyr), 7.68-7.71 (m, 4 H, pyr), 8.47-8.48 (m, 4 H, pyr); 13C-NMR (151 MHz, d6-
DMSO, HSQC, HMBC): δ = 28.0 (+, 3 C, Boc), 35.9−, CH2), 54.0 (−, 2 C, CH2), 55.2 
(+, CH), 58.8 (−, 4 C, CH2), 77.8 (Cquat, Boc), 122.2 (+, 4 C, CH), 122.8 (+, 4 C, CH), 
123.2 (Cquat, 2 C), 127.2 (Cquat, 1 C), 129.8 (+, 2 C, CH), 136.6 (+, 4 C, CH), 148.6 (+, 4 
C, CH), 154.0 (Cquat, 1 C), 155.3 (Cquat, carbamate), 158.5 (Cquat, 4 C), 173.7 (Cquat, 
acid); IR (KBr disk): ν~  [cm-1] = 3256, 3057, 3008, 2974, 2927, 2821, 1706, 1672, 
1592, 1478, 1434, 1365, 1290, 1250; MS (ESI, MeCN/TFA): m/z (%) = 704.4 (100) 
[MH+], 352.8 (10) [M+2H+]2+. 
 
2-Amino-3-3,5-bis{[bis(pyridin-2-ylmethyl)amino]methyl}-4-hydroxyphenyl-
propanoic acid 13 
To an ice cooled solution of 12 (340 mg, 0.48 mmol) in DCM (50 mL) was added 
dropwise a HCl saturated Et2O-solution. The suspension was stirred for 30 min at 0°C 
and the organic phase was evaporated by stirring the solution over night at room 
temperature. The residue was taken up in water and lyophilized. Product 13 (520 mg) 
was obtained as a white solid in quantitative yield. 1H-NMR (600 MHz, d6-DMSO, 
HSQC, HMBC): δ = 3.08-2.98 (m, 2 H, TyrCHCH2), 3.77 (bs, 4 H, TyrCH2N), 4.14-
4.17 (m, 1 H, TyrCH), 4.29 (bs, 8 H, Pyr-CH2-N), 7.16 (s, 2 H, CH-phenol), 7.84 (t, 3J 
= 6.6 Hz, 4 H, pyr), 8.10 (d, 3J = 8.1 Hz, 4 H, pyr), (8.39-8.42 (m, 4 H, pyr), 8.77 (d, 3J 
= 4.8 Hz, 4 H, pyr); 13C-NMR (151 MHz, d6-DMSO, HSQC, HMBC): δ =  34.5 (−, 
CH2), 53.1 (+, CH), 53.3 (−, 2 C, CH2), 55.2 (−, 4 C, CH2), 123.2 (Cquat, 2 C), 125.6 (+, 
4 C, CH), 126.2 (Cquat, 1 C), 126.8 (+, 4 C, CH), 132.7 (+, 2 C, CH), 142.3 (+, 4 C, CH), 
144.9 (+, 4 C, CH), 152.8 (Cquat, 1 C), 153.5 (Cquat, 4 C), 170.3 (Cquat, acid); IR (KBr 
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disk): ν~  [cm-1] = 3056, 2926, 1734, 1615, 1528, 1463, 1288, 1227, 767; MS (ESI, 
H2O/MeCN): m/z (%) = 604.4 (100) [MH+], 302.8 (17) [M+2H+]2+, 626.4 (5) [MNa+]. 
Bis-bpa-Zn(NO3)-complex 15a 
The free ligand 14 (150 mg, 0.18 mmol) was dissolved in methanol (20 mL). To this 
solution, Zn(NO3)2 (108 mg, 0.36 mmol) in 10 mL H2O was added and the mixture was 
stirred at room temperature for 1 h. Methanol was then removed under reduced pressure 
and the remaining aqueous solution was lyophilized to give the desired zinc coordinated 
complex 15a as a white solid in quantitative yield (209 mg). mp: decomposition > 200 
°C; IR (KBr disk): ν~  [cm-1] = 3428, 2924, 2855, 2426, 1707, 1609, 1477, 1441, 1384, 
764; MS (ESI, H2O/MeCN): m/z (%) = 507.3 (100) [K3+ + CH3COO-]2+, 1010.3 (27) 
[K3+ - H+ + CH3COO-]+, 1070.3 (10) [K3+ + 2CH3COO-]+. 
 
Deprotected peptide 23 
Peptide 22 was dissolved in MeOH and cooled to 0 °C in an ice bath. To the solution 
HCl saturated ether (0.7 mL/mmol Boc-group) was added. The mixture was allowed to 
warm to room temperature and was stirred over night. The solvent was evaporated. The 
volatile compounds were removed under vacuum affording the fully deprotected 
compound as a white solid in sufficient purity for use in subsequent step. MS (ESI, 
MeCN/TFA): e/z (%) = 425.8 (100) [(M + 2H+)]2+, 284.2 (36) [(M + 3H+)]3+, 850.7 
(17) [MH+]. 
 
Peptide complex 24 
Peptide 23 was dissolved in H2O and LiOH was added until the pH value was slightly 
basic (pH 8). To this solution was added 2 equivalents of Zn(ClO4)2 and the mixture 
was stirred at 80°C over night. Liophilization gave peptide complex 24 as a white solid. 
MS (ESI, H2O/MeOH + NH4OAc): e/z (%) = 505.9 (100) [M4+ - H+ + Cl-]2+, 517.9 (75) 
[M4+ - H+ + CH3COO-]2+, 537.9 (60) [M4+ - H+ + ClO4-]2+, 487.8 [M4+ - 2H+]2+. 
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2. Modulation of the Ras-Effector Interaction by Structure Activity 
Relationship (SAR) Approach – Synthesis of a Hybridreceptor*  
 
 
Graphical Abstract: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, the methodology of − solid phase synthesis of metal-complex containing 
peptides − described in chapter 1 was successfully applied to the preparation of 
bidentate receptor ligand and its ZnII- and CuII-complexes respectively. The SAR 
approach is used to guide the phosphate-binding bpa-derived metal-complex unit 
exclusively to the location of Ser39 close to γ-phosphate of RAS proteins due to the 
known and expected binding location of the pentapetide the Ras.  
                                                 
* All analytical measurements were performed by Ina Rosnizeck, Institute for Biophysics and Physical 
Biochemistry, University of Regensburg. 
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2.1 Introduction 
 
The discovery of modulators of protein-protein interaction is an emerging field in drug 
design. One promising but still challenging approach in drug discovery is the direct 
protein-protein interaction by small molecules as it is demonstrated for the p53-MDM2 
interaction.1 Another mechanism in drug discovery is the stabilization of the inactive 
conformer of a protein by small molecules that is physically regulated by autoinhibition 
as for example for the neutral Wiskott-Aldrichsyndrome protein (N-WASP).2 Kalbitzer 
et al. reported a novel principle where a stabilization of the very small population of 
excited states is influenced by the activity of small molecules.3 When proteins require 
different conformations for their biological function, all these functional states have to 
coexist simultaneously in solution. However, the Gibbs free energy differences between 
the different states are rather high and thus the conformation with the lowest energy 
predominates in solution. However, the minor populated states with higher energy 
(excited states) can be stabilized as Kalbitzer stabilized the weak binding state of Ras-
Mg2+-GppNHp with Zn2+-cyclen which should decrease the affinity of Ras to its main 
effector Raf. Unfortunately, the affinity of Zn2+-cyclen is only in the milimolar 
concentration range. For an inhibitor of protein-protein interaction, the binding to an 
excited state of the protein should be stronger, at least in the micromolar to nonomolar 
concentration range. This encouraged us to search on the one hand for further metal 
complexes which will have a higher affinity to the weak effector binding state (state 1) 
in oncogenic variants of Ras. On the other hand, as a second binding site, peptide 
sequences were chosen from potentially peptide sequences of Ras binding proteins 
(SOS) and their binding (affinity and location) were examined. The overall strategy was 
to combine the two binding sites following the SAR strategy to enhance the binding to 
Ras-Mg2+-GppNHp and hence interrupt Ras-Raf interaction. 
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2.2 Results and discussion 
 
Binding of (substituted) bispicolylamine amine (bpa) metal-complexes to the different 
states of Ras in the complex with GppNHp 
31P NMR spectroscopy represents a method to identify compounds which preferentially 
bind to the “weak binding” conformation of activated Ras, the state 1, since the two 
conformational states of Ras can be directly observed by this method.4  In collaboration 
with the group of H.R. Kalbitzer, it could be shown by 31P NMR titration experiments 
that the metal-bpa (Figure 1) selectively binds to state 1 of Ras. 
 
N
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N N
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N
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1: M = Cu
2: M = Zn
3: M = Cu
4: M = Zn  
Figure 1. Structures of different metal-bpa complexes. Cu2+-bpa 1, Zn2+-bpa 2, Cu2+-
Fmoc-lys(bpa)-OH 3, Zn2+-Fmoc-lys(bpa)-OH 4. 
 
Binding of selected peptide sequences to the different states of Ras in the complex with 
GppNHp 
A series of modified peptide sequences derived from the Ras interaction site of the Ras 
regulating protein (SOS)5 was synthesized and the binding to Ras was evaluated by 1H-
15N-HSQC titration experiments. Chemical shift mapping on the protein gave 
information about the localization of interaction between protein and ligand. Peptide 5 
was found to bind in the expected region of the Ras. 
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Figure 3. Structures of synthesized peptides with potential affinity to the Ras protein. 
 
 
 
Design and synthesis of a hybridreceptor 
The binding position of the peptide sequence 5 at Tyr64 and the position of Zn-bpa 2 at 
Ser39 close to γ-phosphate were examined using a crystal structure of the Ras. To 
combine these two binding sites, a distance between 23 and 25 Å has to be bridged. 
This linking part of the hybridreceptor was designed to be i) easy to synthesize, ii) 
flexible in its nature and iii) and offer a free carboxylic acid terminus as well as a Fmoc-
protected amino terminus for assembling to the N-terminus of the pentapeptide 5 still 
bound to a resin using solid-phase peptide synthesis (SPPS). As a linker with an 
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appropriate length of 24 Å and distinct requirements compound 13 (Figure 4) was 
selected.  
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Figure 4. Linker design with an appropriate length of about 24 Å. 
 
A retrosynthetic analysis of the hybridreceptor and in particular of the linker is given in 
Scheme 5.  
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Scheme 5. Retrosynthetic analysis of hybrid receptors 16 and 17. 
 
The hybrid receptor is composed of three units which where planed to be assembled on 
solid-phase. Compound 13 was prepared in solution in order to avoid the need of large 
excesses of compounds 10 and 11 if the linker would be prepared using SPPS. 
Unfortunately, the mono protection of the dicarboxylic acid 9 using 1 equivalent of t-
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BuOH, 1.5 equivalents of EDC and 0.1 equivalent of DMAP in dichloromethane 
following a description of a patent was not successful.6 Direct condensation of the 
diacid 9 with the Fmoc protected diamine 11 using standard solution peptide coupling 
conditions resulted in a complicated mixture of compounds and in a rather low yield of 
the desired linker precursor 12. Therefore the linker 13 was also assembled in form of 
its two constituent parts 9 and 11 on solid-phase (Scheme 6). After purification of the 
hybrid receptor-ligand 15 by preparative HPLC, the bpa-function was complexed in 
solution with either ZnCl2 or CuCl2 to obtain the metal-complexed hybrid receptors 16 
and 17. 
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Scheme  6. Synthesis of the hybrid receptor-ligand 15 on solid-phase. 
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2.3 Conclusion and outlook 
 
Substituted ZnII- and CuII-bispicolylamine complexes were synthesized and indentified 
as a new class of coordination compounds that bind with high affinity to the Ras-bound 
nucleotide. In parallel, short peptide sequences derived from known complexes with 
Ras were synthesized and the affinity and binding sites on the Ras-surface was 
evaluated by co-workers of the Kalbitzer group. The methodology of − solid phase 
synthesis of metal-complex containing peptides − described in chapter 1 was 
successfully applied to the preparation of bidentate receptor ligand and their ZnII- and 
CuII-complexes respectively.  
Currently, the superior expected affinities due to the combination of these two different 
binding sites of these metal-complexed hybrid receptors are analysed in the Department 
of Biophysics and Physical Biochemistry of H.R. Kalbitzer and in the working group 
for Protein-Interaction of C. Herrmann. Detailed NMR-investigation, isothermal 
titration calorimetry as well as fluorescence based assays are used for binding studies.  
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2.4 Experimental  
 
Bpa7 and Fmoc-Lys(bpa)-OH8 were prepared by literature known methods. 
 
General notes: 
With regard to NMR experiments of the metal-bpa complexes it was important to avoid 
even traces of uncomplexed metal-salts. Therefore, a slight excess of ligand was used in 
all complexation reactions and it was aspired to remove the excesses of free ligand after 
completion of the reactions by extensive washing procedures of insoluble metal 
complex in an organic solvent. Furthermore, metal salts and constituents of the linker 
were selected with respect to solubility in aqueous solution required for NMR 
experiments. 
 
Bpa-Cu2+ 1 
To a solution of bpa (50.0 mg, 0.25 mmol) in acetonitrile (20 mL) was added dropwise 
a solution of CuCl2 • 2 H2O (37.5 mg, 0.22 mmol) in methanol (5 mL). After a few 
minutes, the copper complex 1 was precipitated and the reaction was stirred for further 
30 min to complete the reaction. The product was filtered and washed 4 times with 
small amounts of cold acetonitrile. After drying under high vacuum, the pure product 1 
was obtained as a blue solid in quantitative yield (73 mg, 0.22 mmol). MS (ESI, 
H2O/MeOH + NH4OAc): e/z (%) = 320.9 (100) [M2+ + AcO-]+, 260.8 (70) [M2+ - H+]+, 
296.8 (13) [M2+ + Cl-]+, 199.9 (4) [bpa + H+]+. – Elemental analysis calcd. (%) for 
C12H13Cl2CuN3 (333.70): C 43.19, H 3.93, N 12.59; found C 43.19, H 3.97, N 12.70. 
 
Bpa-Zn2+ 2 
To a solution of bpa (50.0 mg, 0.25 mmol) in acetonitrile (20 mL) was added dropwise 
a solution of ZnCl2 (30.0 mg, 0.22 mmol) in methanol (5 mL). After a few minutes, the 
copper complex 2 was precipitated and the reaction was stirred for further 30 min to 
complete the reaction. The product was filtered and washed 4 times with acetonitrile to 
get rid of the small excess of the dpa ligand. After drying under high vacuum, the pure 
product 2 was obtained as a white solid in quantitative yield (73 mg, 0.22 mmol). MS 
(ESI, H2O/MeOH + NH4OAc): e/z (%) = 321.9 (100) [M2+ + AcO-]+, 297.8 (13) [M2+ + 
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Cl-]+, 199.9 (11) [bpa + H+]+. – Elemental analysis calcd. (%) for C12H13Cl2N3Zn 
(332.98): C 42.96, H 3.91, N 12.52; found C 42.30, H 3.98, N 12.34. 
 
 
Fmoc-Lys-(bpa-Cu2+)-OH 3 
To a solution of Fmoc-Lys(bpa)-OH (100 mg, 0.18 mmol) in  H2O (25 mL) was added 
dropwise a solution of CuCl2 • 2 H2O (24.5 mg, 0.18 mmol) in methanol (15 mL). After 
stirring the reaction mixture for 30 min at room temperature, the methanol was removed 
under vacuum and the remaining aqueous solution was lyophilized yielding complex 3 
as a blue solid in quantitative yield (117 mg, 0.18 mmol). MS (ESI, H2O/MeOH): m/z 
(%) = 612.1 (100) [M2+ - H+]+, 648.1 (30) [M2+ + Cl-]+, 1261.5 (10) [2M2+ + Cl- - 2H+]+, 
1223.5 (6) [2M-Cu2+ - 3H+]+. 
 
Fmoc-Lys-(bpa-Zn2+)-OH 4 
To a solution of Fmoc-Lys(bpa)-OH (100 mg, 0.18 mmol) in  H2O (25 mL) was added 
dropwise a solution of Zn(NO3)2 • 6 H2O (24.5 mg, 0.18 mmol) in H2O (10 mL). After 
stirring the reaction mixture for 30 min at room temperature, the aqueous solution was 
lyophilized yielding complex 4 as a white solid in quantitative yield (117 mg, 0.18 
mmol). 
 
General procedure for the synthesis of peptides 5 – 8  
Peptides 5 – 8 were synthesized on an Advanced Chemtech 496 MOS synthesizer. Rink 
Amide MBHA resin (0.72 mmol/g) and Fmoc-SPPS strategy were used throughout all 
syntheses. Coupling was achieved by TBTU/HOBt activation and DIPEA was used as 
the base. HOBt was used as a 0.45 M solution, TBTU as a 0.44 M solution and DIPEA 
as a 1.2 M solution, all in DMF. The Fmoc protected amino acids were dissolved in 
NMP as 0.4 M solutions. All peptides were synthesized on 50 mg resin and two 
coupling cycles were performed. Prior to coupling, the resin was allowed to preswell in 
DMF for 30 min. Fmoc cleavage was brought about through the addition of 40 % (v/v) 
piperidine-DMF solution and shaking for 3 min followed by the addition of a 20 % (v/v) 
piperidine-DMF solution and shaking for 10 min. The solution was drained of, the 
deprotected resin bound peptide was washed 6 times with DMF and subsequently 
 114
coupled to the next Fmoc protected amino acid. Cleavage from the solid support was 
performed using a TFA cocktail containing TFA/TIS/H2O (90:5:5 v/v/v) for 3 hours. In 
order to precipitate the peptide, cold Et2O was added and the resulting heterogeneous 
solution centrifuged for 10 min at -4°C. The supernatant was decanted and the resulting 
pellet was washed with colt Et2O. This procedure was repeated several times before the 
precipitate was dissolved in water and lyophilized. The peptides were analysed by ES-
MS and HPLC-MS. Peptides 5 and 6 were purified by HPLC. As the yield of the 
peptides synthesized on the Advanced Chemtech 496 MOS synthesizer were not 
satisfied due to the occurrence of several fragments of the sequences, the amino acid 
sequence 20 for the hybrid receptor-ligand was synthesized manually using syringe 
technique and methodologies developed before.9 
 
Leu-Gly-Gly-Ile-Arg-NH2 5 
Peptide 5 was synthesized following the general procedure. MS (ESI, AcN/TFA): e/z 
(%) = 257.6 (100) [M2+ + 2H+]2+, 514.4 (16) MH+. 
 
Ala-Arg-Thr-Leu-Ile-Val-Ala-NH2 6 
Peptide 6 was synthesized following the general procedure. MS (ESI, 
MeOH/AcN/TFA): e/z (%) = 371.8 (100) [M2+ + 2H+]2+, 742.6 (47) MH+.  
 
Hybridreceptor ligand 15 
The synthesis was performed manually in a 10 mL syringe equipped with porous filter 
using Fmoc protected Rink amide MBHA resin 18 (200 mg, subst.: 0.72 mmol/g). Rink 
amide MBHA resin 18 was added to a frit-syringe, suspended in DMF and allowed to 
swell for 30 min. Prior to the first amino acid coupling the cleavage of the Fmoc-group 
was brought about through the addition of 40 % (v/v) piperidine-DMF solution and 
shaking for 3 min followed by the addition of a 20 % (v/v) piperidine-DMF solution and 
shaking for 10 min. The solution was drained off and the deprotected resin was washed 
6 times with DMF. Fmoc protected amino acids (5 eq) arginine, iso-leucine, 2x glycine 
and leucine were coupled by HOBt/TBTU activation and DIPEA in NMP/DMF. More 
precisely, after the amino acids were dissolved in 5 equivalents of a 0.45 M HOBt-
solution in DMF/NMP (4:1), 5 equivalents of a 0.44 M TBTU solution in DMF/NMP 
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(4:1) and 10-fold excess of DIPEA as a 1.2 M solution in NMP were added in 
succession. The syringe was subsequently shaken for each 120 min when coupling 
Fmoc-Arg as the first amino acid to the resin and when iso-leucine was coupled to the 
resin-bound bulky and polar arginine 19. In case of Fmoc protected glycines and 
leucine, the syringe was shaken for 40 min. All coupling steps where carried out twice. 
Fmoc-deprotection and washing cycles as outlined above were performed after each 
coupling step. Two times 10 equivalents were used to couple 3,6,9-
trioxaundecandisäure 9 to the resin bound amino acid sequence 20 in addition with the 
appropriate amount of coupling reagents. After shaking (2x 150 min), 5 equivalents of 
each HOBt-and TBTU-solutions were added to the resin-bound sequence 21 followed 
by the addition of 2[2-(Fmoc-amino)ethoxy]ethylamine hydrochloride 11 in a 1.2 M 
solution of DIPEA in NMP. The syringe was subsequently shaken (2x 120 min) and 
Fmoc-deprotection and washing cycles as outlined above were performed. Two times 5 
equivalents were used to couple SAAC 14 to the resin-bound sequence 22 in addition 
with the appropriate amount of coupling reagents. After shaking (2x 150 min) the N-
terminus was deprotected by piperidine-DMF solution and the final resin-bound 
hybridreceptor-ligand 23 was washed 4 times each with DMF, DCM and Et2O. 
Cleavage from the solid support was performed using a TFA cocktail containing 
TFA/TIS/H2O (90:5:5 v/v/v) for 3 hours. In order to precipitate the peptide, cold Et2O 
was added and the resulting heterogeneous solution centrifuged for 10 min at -4°C. The 
supernatant was decanted and the resulting pellet was washed with colt Et2O. This 
procedure was repeated several times before the precipitate was dissolved in water and 
lyophilized. The crude product was purified by preparative HPLC to obtain pure hybrid 
receptor ligand 15. MS (ESI, AcN/TFA): e/z (%) = 372.4 (100) [M + 3H+]3+, 558.1 (38) 
[M + 2H+]2+, 1114.8 (2) MH+. For copies of 1H-NMR and 13C-NMR spectra, see 
supporting information.      
 
Copper(II)-hybrid receptor 16 
To a solution of hybrid receptor-ligand 15 (15 mg, 13.5 µmol) in 10 mL H2O was added 
1 mL of a 12.1 mM solution of CuCl2 • 2 H2O (2.1 mg, 12.1 µmol) in MeOH and the 
resulting blue solution was stirred at room temperature over night. MeOH was removed 
under vacuum and the remaining aqueous solution was lyophilized yielding 17 mg of 16 
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as a blue solid in quantitative yield. MS (ESI, AcN/H2O): e/z (%) = 392.7 (100) [M2+ + 
H+]3+, 588.7 (20) M2+, 606.5 (10) [M2+ + TFA]2+, 606.5 (8) [M2+ + HCl]2+. 
 
Zn2+-hybridreceptor 17 
To a solution of hybridreceptor-ligand 15 (7 mg, 6.3 µmol) in 5 mL H2O was added 1 
mL of a 5.7 mM solution of ZnCl2 (0.77 mg, 5.7 µmol) in H2O and the solution was 
stirred at room temperature over night. The aqueous solution was lyophilized yielding 8 
mg of 17 as a white solid in quantitative yield. MS (ESI, AcN/H2O + 10 mmol/L 
NH4OAc): e/z (%) = 598.0 (100) M2+, 558.0 (91) [L + 2H+]2+, 608.0 (37) [M2+ + 
HCl]2+, 393.1 (31) [M2+ + H+]3+, 619.0 (30) [M2+ + HOAc]2+, 646.0 (26) [M2+ + TFA]2+, 
372.4 (5) [L + 3H+]3+. 
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3. Enhancing the Separation of Phosphorylated Proteins in Gel 
Electrophoresis with Dinuclear Bispyridylmethylamine-Tyrosine-
Acrylamide Complexes* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter is reported the facile preparation of phosphate bonding ligands from the 
amino acid tyrosine, formation of its zinc(II) and manganese(II) complexes and their 
use as mobility shift additive for the detection of phosphorylated proteins in SDA-
PAGE gel electrophoresis. 
 
 
 
 
 
                                                 
* This chapter is aimed at publishing: G. Dirscherl, M. Schwab, W. Seufert, B. König, in preparation. 
SDS-PAGE gel electrophoreses were performed by Dr. M. Schwab, Institute of Biochemistry, Genetic 
and Microbiology. 
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3.1 Introduction 
 
Post-translational modification of proteins by phosphorylation is fundamental for the 
regulation of biological processes, such as signal transduction, apoptosis, proliferation, 
differentiation and metabolism, in all living organisms.1 Phosphorylation occurs on 
different amino acid residues. In eukaryotic cells, the hydroxyl groups of serine, 
threonine and tyrosine are phosphorylated.2 Incorrect protein phosphorylation can cause 
severe disorders including cancer and neuropathogenesis. Methods for determining the 
phosphorylation status of proteins are thus very important for a better understanding of 
the molecular origin of diseases and biological and pathological processes. Historically, 
phosphorylation detection methods relay on either radioisotopes or phosphoamino acid-
selective antibodies. More recently, specific dyes for phosphorylation detection in 
arrays,3 biosensors for kinase activity4 and artificial phosphoprotein sensors based on 
dinuclear Zn25+ or Zn24+ metal complexes (Scheme 1) have been described.  
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Scheme 1. Hamachi´s (top left) and Koike´s (top right) phosphate-binding dinuclear 
metal complexes 1 and 2; polymerizable additives for the detection of phosphorylated 
proteins by mobility shift in gel electrophoresis: Phos-tagTM 3 (bottom left), a tyrosine-
based ligand 4 (bottom right) 
 
Koike et al. combined the specific reversible coordination of metal complexes to 
phosphorylated protein surfaces with SDS-PAGE gel electrophoresis, the standard 
biochemical technique for protein separation and analysis. A derivative 3 (called Phos-
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tagTM by the authors, Scheme 1) of their hydroxyl-bis-DPA (dipicolylamine) ligand 
bearing a polymerizable acryl amide moiety was immobilized within the 
polyacrylamide gel and subsequently complexed by zinc(II) or magnesium(II) ions.5 In 
aqueous solution, the di-zinc(II) phos-tag complex strongly binds to phenyl phosphate 
(Kd = 2.5 • 10-8 mol/L) under physiological conditions whereas at pH > 9, the binding 
ability decreases. The dinuclear manganese(II) phos-tag complex captures R-OPO32- 
anions preferentially, such as phosphoserine and phosphortyrosine at alkaline pH of ca. 
9.6 Such modified gels retain phosphorylated proteins stronger than corresponding non-
phosphorylated proteins in SDS-PAGE gel electrophoresis which allows for their 
mobility shift detection. 7,8 
However, the preparation of compound 3 requires a multistep protocol.9 In this chapter 
is reported the facile preparation of ligand 4 from the amino acid tyrosine, formation of 
its zinc(II) and manganese(II) complexes and their use as mobility shift additive for the 
detection of phosphorylated proteins in SDA-PAGE gel electrophoresis. 
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3.2 Results and discussion 
 
The twofold Mannich reaction of Boc-Tyr-OMe 5-Boc, dpa 6 and paraformaldehyde 
provides ligand 7-Boc according to a literature known procedure in 51% yield.10 The 
Boc protecting group is removed by treatment with HCl saturated ether and the crude 
product reacted with acrylchloride to give the target acrylamide-pendant ligand 4 in 
overall good yield. 
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Scheme 2. Synthesis of acrylamide-pendant ligand 4 in three steps from protected 
tyrosine 
 
For some applications a modification of the acryl amide position may be desirable. 
Using 5-Cbz as starting material, the analogous protected ligand 7-Cbz is obtained from 
twofold Mannich reaction in the same yield. Saponification of the methyl ester with 
LiOH gave compound 9, which was reacted with mono Boc-protected 
diethylenediamine under standard peptide coupling conditions to give amide 11-Boc. 
Boc-deprotection and reaction with acrylic acid chloride gave ligand 12 in good overall 
yield. The ligand is converted into the di-manganese(II) or di-zinc(II) complex by 
treatment with the respective chloride salt in aqueous methanol solution. 
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Scheme 3. Synthesis of acrylamide-pendant ligand 12 and its di-manganese (12-Mn) 
and di-zinc (12-Zn) complexes 
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The ability of the compounds to specifically retain phosphorylated proteins was 
investigated in SDS-PAGE polyacrylamide gel electrophoresis, which was conducted 
according to Laemmli´s method.11 Either acrylamide-pendant ligands 4 or 12 with two 
equivalents of MnCl2 or the metal complexes 12-Mn or 12-Zn were added in different 
amounts to the acryl amide mixture before polymerisation of the separation gel. While 
there was no significant difference if the ligand was used in polymerization and its 
complex was formed subsequently or the metal complex was directly used in gel 
preparation, clearly only the manganese(II) complex led to retardation of 
phosphorylated proteins. For direct comparison, unphosphorylated trypsinogen was not 
affected whereas α-casein was dephosphorylated by treatment with λ-protein 
phosphatise and analysed by SDS-PAGE with and without the addition of 100µM of 
12-Mn to the acryl amide gel. Figure 1 clearly shows the stronger retardation of the 
phosphorylated α-casein in the presence of 12-Mn in the gel. To investigate if the 
observed mobility change is caused by masking the phosphate charges or by altered 
interactions of the phosphorylated protein with the polymeric gel structure, complex 12-
Mn and or other coordination compounds (see supporting information for data) were 
added to the protein sample to be analyzed. After incubation the sample was subjected 
to standard SDS-PAGE gel electrophoresis. Even up to concentrations of 100 µM of 
added metal complex no mobility shift was detected in SDS-PAGE. This clearly shows 
that it is necessary to immobilize the metal complex phosphate binding during gel 
preparation. 
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Figure 1. Specific mobility shift of phosphorylated α-casein compared to 
dephosphorylated α-casein in a gel containing 12-Mn. 
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3.3 Conclusion 
 
Complex 12-Mn was successfully utilized as a gel additive to increase phosphate 
affinity in SDS-PAGE. The modified gel showed a distinct mobility shift of 
phosphorylated α-casein in comparison to the dephosphorylated protein. The stranger 
retention is caused by reversible interactions of the proteins phosphate groups with the 
metal complex binding sites immobilized in the gel. The investigated zinc(II) 
complexes were not able to induce specific mobility shifts. Overall, an easily accessible 
polymer additive as ligand or metal complex was synthesized, which allows the 
preparation of SDS-PAGE gels with enhanced resolution of phosphorylated versus non-
phosphorylated proteins. If compared to the previously reported compounds, the facile 
synthetic modification of ligands 4 and 12 and the use as preformed di-manganese(II) 
complex 12-Mn may be advantageous for specific tasks in bioseparation. 
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3.4 Experimental 
 
Compounds 6,12 7-Cbz,10 and 10,13 were prepared by literature known methods. 
 
Cbz-L-Tyr 3-[3,5-bis (2,2´-dipicolylamine)methyl]-OMe (7-Cbz): 1 M HCl (5.0 mL) 
and Cbz-L-Tyr-OMe 5-Cbz (6.59 g, 20.0 mmol) were added to a suspension of 
paraformaldehyde (1.97 g) and 2, 2´-dipicolylamine (9.85 g, 49.4 mmol) in ethanol (40 
mL) and water (120 mL). The solution was refluxed for 36 h, then cooled to room 
temperature and neutralized with Na2CO3. The crude product was extracted with 
chloroform, the organic phase was dried over magnesium sulphate, and the solvent was 
evaporated to yield a yellow oil. The crude compound was purified by silica gel column 
(EtOH/EtOAc = 1:1, Rf = 0.51) to give 7-Cbz as a yellow oil (7.9 g, 10.5 mmol, 53 %). 
[a]20D = -3.7° (c = 0.007 in MeOH); 1H NMR (600 MHz, CDCl3) δ = 11.04 (s, 1 H, 
OH), 8.52 (d, 3JH,H = 4.12, 4 H, H-11), 7.60-7.55 (m, 4 H, H-13), 7.46-7.41 (m, 4 H, H-
14), 7.30-7.25 (m, 3 H, H-Cbz), 7.23-7.20 (m, 2 H, H-Cbz), 7.13-7.08 (m, 4 H, H-12), 
7.01 (s, 2 H, H-3, H-7), 5.64 (d, 3JH,H = 8.23, 1 H, N-H), 5.05-4.94 (m, 2 H, CH2-Ph), 
4.63-4.55 (m, 1 H, H-0), 3.86 (s, 8 H, H-9), 3.76 (s, 4 H, H-8), 3.64 (s, 3 H, OMe), 3.07-
2.94 (m, 2 H, H-1); 13C-NMR (600 MHz, CDCl3): δ = 37.4 (−, C-1), 52.2 (+, Me), 54.7 
(−, C-8), 55.1 (+, C-0), 59.6 (−, C-9), 66.8 (−, C-CH2-Ph), 122.0 (+, C-12), 123.1 (+. C-
14), 125.4 (+, C-4/6), 128.0 (+, C-Ph), 128.4 (+, C-Ph), 130.2 (−, C-7), 136.6 (+, C-13), 
148.9 (+, C-11), 155.1 (Cquat, C-5), 155.8 (Cquat, Cbz-ester), 159.0 (Cquat, C-pyridine), 
172.3 (Cquat, methyl-ester); IR (neat): ν~  [cm-1] =  3057, 2951, 2824, 1716, 1690, 1591, 
1475, 1434, 1200, 1124, 1150, 1001, 752; MS (ES-MS, CH2Cl2/MeOH +  10 mmol/L 
NH4Ac): e/z (%) = 752.5 (100) [MH+]; HR-MS calcd. for C44H46N7O5 [MH+]: 
752.3560, found: 752.3572 ± 1.54 ppm. 
 
Acrylamido-L-Tyr 3-[3,5-bis (2,2´-dipicolylamine)methyl]-OMe (4): 7-Boc (570 mg, 
0.79 mmol) was dissolved in MeOH (20 mL) and cooled to 0 °C using an ice bath. To 
this mixture 5 mL of an HCl saturated Et2O-solution was added and the mixture was 
allowed to warm to room temperature and stirred over night. The reaction progress was 
monitored by 1H-NMR. The reaction mixture was concentrated under reduced pressure 
and the residue was taken up in water and lyophilized to give compound 8-HCl (520 
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mg) as white solid in quantitative yield which was subsequently used in the next step 
without purification. 
To a solution of 8-HCl (300 mg, 0.42 mmol) in H2O (20 mL) was added NaHCO3 in 
small portions until the solution was slightly alkaline. The solution was cooled to 0°C 
with an ice-bath and a solution of acryl chloride (38 mg, 0.42 mmol) in 
dichloromethane (20 mL) was added dropwise. After stirring the reaction mixture for 15 
min at 0°C, the reaction was stirred for an additional 1 h at room temperature. The 
organic layer was separated, washed with H2O (3 x 10 mL) and dried over MgSO4. The 
solvent was evaporated and the crude product purifiied using on flash-silica gel 
(CHCl3:MeOH = 95:5, Rf = 0.05) yielding 4 (242 mg, 0.36 mmol, 86 %) as a white 
solid, m.p. = 63°C; [a]20D = +21.0° (c = 0.006 in CHCl3); IR (neat): ν~  [cm-1] = 2984, 
2363, 1721, 1668, 1608, 1444, 1215, 745, 667, 632; MS (ES-MS, H2O/MeOH + 10 
mmol/L NH4Ac): e/z (%) = 403.7 (100) [M + 2H+]2+, 726.5 (98) [M + H]+, 749.5 (14) 
[M + Na]+.  
 
Benzyl 1-(2-acrylamidoethylamino)-3-(3,5-bis((bis(pyridin-2-
ylmethyl)amino)methyl)-4-hydroxyphenyl)-1-oxopropan-2-ylcarbamate (12): 
Compound 11-Boc (830 mg, 0.94 mmol) was dissolved in MeOH (20 mL) and cooled 
to 0 °C using an ice bath. To this mixture 6 mL of an HCl saturated Et2O-solution was 
added and the mixture was allowed to warm to room temperature and stirred over night. 
The reaction progress was monitored by 1H-NMR. The reaction mixture was 
concentrated under reduced pressure and the residue was taken up in water and 
lyophilized to obtain compound 11-HCl as white solid in quantitative yield which was 
subsequently used in the next step without purification. MS (ES, H2O/MeCN/TFA): m/z 
(%) = 390.9 (100) [M + 2H]2+, 780.5 (12) [M + H]+. 
To a solution of 11-HCl (973 mg, 0.94 mmol) in H2O (30 mL) was added NaHCO3 in 
small portions until the solution was slightly alkaline. The solution was cooled to 0°C 
with an ice-bath and a solution of acryl chloride (85 mg, 0.94 mmol) in 
dichloromethane (30 mL) was added dropwise. After stirring the reaction mixture for 15 
min. at 0°C, the reaction was stirred for an additional 1 h at room temperature. The 
organic layer was separated, washed with H2O (3 x 15 mL) and dried over MgSO4. The 
solvent was evaporated and the crude product purification using column 
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chromatography on flash-silica gel (CHCl3:MeOH = 95:5, Rf = 0.05) yielding 12 (536 
mg, 0.64 mmol, 68 %) as a white solid, m.p. = 58°C; [a]20D = +6.5° (c = 0.006 in 
MeOH); 1H-NMR (600 MHz, DMSO, DQF-COSY, HSQC, HMBC): δ = 2.62-2.73 (m, 
1 H, H-15A), 2.87-2.98 (m, 1 H, H-15B), 3.06-3.23 (m, 4 H, H-19, H-20), 3.65 (s, 4 H, 
H-7), 3.75 (s, 8 H, H-8), 4.11-4.26 (m, 1 H, H-16), 4.75-4.95 (m, 2 H, H-28), 5.56 (dd, 
3JH,H = 9.64, 2JH,H = 2.68, 1 H, H-24cis), 6.06 (dd, 3JH,H = 17.08, 2JH,H = 2.68, 1 H, H-
24trans), 6.17 (dd, 3JH,H = 17.08, 3JH,H = 9.64, 1 H, H-23), 7.03-7.13 (m, 3 H, H-31, H-
32), 7.14-7.28 (m, 8 H, H-12, H-30, H-3, H-5), 7.39 (d, 3JH,H = 8.45, 1 H, H-25), 7.46 
(d, 3JH,H = 7.68, 4 H, H-14), 7.60-7.77 (m, 4 H, H-13), 8.07 (t, 3JH,H = 4.48, 1 H, H-21), 
8.11 (t, 3JH,H = 4.48, 1 H, H-18), 8.48 (d, 3JH,H = 10.92, 4 H, H-11), 10.91 (s, 1 H, OH); 
13C-NMR (600 MHz, DMSO): δ = 37.1 (−, C-15), 38.3 (−, C-19/20), 38.4 (−, C-19/20), 
54.1 (−, C-7), 56.0 (+, C-16), 58.8 (−, C-8), 65.1 (−, C-28), 122.1 (+, C-12), 122.8 (+, 
C-14), 123.2 (Cquat, C-2/6), 125.1 (−, C-24), 127.3 (+, C-31), 127.5 (Cquat, C-4), 128.1 
(+, C-30), 128.2 (+, C-32), 129.9 (+, C-3/5), 131.7 (+, C-23), 136.6 (+, C-13), 136.9 
(Cquat, C-29), 148.7 (+, C-1), 154.0 (Cquat, C-1), 155.8 (Cquat, C-26), 155.8 (Cquat, C-9), 
164.8 (Cquat, C-22), 171.7 (Cquat, C-17); IR (neat): ν~  [cm-1] = 3060, 2928, 1715, 1659, 
1591, 1535, 1476, 1433, 1234, 1048, 995, 753; MS (ES, MeCN/TFA): m/z (%) = 834.5 
(10) [M + H]+, 417.8 (100) [M + 2H]2+; HR-MS calcd. for C48H52N9O5 [MH+]: 
834.4091, found: 834.4077 ± 1.73 ppm. 
 
Compound 11-Boc: LiOH (35.9 mg, 1.50 mmol) was dissolved in H2O (5 mL) and 
added dropwise to a solution of 7-Cbz in water/methanol (25 %, 50 mL). The mixture 
was stirred at room temperature for 12 h. The completion of the reaction was monitored 
by 1H-NMR. After the methanol was evaporated, the suspension was neutralized with a 
saturated NH4Cl solution and extracted 3 times with dichloromethane. The combined 
organic layers were dried over anhydrous magnesium sulphate and concentrated under 
reduced pressure. Compound 9 was obtained as a yellow solid (494 mg, 0.67 mmol) in 
quantitative yield and was subsequently used in the next step without purification. 
To a solution of 9 (146 mg, 0.20 mmol) and HOBt • H2O (37 mg, 0.24 mmol) in DMF 
(20 mL) were added EDC (32.7 µL, 0.24 mmol) and tert-butyl 2-aminoethylcarbamate 
10 (38.5 mg, 0.24 mmol) in DMF (5 mL) and the reaction was stirred for 1 h at room 
temperature and over night at 60°C. The solvent was removed in vacuum, the residue 
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was dissolved in dichloromethane (30 mL) and extracted with H2O (3x 20 mL). 
Purification of the crude product using column chromatography on flash-silica gel 
(CHCl3:MeOH = 95:5, Rf = 0.05) gave 11-Boc (144 mg, 0.16 mmol, 83 %) as a 
colourless oil. [a]20D = +10.7° (c = 0.007 in MeOH); 1H-NMR (600 MHz, DMSO, 
DQF-COSY, HSQC, HMBC): δ = 1.24 (s, 9 H, Boc), 2.58-2.71 (m, 1 H, H-15A), 2.81-
2.97 (m, 3 H, H-15B, H-20), 2.99-3.13 (m, 2 H, H-19), 3.71 (s, 4 H, H-7), 3.81 (s, 8 H, 
H-8), 4.08-4.24 (m, 1 H, H-16), 4.78-4.90 (m, 2 H, H-28), 6.63-6.78 (m, 1 H, H-21), 
7.02-7.13 (m, 3 H, H-31, H-32), 7.14-7.30 (m, 8 H, H-12, H-30, H-3, H-5), 7.34 (d, 
3JH,H = 8.86, 1 H, H-25), 7.43 (d, 3JH,H = 7.83, 4 H, H-14), 7.63-7.78 (m, 4 H, H-13), 
7.95-8.09 (m, 1 H, H-18), 8.52-8.55 (m, 4 H, H-11); 13C-NMR (600 MHz, DMSO): δ = 
28.2 (+, Boc), 37.1 (−, C-15), 38.8 (−, C-19/20), 38.9 (−, C-19/20), 54.2 (−, C-7), 56.3 
(+, C-16), 58.5 (−, C-8), 65.1 (−, C-28), 77.6 (Cquat, Boc), 122.3 (+, C-12), 122.9 (+, C-
14), 127.3 (+, C-Ph), 127.4 (+, C-Ph), 127.5 (Cquat, C-2/6), 128.1 (−, C-2/6, C4), 130.3 
(+, C-3/5), 136.7 (+, C-13), 136.9 (Cquat, C-29), 148.6 (+, C-1), 154.1 (Cquat, C-1), 155.5 
(Cquat, C-26/27), 155.71 (Cquat, C-26/27), 157.8 (Cquat, C-9), 162.3 (Cquat, C-22), 171.5 
(Cquat, C-17); IR (neat): ν~  [cm-1] = 3273, 2932, 1703, 1671, 1591, 1531, 1476, 1365, 
1250, 1169, 1049, 1026, 1005, 623; MS (ES, CH2Cl2/MeCN/TFA): m/z (%) = 440.8 
(100) [M + 2H+]2+, 880.6 (38) [MH+]; HR-MS calcd. for C50H59N9O6 [MH+]: 880.4510, 
found: 880.4524 ± 1.58 ppm. 
 
Complex 12-Mn 
To a solution of compound 12 (50 mg, 0.06 mmol) in H2O (15 mL) was added dropwise 
a solution of MnCl2 • 4 H2O (23.7 mg, 0.12 mmol) in methanol (5 mL). After stirring 
the reaction mixture for 30 min at room temperature, the methanol was removed under 
vacuum and the remaining aqueous solution was lyophilized yielding complex 12-Mn 
as a white solid in quantitative yield, decomposition > 95 °C; [a]20D = +6.7° (c = 0.003 
in MeOH); IR (neat): ν~  [cm-1] = 3279, 3057, 2928, 1657, 1602, 1535, 1472, 1433, 
1244, 1014, 760; MS (ES-MS, MeOH + 10 mmol/L NH4Ac): e/z (%) = 1060.3 (100) 
[M3+ + 2CH3COO-]+, 500.8 (32) [M3+ + CH3COO-]2+. 
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Complex 12-Zn 
To a solution of compound 12 (50.0 mg, 0.06 mmol) in H2O (15 mL) was added 
dropwise a solution of ZnCl2 (16.4 mg, 0.12 mmol) in methanol (5 mL). After stirring 
the reaction mixture for 30 min at room temperature, the methanol was removed under 
vacuum and the remaining aqueous solution was lyophilized yielding complex 12-Zn as 
a white solid in quantitative yield, decomposition > 135 °C; [a]20D = -13.7° (c = 0.004 in 
MeOH); IR (neat): ν~  [cm-1] = 3285, 3081, 2933, 1710, 1659, 1608, 1538, 1441, 1247, 
1053, 1024, 763; MS (ES-MS, H2O/MeOH + 10 mmol/L NH4Ac): e/z (%) = 1078.3 
(100) [M3+ + 2CH3COO-]+, 509.8 (44) [M3+ + CH3COO-]2+, 1000.3 (16)  [M3+ + 2OH-]+. 
 
Compound 14 
To a solution of compound 7-Cbz (100 mg, 0.13 mmol) in H2O (25 mL) was added 
dropwise a solution of MnCl2 • 4 H2O (52.6 mg, 0.27 mmol) in methanol (5 mL). After 
stirring the reaction mixture for 30 min at room temperature, the methanol was removed 
under vacuum and the remaining aqueous solution was lyophilized yielding complex 14 
as a white solid in quantitative yield, decomposition > 110 °C; [a]20D = +6.6° (c = 0.003 
in MeOH); IR (neat): ν~  [cm-1] = 3346, 2952, 1687, 1603, 1473, 1434, 1293, 1265, 
1201, 1156, 1051, 758, 642; MS (ES-MS, H2O/MeOH + 10 mmol/L NH4Ac): e/z (%) = 
752.5 (100) [M3+ + 2CH3COO-]+. 
 
Compound 15 
To a solution of compound 7-Cbz (100.0 mg, 0.13 mmol) in H2O (25 mL) was added 
dropwise a solution of ZnCl2 (36.3 mg, 0.27 mmol) in methanol (5 mL). After stirring 
the reaction mixture for 30 min at room temperature, the methanol was removed under 
vacuum and the remaining aqueous solution was lyophilized yielding complex 15 as a 
white solid in quantitative yield, decomposition > 103 °C; [a]20D = -6.2° (c = 0.004 in 
MeOH); IR (neat): ν~  [cm-1] = 3259, 3053, 2927, 1715, 1661, 1592, 1331, 1476, 1433, 
1243, 1050, 759; MS (ES-MS, H2O/MeOH + 10 mmol/L NH4Ac): e/z (%) = 996.2 
(100) [M3+ + 2CH3COO-]+, 470.3 (3) [M3+ + CH3COO-]2+. 
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SDS-PAGE gel electrophoresis conditions: 
 
Untreated or phosphatase-treated proteins (2 µg each) were separated by SDS-PAGE 
and stained with RAPID Stain solution. 
Phosphatase treatment: 
100 µg protein + 500U λ-protein phosphatase (New England Biolabs) in 50 mM 
HEPES, pH 7.5, 5 mM DTT, 2 mM MnCl2. Incubation for 1h at 30°C (without 
phosphatase, incubation only in buffer for 1h 30°C). 
Reaction stopped by addition of 2x LSB (Laemmli sample buffer) and boiling for 
10min. 
Gels: 11% MnCl2 or additionally 50 µM of Mn2+-complex 14. 
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4. Synthesis of a Heterocyclic Ansa Pyrrol Amino Acid * 
 
 
 
 
 
Graphical Abstract   
 
 
 
 
 
 
 
 
 
 
 
In this chapter is reported the synthesis of a planar-chiral amino acid, in which the ansa-
bridge is formed by an olefin ring closing metathesis. 
 
 
 
 
 
                                                 
* This chapter is aimed at publishing: G. Dirscherl, P. Rooshenas, P.R. Schreiner, F. Lamaty, B. König, in 
preparation.  
Synthetic work was partially carried out during research periods at the University of Montpellier II, 
France.  Energy barrier calculations were performed by P. Rooshenas, Institute of Organic Chemistry, 
University of Giessen, Germany. 
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4.1 Introduction 
 
Planar chirality can be described as a form of chirality originating from a helix. In 
addition, the terms “stereogenic center”, “axis” and “plane” are accepted. Thus, a chiral 
plane can be described as a planar arrangement of at least four atoms with a fifth or 
more centres placed outside of this plane.1 A “chiral plane” arises therefore from the 
chirality resulting from the arrangement of out-of-plane groups with respect to a 
reference plane.2 Structural studies of molecules possessing an element of planar 
chirality started in the 1940s with the synthesis and resolution of 1,12-
dioxa[12]paracyclophane as the first chiral “ansa” compound.3 Lüttringhaus was the 
first who realized and correctly predicted the possible existence of enantiomeric ansa 
compounds.4 
Compounds with planar chirality are found among ηn-olefinmetal5 and ηn-arenemetal 
complexes,6 cyclophanes7 and ansa compounds8. Although many of such planar chiral 
molecules have been synthesized, only one example of an amino acid with planar 
chirality exists, to the best of our knowledge. Pelter et al. prepared homochiral amino 
acids, where the chirality depends solely on the chirality of the [2.2]paracyclophane 
unit.9 However, MOPAC calculation of simple peptides derived from this amino acid 
showed, that due to the close proximity of the amino and carboxyl groups, the chain was 
distorted, so that there was no hydrogen bonding between the second carbonyl and 
amide NH groups.10 
We report here the synthesis of a planar-chiral amino acid, in which the ansa-bridge is 
formed by an olefin ring closing metathesis. Scheme 1 shows the general structure of 
the target heterocyclic amino acids 1 with planar chirality and the intended synthetic 
strategy consisting of ring closing metathesis (RCM) of suitable dienes 2 in the presence 
of Grubbs´ catalyst and the preparation of dienes from sulfinyl imines. RCM is an 
appropriate method for the synthesis of macrocycles11 and is also employed as a key 
step for the synthesis of cyclophane derivatives.12 The successful RCM to a 13-
membered ring was reported in the synthesis of the macrotricyclic core of roseophilin 
6.13 The formation of the rather strained ansa-chain in this target molecule was 
supported by conformational control in the precursor bringing the alkene moieties closer 
together and lowering the enthalpic barrier during ring-formation. 
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To allow resolution of enantiomers in planar chirality, the energy barrier of rotation 
must be high enough. Optimization on the target structures 1 using B31yp/6-31G and 
either CGST- or GIAO-method with B31yp/6-311G revealed, that the ansa-bridge of a 
compound with m = 3 and n = 3 should exhibit sufficient stability, due to the restricted 
aromatic ring flip.Therefore no racemisation within the range of thermal stability of the 
compound is expected.14 Studies by König15 on the influence of substitution on the 
rotational energy barrier of structurally related planar chiral cyclophanes 7 using 
dynamic enantioselective gas chromatography and computer simulation support our 
estimation for compound 1: All substituents of compounds 7 were found to be too bulky 
to permit a rotation of the arene at the experimental conditions (133-145°C). 
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Scheme 1. Top: Retrosynthetic analysis of the target heterocylic amino acids 1 with 
planar chirality. Bottom: Roseophilin 6 and planar chiral cyclophanes 7. 
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4.2 Results and discussion 
 
In earlier studies, we have prepared hydroxypyrrole amino acids (HOPAS)16 and 
incorporated them into small peptides with hairpin structures.17 The heterocyclic amino 
acid is a dipeptide mimic and shows a peptide ß-sheet hydrogen bonding pattern. The 
chemistry of the HOPAS dipeptide mimic was extended by palladium catalysed 
allylation reaction, which allowed introducing a quaternary chiral center.18 We now use 
the dipeptide mimic skeleton in the synthesis of a suitable precursor molecule for RCM.  
Ethyl 3-hydroxy-4-methyl-pyrrole-2-carboxylate 8 was prepared as starting material in 
three steps according to a literature procedure.19 The first alkene functionality was 
introduced by alkylation of the hydroxyl group (Scheme 2). Williamson ether synthesis 
gave alkenyloxy pyrrole derivatives 9 – 11 in 61-85 % yield, using KBBB2 BBBCOBBB3 BBB as base and 
DMF as solvent. Next, pyrrole-aldehydes 12 – 14 were prepared by Vilsmeier-Haack 
formylation of 9 – 11 and obtained crystalline in 73-84 % yield. 
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8  9: n = 2, 61 %
10: n = 3, 85 %
11: n = 4, 63 %
12: n = 2, 73 %
13: n = 3, 84 %
14: n = 4, 75 %  
Scheme 2. Synthesis of pyrrole-aldehydes 12 – 14 
 
N-Sulfinyl imines are versatile intermediates in the asymmetric synthesis of chiral 
amines. Ellman and co-workers have employed Lewis acidic dehydrating agents 
MgSO4, CuSO4 and Ti(OEt)4 (2 eq) for the condensations of (R)-tert-butanesulfinamide 
(15) with aldehydes.20 Recently, the formation of sulfinimines by the catalytic action of 
Yb(OTf)3 was achieved and reaction conditions extended to Ellman´s sulfinyl imines.21 
The different conditions were tested on pyrrole aldehyde 13, giving best results with 
Ti(OEt)4 to afford the (R)-N-tert-butanesulfinyl aldimines 16 – 18  in excellent yields 
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(Table 1). The structure of compound 17 was confirmed by an X-ray structure analysis 
(Figure 1). 
 
Table 1. Synthesis of N-tert-butanesulfinyl aldimines 16 – 18 exploring Lewis acidic 
dehydrating agents CuSO4, Ti(OEt)4 and Yb(OTf)3. 
S
O
NH2+N
H
OEt
O
O
O
n
N
H
OEt
O
N
O
n
S
O
Lewis acid
solvent, rt
16: n = 2
17: n = 3
18: n = 4
12: n = 2
13: n = 3
14: n = 4
15
 
Entry Aldehyde Lewis Acid Solvent Product Yield (%) 
1 13 CuSO4 CH2Cl2 17 36 
2 13 Yb(OTf)3 THF 17 0 
3 13 Ti(OEt)4 CH2Cl2 17 100 
4 12 Ti(OEt)4 CH2Cl2 16 92 
5 14 Ti(OEt)4 CH2Cl2 18 91 
 
 
Figure 1. Structure of compound 17 in the solid state 
 
A series of dienes with different chain length was prepared via nucleophilic addition of 
Grignard reagents to imines 16 – 18. The nucleophilic additions of organomagnesium 
reagents to sulfinyl imines have been explored in detail by Ellman, Tang and others.22 
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General protocols are described for the addition of alkyl and aryl Grignard reagents to 
N-sulfinyl aldimines with high diastereoselectivity and good yields. Typically, about 
two equivalents of Grignard reagents are added at -78 or -48 °C to the N-sulfinyl imines 
to achieve addition, but in our case no nucleophilic addition of the organomagnesium 
reagents to the sulfinyl imine occurred in different solvents (THF toluene, diethyl ether, 
dichloromethane), even if the reaction temperature was allowed to reach room 
temperature. Starting material was recovered in all attempts. Only if the reaction 
mixture was heated to 50 °C nucleophilic addition occurred. The addition products were 
isolated in moderate to good chemical yields and syn:anti ratios of 9:1 (Table 2). 
 
Table 2. Addition of unsaturated Grignard reagents to N-sulfinyl imines 16 – 18 
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50°C
3 h
Et2O/THF
19: n = 2, m = 2
20: n = 2, m = 3
21: n = 2, m = 4
22: n = 3, m = 2
23: n = 3, m = 3
24: n = 3, m = 4
25: n = 4, m = 2
26: n = 4, m = 3
27: n = 4, m = 4
16: n = 2
17: n = 3
18: n = 4
 
Entry Product Imine Yielda 
(%) 
Diastereomeric 
ratiob 
(syn:anti) 
1 19 16 61 91:9 
2 20 16 63 93:7 
3 21 16 64 91:9 
4 22 17 68 90:10 
5 23 17 71 90:10 
6 24 17 65 93:7 
7 25 18 68 94:6 
8 26 18 50 91:9 
9 27 18 72 94:6 
a Yields were determined by mass balance of purified material. 
b Ratios of diastereomers were determined by 1H NMR or HPLC analysis. 
 
Ring closing diene metathesis has been applied in the synthesis of medium size rings (9 
to 21-membered ring macrocycles), but yields and optimal conditions (choice of 
catalyst; solvent) vary and are still difficult to predict.23 Therefore, the series of dienes 
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19 – 2724 with different side chain lengths (Table 2) were reacted with different 
catalysts. High dilution was used to avoid polymerization via acyclic diene metathesis. 
Commercially available Grubbs´ I, Grubbs´ II and 2nd generation Hoveyda-Grubbs´25 
catalysts were tested in dry and degassed dichloromethane and toluene.  
The outcome of the RCM reactions was monitored by TLC, mass spectrometry and 
HPLC-MS analyses. Only a small fraction of all tested dienes gave macrocyclic 
products and the best conditions were found using the Grubbs I catalyst (2 x 15 mol%) 
in high dilution conditions (0.0005 M) in dichloromethane. The formation of the 
expected macrocyclic structure, although in minor amounts, was indicated by HPLC 
and mass spectrometry for dienes 23-Boc, 24, 25, 26 and 27, but only for 23 the HPLC-
MS analysis confirmed sufficient product amounts for isolation. In the case of diene 23, 
beside the 13-membered ansa-compound 28, a 26-membered macrocycle 29 was 
obtained as a minor product.26 Both products were isolated by preparative HPLC and 
investigated in detail by NMR spectroscopy. Isomeric products resulting from the minor 
anti diastereomer of 23 were detected analytically, but the amount was too small for 
isolation. The intramolecular cyclization of compound 23 to macrocycle 28 (yield: 
47%) resulted in a 9:1 ratio of Z/E double bond isomers, inseparable by HPLC, 
favouring the Z-configuration.27 The observed coupling constant (J = 10.8 Hz) of the 
olefinic protons in the 1H-NMR spectrum confirms this assignment (see supporting 
information). The proton resonance in the open-chain precursor 23 has a chemical shift 
of δ = 5.86, while in the cyclic form this resonance is shifted downfield by ∆δ = 0.8 - 
0.6. The larger macrocyclic structure 29 (yield: 12%) was isolated as a mixture of 
stereoisomers (cis/trans double bonds; head to tail and head to head orientation). Under 
the reaction conditions and on standing the products loose their tert-butanesulfinamide 
group.  
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Scheme 3. Synthesis of 13-membered ansa-heterocyclic amino acid 28 by ring-closing 
olefin metathesis reaction of compound 23. 
 
The stereochemical analysis of the RCM reaction is hindered due to syn/anti-
diastereomers of the starting material, diene 23, and the formation of double bond E/Z 
isomers in the product. With the assumption that stable, non-interconverting 
atropisomers are formed, eight product stereoisomers are possible in total. However, the 
9:1 ratio of the syn/anti stereoisomers and the Z/E double bond isomers lead to 
significantly different amounts of the product isomers, even in the absence of any 
stereoinduction in the RCM. Therefore the detection of all minor compounds is difficult 
or even impossible.  
Detailed HPLC-MS analysis of compound 28 revealed four isomeric compounds: one 
major isomer, two minor isomers and one isomer in traces (see supporting information). 
The major isomer has 18-R, 14-S syn stereochemistry and Z-configuration of the 9,10-
double bond as determined by NMR (see supporting information). Using a chiral HPLC 
column, the major isomer peak splits into two peaks in a ratio of about three to one. 
This may indicate a stereochemical induction of the sulfinylamine and C-14 
stereocenters on the ring closing process.28 However, the overall large number of 
possible isomers and small amount of product available did not allow elucidating and 
assigning the absolute configuration of the product isomers. 
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4.3 Conclusion 
 
In conclusion, the synthetic route to ansa pyrrol amino acids is reported. The ansa-
bridge is formed by an olefin ring closing metathesis reaction of diene precursors in the 
presence of Grubbs I catalyst. Diene precursors were in turn prepared by Grignard 
addition to pyrrol sulfinyl imines. Only some of the dienes give macrocyclic ring 
closing products, as identified by HPLC-MS analyses and yield and selectivity of the 
ring closing reaction is low. Only in the case of the 13-membered compound 28 
sufficient material could be obtained by preparative HPLC separation to investigate its 
structure spectroscopically. Overall, the reported synthetic approach to ansa pyrrol 
amino acids is feasible, but suffers from poor efficiency of the ring closing metathesis 
reaction. 
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4.4 Experimental 
 
Ethyl 3-(but-3-enyloxy-1H-pyrrole-2-carboxylate (9) 
To a suspension of K2CO3 (364 mg, 2.63 mmol) in dry DMF (25 mL) was added ethyl 
3-hydroxy-4-methyl-pyrrole-2-carboxylate 8 (420 mg, 2.48 mmol). After the reaction 
mixture was stirred for 10 min at room temperature, 4-bromo-1-butene (282 µL, 2.63 
mmol) was added dropwise and the reaction was stirred for 40 h at 80°C. The reaction 
mixture was quenched with H2O (100 mL) and extracted 7 times with each 15 mL of 
CH2Cl2. The collected organic layer was washed with each 25 mL of 0.5 m NaOH, H2O 
und saturated KHSO4 and dried over MgSO4. The solvent was evaporated and the crude 
product purification using column chromatography on silica gel (PE:EtOAc = 8:2, Rf = 
0.37) yielding 9 (339 mg, 1.52 mmol, 61 %) as a colourless oil. 1H-NMR (300 MHz, 
CDCl3): δ = 1.35 (t, 3J = 7.1, 3 H, H-12), 1.96 (d, 4J = 0.8, 3 H, CH3), 2.49 (ddt, 3J = 
13.6, 3J = 6.8, 2J = 1.4, 2 H, H-7), 4.04 (t, 3J = 6.8, 2 H, H-6), 4.29 (q, 3J = 7.1, 2 H, H-
11), 5.00-5.19 (m, 2 H, H-9), 5.91 (ddt, 3J = 17.2, 3J = 10.3, 3J = 6.8, 1 H, H-8), 6.54 
(dd, 3J= 3.4, 4J = 0.7, 1 H, H-5), 9.03 (bs, 1H, NH); 13C-NMR (75 MHz, CDCl3): 
δ = 8.4 (+, CH3), 14.5 (+, C-12), 34.6 (−, C-7), 60.0 (−, C-11), 74.0 (−, C-6), 111.4 
(Cquat, C-2), 113.2 (Cquat, C-4), 116.5 (−, C-9), 119.7 (+, C-5), 134.9 (+, C-8), 149.8 
(Cquat, C-3), 160.7 (Cquat, C-10); IR (neat): ν~  [cm-1] = 3318, 3078, 2981, 2933, 2873, 
2744, 1668, 1285, 1028; MS (CI-MS, NH3): m/z (%) = 224.2 MH+ (100), 241.2 
[MNH4]+ (37); HR-MS calcd. for C12H17NO3 [M+●]: 223.1208; found: 223.1206 ± 0.6 
ppm. – C12H17NO3 (223.27). 
 
Ethyl 4-methyl-3-(pent-4-enyloxy)-1H-pyrrole-2-carboxylate (10) 
To a suspension of K2CO3 (1.62 g, 11.7 mmol) in dry DMF (75 mL) was added ethyl 3-
hydroxy-4-methyl-pyrrole-2-carboxylate 8 (1.80 g, 10.6 mmol). After the reaction 
mixture was stirred for 10 min at room temperature, 5-bromo-1-pentene (1.39 mL, 11.7 
mmol) was added dropwise and the reaction was stirred for 2 d at 80°C. The reaction 
mixture was quenched with H2O (400 mL) and extracted 7 times with each 50 mL of 
CH2Cl2. The collected organic layer was washed with each 100 mL of 0.5 m NaOH, 
H2O, saturated KHSO4 and dried over MgSO4. The solvent was evaporated and the 
crude product purification using column chromatography on silica gel (PE:EtOAc = 7:3, 
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Rf = 0.45) yielding 10 (2.14 g, 9.02 mmol, 85 %) as a colourless oil. 1H-NMR (600 
MHz, CDCl3): δ = 1.35 (t, 3J = 7.1, 3 H, H-13), 1.86 (m, 2 H, H-7), 1.99 (d, 4J = 0.8, 3 
H, CH3), 2.28 (m, 2 H, H-8), 4.02 (t, 3J = 6.5, 2 H, H-6), 4.31 (q, 3J = 7.4, 2 H, H-12), 
4.98 (ddt, 3J = 10.2, 3J = 2.0, 4J = 1.3, 1 H, H-10cis), 5.05 (ddt, 3J = 17.2, 3J  = 2.0, 4J = 
1.6, 1 H, H-10trans), 5.86 (ddt, 3J = 17.2, 3J = 10.2, 3J = 6.6, 1 H, H-9), 6.57 (dq, 3J = 
3.4, 4J = 0.8, 1 H, H-5), 8.58 (d, 3J = 3.4, 1 H, NH); 13C-NMR (150 MHz, CDCl3): 
δ = 8.5 (+, CH3), 14.5 (+, C-13), 29.4 (−, C-7), 30.2 (−, C-8), 60.0 (−, C-12), 74.2 (−, C-
6), 111.5 (Cquat, C-2), 113.3 (Cquat, C-4), 114.8 (−, C-10), 119.6 (+, C-5), 138.2 (+, C-9), 
149.9 (Cquat, C-3), 160.5 (Cquat, C-11); IR (neat): ν~  [cm-1] = 3318, 3076, 2979, 2938, 
2872, 2743, 1668 1285, 1029q1; MS (EI, 70 eV): m/z (%) = 237.1 (23) [M+●], 169.0 
(26) [M – C4H8]+● 123.0 (100) [M – C4H8 – C2H6O]+●; HR-MS calcd. for C13H19NO3 
[M+●]: 237.1369; found: 237.1363 ± 2.0 ppm. – C13H19NO3 (237.30). 
 
Ethyl 3-(hex-5-enyloxy)-4-methyl-1H-pyrrole-2-carboxylate (11) 
To a suspension of K2CO3 (491 mg, 3.55 mmol) in dry DMF (15 mL) was added Ethyl 
3-hydroxy-4-methyl-pyrrole-2-carboxylate 8 (600 mg, 3.55 mmol). After the reaction 
mixture was stirred for 10 min at room temperature, 6-bromo-1-hexene (460 µL, 3.55 
mmol) was added drop wise and the reaction was stirred for 40 h at 80°C. The reaction 
mixture was quenched with H2O (75 mL) and extracted 7 times with each 10 mL of 
CH2Cl2. The collected organic layer was washed with each 20 mL of 0.5 m NaOH, H2O 
und saturated KHSO4 and dried over MgSO4. The solvent was evaporated and the crude 
product purification using column chromatography on silica gel (PE:EtOAc = 8:2, Rf = 
0.40) yielding 6 (565 mg, 2.25 mmol, 63 %) as a colourless oil. 1H-NMR (300 MHz, 
CDCl3): δ = 1.28 (t, 3J = 7.1, 3 H, H-14), 1.46-1.58 (m, 2 H, H-8), 1.64-1.76 (m, 2 H, H-
7) 1.92 (d, 4J = 0.7, 3 H, CH3), 2.00-2.11 (m, 2 H, H-9), 3.94 (t, 3J = 6.5, 2 H, H-6), 4.25 
(q, 3J = 7.1, 2 H, H-13), 4.83-5.03 (m, 2 H, H-11), 5.76 (ddt, 3J = 17.0, 3J = 10.3, 3J = 
6.7,1 H, H-10), 6.50 (dd, 3J = 3.4, 4J = 0.7, 1 H, H-5), 8.82 (bs, 1H, NH); 13C-NMR (75 
MHz, CDCl3): δ = 7.5 (+, CH3), 13.5 (+, C-14), 24.3 (−, C-8), 28.7 (−, C-7), 32.6 (−, C-
9), 58.9 (−, C-13), 73.7 (−, C-6), 110.4 (Cquat, C-2), 112.2 (Cquat, C-4), 113.5 (−, C-11), 
118.8 (+, C-5), 137.7 (+, C-10), 149.0 (Cquat, C-3), 150.7 (Cquat, C-12); IR (neat): ν~  
[cm-1] = 3315, 2978, 2936, 2868, 1666, 1285, 1028; MS (EI, 70 eV): m/z (%) = 251.3 
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(11) [M+●], 169.2 (36) [M – C6H10]+●, 123.0 (100) [M – C6H10 – C2H6O]+●; HR-MS 
calcd. for C14H21NO3 [M+●]: 251.1521; found: 251.15 ± 0.9 ppm. – C14H21NO3 (251.32). 
 
Ethyl 3-(but-enyloxy)-5-formyl-4-methyl-1H-pyrrole-2-carboxylate (12) 
Compound 9 (220 mg, 0.99 mmol) in C2H4Cl2 (10 mL) was added dropwise to an ice 
cooled solution of DMF (85.5 µL, 1.10 mmol) and POCl3 (101 µL, 1.10 mmol) in 
C2H4Cl2 (10 mL), the mixture was stirred for 30 min, another 30 min at room 
temperature and was refluxed for 24 h. H2O (40 mL) and EtOAc (20 mL) were added to 
the cooled mixture and the aqueous layer was extracted 3 times with each 20 mL of 
EtOAc. The combined organic layers were washed 3 times with 10 % solution of 
Na2CO3 and dried over MgSO4. The solvent was evaporated and the crude product was 
purified using column chromatography on flash-silica gel (PE:EtOAc = 8:2, Rf = 0.21) 
yielding 12 (182 mg, 0.72 mmol, 73 %), as white crystals, m.p. = 62 °C; 1H-NMR (300 
MHz, CDCl3): δ = 1.34 (t, 3J = 7.1, 3 H, H-12), 2.23 (s, 3 H, CH3), 2.37-2.56 (m, 2 H, 
H-7), 4.03 (t, 3J = 6.7, 2 H, H-6), 4.32 (q, 3J = 7.1, 2 H, H-11), 4.92-5.24 (m, 2 H, H-9), 
5.72-6.06 (m, 1 H, H-8), 9.20 (bs, 1 H, NH), 9.69 (s, 1 H, CHO); 13C-NMR (300 MHz, 
CDCl3): δ = 6.9 (+, CH3), 14.3 (+, C-12), 34.5 (−, C-7), 61.1 (−, C-11), 74.5 (−, C-6), 
117.0 (−, C-11), 117.6 (Cquat, C-2), 122.6 (Cquat, C-4), 127.8 (Cquat, C-5), 134.5 (+, C-8), 
149.1 (Cquat, C-3), 159.6 (Cquat, C-10), 179.1 (+, CHO); IR (KBr): ν~  [cm-1] = 3442, 
3261, 2982, 2928, 2861, 2263, 1676, 1280, 1023; MS (EI, 70 eV): m/z (%) = 251.2 (26) 
[M+●], 151.1 (100) [M+● - ●NH-(S=O)(CH3)3]; HR-MS calcd. for C13H17NO4 [M+●]: 
251.1158; found: 251.1162 ± 1.6 ppm. 
 
Ethyl 5-formyl-4-methyl-3-(pent-4-enyloxy)-1H-pyrrole-2-carboxylate (13) 
Compound 10 (1.94 g, 8.15 mmol) in C2H4Cl2 (10 mL) was added dropwise to an ice 
cooled solution of  DMF (698 µL, 8.97 mmol) and POCl3 (821 µL, 8.97 mmol) in 
C2H4Cl2 (20 mL), the mixture was stirred for 30 min, another 30 min at room 
temperature and was refluxed for 24 h. H2O (80 mL) and EtOAc (40 mL) were added to 
the cooled mixture and the aqueous layer was extracted 3 times with each 70 mL 
EtOAc. The combined organic layers were washed 3 times with 10 % solution of 
Na2CO3 and dried over MgSO4. The solvent was evaporated and the crude product was 
purified using column chromatography on flash-silica gel (PE:EtOAc = 9:1, Rf = 0.40) 
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yielding 13 (1.82 g, 6.87 mmol, 84 %) as white crystals, m.p. = 49 °C; 1H-NMR (400 
MHz, CDCl3): δ = 1.34 (t, 3J = 7.2, 3 H, H-13), 1.83 (m, 2 H, H-7), 2.22 (m, 2 H, H-8), 
2.24 (s, 3 H, CH3), 3.98 (t, 3J = 6.5, 2 H, H-6), 4.34 (q, 3J = 7.2, 2 H, H-12), 4.96 (ddt, 
3J = 10.2, 3J = 2.0, 4J = 1.3, 1 H, H-10cis), 5.02 (ddt, 3J = 17.1, 3J = 2.0, 4J = 1.6, 1 H, H-
10trans), 5.82 (ddt, 3J = 17.1, 3J = 10.2, 3J = 6.6, 1 H, H-9), 9.55 (bs, 1 H, NH), 9.71 (s, 
1 H, CHO); 13C-NMR (100 MHz, CDCl3): δ= 7.0 (+, CH3), 14.3 (+, C-13), 29.3 (−, C-
7), 30.1 (−, C-8), 61.1 (−, C-12), 74.7 (−, C-6), 115.0 (+, C-10), 117.7 (Cquat, C-2), 
122.4 (Cquat, C-4), 128.0 (Cquat, C-5), 137.9 (+, C-9), 149.2 (Cquat, C-3), 160.5 (Cquat, C-
11), 179.4 (+, CHO); MS (CI, NH3): m/z (%) = 283.3 (100) [MNH4]+, 266.2 MH+ (57). 
– Elemental analysis calcd. (%) for C14H19NO4 (265.31): C 63.36, H 7.22, N 5.28; 
found C 63.16, H 7.57, N 5.21. 
 
Ethyl 5-formyl-3-(hex-5-enyloxy)-4-methyl-1H-pyrrole-2-carboxylate (14) 
Compound 11 (315 mg, 1.25 mmol) in C2H4Cl2 (10 mL) was added dropwise to an ice 
cooled solution of DMF (107 µL, 1.38 mmol) and POCl3 (125 µL, 8.97 mmol) in 
C2H4Cl2 (10 mL), the mixture was stirred for 30 min, another 30 min at room 
temperature and was refluxed for 24 h. H2O (40 mL) and EtOAc (20 mL) were added to 
the cooled mixture and the aqueous layer was extracted 3 times with 20 mL of EtOAc. 
The combined organic layers were washed 3 times with 10 % solution of Na2CO3 and 
dried over MgSO4. The solvent was evaporated and the crude product purification using 
column chromatography on flash-silica gel (PE:EtOAc = 9:1, Rf = 0.41) yielding 9 (265 
mg, 0.95 mmol, 75 %) as white crystals, m.p. = 48 °C; 1H-NMR (300 MHz, CDCl3): 
δ = 1.38 (t, 3J = 7.1, 3 H, H-14), 1.48-1.87 (m, 4 H, H-7 and H-8), 2.05-2.20 (m, 2 H, H-
9), 2.27 (s, 3 H, CH3), 4.01 (t, 3J = 6.6, 2 H, H-6), 4.36 (q, 3J = 7.1, 2 H, H-13), 4.90-
5.10 (m, 2 H, H-11), 5.72-5.93 (m, 1 H, H-10), 9.24 (bs, 1 H, NH), 9.73 (s, 1 H, CHO); 
13C-NMR (75 MHz, CDCl3): δ = 6.9 (+, CH3), 14.4 (+, C-14), 25.3 (−, C-8), 29.5 (−, C-
7), 33.5 (−, C-9), 61.1 (−, C-13), 75.3 (−, C-6), 114.7 (−, C-11), 117.6 (Cquat, C-2), 
122.5 (Cquat, C-4), 127.8 (Cquat, C-5), 138.5 (+, C-10), 149.3 (Cquat, C-3), 159.7 (Cquat, C-
12), 179.1 (+, CHO); IR (KBr): ν~  [cm-1] = 3447, 3268, 2979, 2940, 2867, 2362, 1672, 
1277, 1027; MS (EI, 70 eV): m/z (%) = 279.3 (5) [M+●], 197.1 (48) [M – C6H10]+●, 
151.1 (100) [M– C6H10 – C2H6O]+●; HR-MS calcd. for C15H21NO4 [M+●]: 279.1471; 
found: 279.1475 ± 1.9 ppm. – C15H21NO4 (279.34). 
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General procedure (GP1) for the synthesis of tert-butanesulfinyl imines  
To a solution of the pyrrol aldehyde (1.0 eq) and Ti(OEt)4 (2.0 eq) in dry 
dichloromethane (5 mL) was added (R)-tert-butanesulfinamide (1.2 eq) under 
dinitrogen, and the mixture was stirred at the given temperature and time. The reaction 
mixture was quenched with a mixture of saturated NH4Cl solution (10 mL) and brine 
(10 mL) while vigorously stirred. The resulting suspension was filtered through a plug 
of Celite and the filter cake was washed well with EtOAc (30 mL). The filtrate was 
transferred to a separatory funnel, where the organic layer was washed 3 times with 
each 10 mL of brine. The brine layer was extracted once with a small volume of EtOAc 
and the combined organic portions were dried over MgSO4, filtered and concentrated 
under vacuum. The sulfinyl imines were purified by silica gel chromatography if no 
other method is given. 
 
(R)-Ethyl 3-(but-3-enyloxy)-4-methyl-5-((2-methylpropan-2-ylsulfinamido)methyl)-
1H-pyrrole-2-carboxylate (16) 
Compound 12 (251 mg, 0.64 mmol), (R)-tert-butanesulfinamide (15, 93 mg, 0.77 
mmol) and Ti(OEt)4 (292 mg, 1.28 mmol) in dry dichloromethane (5 mL) were allowed 
to react according to the GP1 at room temperature for 36 hours yielding 152 mg (0.43 
mmol, 92 %, conversion corrected yield, 43 mg of starting material regained) of 16 
(Et2O: hexanes = 1:1; Rf = 0.22), as  colourless crystals, m.p = 81 °C; 1H-NMR (300 
MHz, CDCl3): δ = 1.25 (s, 9 H, tert-Bu), 1.40 (t, 3J = 7.1, 3 H, H-12), 2.21 (s, 3 H, 
CH3), 2.52-2.55 (m, 2 H, H-7), 4.06 (t, 3J = 6.8, 2 H, H-6), 4.39 (q, 3J = 7.1, H-11), 
5.09-5.21 (m, 2 H, H-9), 5.92-5.94 (m, 1 H, H-8), 8.47 (s, 1 H, CHN), 9.28 (bs, 1 H, 
NH); 13C-NMR (75 MHz, CDCl3): δ = 7.5 (+, CH3), 14.4 (+, C-12), 22.5 (+, tert-Bu), 
34.5 (−, C-7), 57.8 (+, tert-Bu), 60.9 (−, C-11), 74.4 (−, C-6), 116.1 (Cquat, C-2), 116.9 
(−, C-9), 120.2 (Cquat, C-4), 126.2 (Cquat, C-5), 134.5 (+, C-8), 149.5 (Cquat, C-3), 150.5 
(+, CHN), 160.1 (Cquat, C-10); IR (KBr): ν~  [cm-1] = 3447, 3256, 2980, 2959, 2926, 
2868, 1701,1593, 1272, 1059, 744; MS (FAB+): m/z (%) = 355 (100) [MH]+, 289 (43) 
[M - C4H8]+; HR-MS calcd. for C17H27N2O4S+: 355.1697; found: 355.1692 + 1.5 ppm. – 
C17H26N2O4S (354.46). 
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 (R)-Ethyl 4-methyl-5-[(2-methylpropan-2-ylsulfinamido)-methyl]-3-pent-4-
enyloxy-1H-pyrrole-2-carboxylate (17)  
Compound 13 (450 mg, 1.70 mmol), (R)-tert-butanesulfinamide (15, 247 mg, 2.04 
mmol) and Ti(OEt)4 (776 mg, 3.4 mmol) in dry dichloromethane were allowed to react 
according to the GP1 at 35°C for 48 hours yielding 625 mg (quantitative) of 17 (Et2O: 
hexanes = 1:1; Rf = 0.32), as  colourless crystals, m.p = 79 °C; 1H-NMR (400 MHz, 
CDCl3): δ = 1.24 (s, 9 H, tert-Bu), 1.39 (t, 3J= 7.1, 3 H, H-13), 1.80-1.93 (m, 2 H, H-7), 
2.20 (s, 3 H, CH3), 2.22-2.31 (m, 2 H, H-8), 4.01 (t, 3J = 6.5, 2 H, H-6), 4.37 (dq, 3J = 
7.1, 2J = 1,1, 2 H, H-12), 4.93-5.15 (m, 2 H, H-10), 5.86 (ddt, 3J = 17.0, 3J = 10.3, 3J = 
6.7, 1 H, H-9), 8.44 (s, 1 H, CHN), 9.11 (bs, 1 H, NH); 13C-NMR (100 MHz, CDCl3): 
δ = 7.4 (+, CH3), 14.4 (+, C-13), 22.6 (+, tert-Bu), 29.3 (−, C-7), 30.1 (−, C-8), 57.9 (+, 
tert-Bu), 60.9 (−, C-12), 74.7 (−, C-6), 115.0 (−, C-10), 116.2 (Cquat, C-2), 120.3 (Cquat, 
C-4), 126.2 (Cquat, C-5), 138.0 (+, C-9), 149.6 (Cquat, C-3), 150.3 (+, CHN), 160.1 (Cquat, 
C-11); IR (KBr): ν~  [cm-1] = 3437, 3227, 2980, 2935, 2869, 1693, 1265, 1057, 1025, 
746; MS (EI, 70 eV): m/z (%) = 368.2 (6) [M+●], 312.0 (100) [M – C4H8]+●. – Elemental 
analysis calcd. (%) for C18H28N2O4S (368.49): C 58.67, H 7.66, N 7.60; found C 58.61, 
H 7.68, N 7.31; Crystal data: C18H28N2O4S, Mr = 368.49, colourless flat prism, triclinic, 
space group P 1, a = 8.9068(9) Å, b = 10.5174(12) Å, c = 11.9303(12) Å, α = 
71.989(12) °, β = 84.932(12) °, γ = 70.971(13) °, Z = 2, V = 1004.7(2) Å3, Dx = 1.218 
mg/m3, µ = 0.184 mm-1, F(000) = 396, crystal size 0.44 x 0.30 x 0.12 mm, θ-range for 
data collections 2.35 to 26.82 °, index ranges –11 <= h <= 11, -13 <= k <= 13, -15 <= l 
<= 15, reflections collected/unique 10549/7803 [Rint = 0.0218], 
data/restraints/parameters 7803/3/461, goodness-of-fit on F2 0.993, final R indices 
[I>2σ(I)] R1 = 0.0278, wR2 = 0.0654 R indices (all data) R1 = 0.0307, wR2 = 0.0663, 
largest diff. peak and hole 0.328 and –0.136 e. Å-3. 
 
(R)-Ethyl 3-(hex-5-enyloxy)-4-methyl-5-((2-methylpropan-2-
ylsulfinamido)methyl)-1H-pyrrole-2-carboxylate (18) 
Compound 14 (240 mg, 0.86 mmol), (R)-tert-butanesulfinamide (15, 125 mg, 1.03 
mmol) and Ti(OEt)4 (392 mg, 1.72 mmol) in dry dichloromethane were allowed to react 
according to the GP1 at room temperature for 36 hours yielding 240 mg (92 %, 
conversion corrected yield, 48 mg of 14 regained) of 18 (Et2O: hexanes = 1:1; Rf = 
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0.22), as white crystals, m.p = 75 °C; 1H-NMR (300 MHz, CDCl3): δ = 1.26 (s, 9 H, 
tert-Bu), 1.40 (t, 3J = 7.1, 3 H, H-14), 1.57-1.62 (m, 2 H, H-8), 1.77-1.83 (m, 2 H, H-7), 
2.10-2.15 (m, 2 H, H-9), 2.21 (s, 3 H, CH3), 4.01 (t, 3J = 6.5, 2 H, H-6), 4.39 (q, 3J = 
7.1, 2 H, H-13), 4.96-5.07 (m, 2 H, H-11), 5.83-5.85 (m, 1 H, H-10), 8.46 (s, 1 H, 
CHN), 9.25 (bs, 1 H, NH); 13C-NMR (75 MHz, CDCl3): δ = 6.7 (+, CH3), 13.7 (+, C-
14), 21.8 (+, tert-Bu), 24.6 (−, C-8), 28.9 (−, C-7), 32.8 (−, C-9), 57.1 (+, tert-Bu), 60.2 
(−, C-13), 74.5 (−, C-6), 114.2 (−, C-11), 115.5 (Cquat, C-2), 119.6 (Cquat, C-4), 125.5 
(Cquat, C-5), 137.8 (+, C-10), 149.0 (Cquat, C-3), 149.7 (+, CHN), 159.4 (Cquat, C-12); IR 
(KBr): ν~  [cm-1] = 3445, 3120, 2989, 2939, 2866, 2701, 1693 1504, 1267, 1056,747; 
MS (FAB+): m/z (%) = 383 (100) [MH]+, 326 (40) [M+ - C4H8]+; HR-MS calcd. for 
C19H31N2O4S+: 382.2015; found: 383.2005 + 2.8 ppm. 
 
General Procedure (GP2) for the Grignard addition to N-tert-butansulfinyl imines. 
To a solution of the sulfinyl imine (1 eq) in THF, the appropriate Grignard reagent (2.5 
- 3.3 equiv.) in dry Et2O (5 ml) was added dropwise and the conversion was monitored 
by TLC. The reaction was stirred at 50 – 60°C for approximately 4 h. Upon reaction 
completion, the excess organometallic reagent was destroyed with sat. aqueous NH4Cl 
(10 mL) and the resulting suspension was diluted with brine (10 mL). The suspension 
was filtered through a plug of Celite and the filter cake was washed with EtOAc (2 x 10 
mL). The filtrate was transferred into a separatory funnel, the aqueous layer was washed 
with EtOAc (3 x 10 mL), organic layers were combined, dried over MgSO4 and 
concentrated to afford the crude product. Diastereomeric ratios were determined by 
HPLC analyses or by NMR of the crude product. Purification was performed by flash-
silica chromatography using Biotage SP4 chromatography system. Yields correspond to 
the mass balance of purified material.  
 
(R)-Ethyl 3-(but-3-enyloxy)-5-(1-(1,1-dimethylethylsulfinamido)pent-4-enyl)-4-
methyl-1H-pyrrole-2-carboxylate (19) 
Sulfinyl imine 16 (44 mg, 0.12 mmol) and but-3-enylmagnesium bromide (0.24 ml, 1.3 
M in Et2O, 0.3 mmol) were reacted according to the GP2. Flash-silica chromatography 
(Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) gave 30 mg (61%) 
of 19 in a diastereomeric syn/anti ratio of 91:9. The diastereomeric ratio was determined 
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by 1H NMR. 1H-NMR (300 MHz, CDCl3): δ = 1.18 (s, 9 H, (CH3)3), 1.31 (t, 3J = 7.1, 3 
H, H-12), 1.80-2.06 (m, 4 H, H-14, H-15), 1.90 (s, 3 H, CH3), 2.40-2.52 (m, 2 H, H-7), 
3.95-4.06 (m, 2 H, H-6), 4.20-4.32 (m, 2 H, H-11), 4.41-4.50 (m, 1 H, H-13), 4.90-5.16 
(m, 4 H, H-9, H-17), 5.71 (dddd, 3J = 16.9, 3J = 10.3, 3J = 6.5, 3J = 6.1, 1 H, H-8), 5.80-
5.96 (m, 1 H, H-16), 9.04 (bs, 1 H, N-H). 
 
(R)-Ethyl 3-(but-3-enyloxy)-5-(1-(1,1-dimethylethylsulfinamido)hex-5-enyl)-4-
methyl-1H-pyrrole-2-carboxylate (20) 
Sulfinyl imine 16 (32 mg, 0.09 mmol) and pent-4-enylmagnesium bromide (0.25 ml, 
0.94 M in Et2O, 0.23 mmol) were reacted according to the GP2. Flash-silica 
chromatography (Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) 
gave 24 mg (63%) of 20 in a diastereomeric syn/anti ratio of 93:7. The diastereomeric 
ratio was determined by 1H NMR. 1H-NMR (400 MHz, CDCl3): δ = 1.14 (s, 9 H, 
(CH3)3), 1.29 (t, 3J = 7.1, 3 H, H-12), 1.32-1.38 (m, 2 H, H-15), 1.88 (s, 3 H, CH3), 
1.92-2.01 (m, 2 H, H-16), 2.40-2.48 (m, 2 H, H-7), 3.99 (dt, 3J = 6.7, 2J = 2.3, 2 H, H-
6), 4.16-4.29 (m, 2 H, H-11), 4.40 (ddd, 3J = 7.3, 3J = 7.3, J = 1.6, 1 H, H-13), 4.83-5.24 
(m, 4 H, H-9, H-18), 5.65 (dddd, 3J = 17.0, 3J = 10.1, 3J = 6.8, 3J = 6.7, 1 H, H-8), 5.85 
(dddd, 3J = 17.1, 3J = 10.3, 3J = 6.8, 3J = 6.7, 1 H, H-17), 9.01 (bs, 1 H, N-H); 13C-NMR 
(100 MHz, CDCl3): δ = 7.5 (+, CH3), 14.5 (+, C-12), 22.6 (+, (CH3)3, 25.2 (−, C-15), 
33.2 (−, C-14), 34.6 (−, C-16), 35.5 (−, C-7), 52.1 (+, C-13), 55.7 (Cquat, C-(CH3)3), 60.0 
(−, C-11), 74.1 (−, C-6), 110.5 (Cquat, C-2), 111.0 (Cquat, C-4), 115.2 (−, C-18), 116.6 (−, 
C-9), 131.5 (Cquat, C-5), 134.9 (+, C-8), 137.9 (+, C-17), 149.8 (Cquart, C-3), 160.4 (Cquat, 
C-11); IR (neat): ν~  [cm-1] = 3448, 3255, 3077, 2979, 2929, 2866, 1665,1468, 1032, 
911; MS (FAB+): m/z (%) = 425 (23) [M+H]+, 304 (100) [M+ - NH-(S=O)(CH3)3]+; 
HR-MS calcd. for C22H37O4N2S: 425.2574; found: 425.2487 + 3.1 ppm. 
 
(R)-Ethyl 3-(but-3-enyloxy)-5-(1-(1,1-dimethylethylsulfinamido)hept-6-enyl)-4-
methyl-1H-pyrrole-2-carboxylate (21) 
Sulfinyl imine 16 (40 mg, 0.11 mmol) and hex-5-enylmagnesium bromid (0.34 ml, 0.82 
M in Et2O, 0.28 mmol) were reacted according to the GP2. Flash-silica chromatography 
(Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) gave 31 mg (64%) 
of 21 in a diastereomeric syn/anti ratio of 91:9. The diastereomeric ratio was determined 
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by 1H NMR. 1H-NMR (400 MHz, CDCl3): δ = 1.11-1.36 (m, 4 H, H-15, H-16), 1.15 (s, 
9 H, (CH3)3), 1.29 (t, 3J = 7.1, 3 H, H-12), 1.67-1.83 (m, 2 H, H-14), 1.88 (s, 3 H, CH3), 
1.90-1.99 (m, 2 H, H-17), 2.44 (ddt, 3J = 6.8, 3J = 6.8, 2J = 1.4, 2 H, H-7), 3.50 (d, 3J = 
2.2, 1 H, N-H), 3.94-4.05 (m, 2 H, H-69, 4.17-4.30 (m, 2 H, H-11), 4.35-4.44 (m, 1 H, 
H-13), 4.83-4.93 (m, 2 H, H-9), 4.98-5.12 (m, 2 H, H-19), 5.67 (dddd, 3J = 17.0, 3J = 
10.2, 3J = 6.7, 3J = 6.7, 1 H, H-8), 5.86 (dddd, 3J = 17.1, 3J = 10.3, 3J = 6.7, 3J = 6.7, 1 
H, H-18), 9.00 (bs, 1 H, H-pyrrole); 13C-NMR (100 MHz, CDCl3): δ = 7.5 (+, CH3), 
14.5 (+, C-12), 22.6 (+, (CH3)3, 25.4 (−, C-16), 28.4 (−, C-15), 33.4 (−, C-14), 34.6 (−, 
C-17), 35.9 (−, C-7), 52.1 (+, C-13), 55.7 (Cquat, C-(CH3)3), 59.9 (−, C-11), 74.1 (−, C-
6), 110.5 (Cquat, C-2), 111.0 (Cquat, C-4), 114.7 (−, C-19), 116.6 (−, C-9), 131.6 (Cquat, C-
5), 135.0 (+, C-8), 138.4 (+, C-18), 149.8 (Cquart, C-3), 160.4 (Cquat, C-11); IR (neat): ν~  
[cm-1] = 3422, 2979, 2929, 2861, 1647, 1465, 1280, 1032; MS (EI, 70 eV): m/z (%) = 
438.2 (6) [M+●], 318.2 (100) [M+● - ●NBoc-(S=O)(CH3)3]; HR-MS calcd. for 
C23H38N2O4S [M+●]: 438.2548; found: 438.2548 ± 1.9 ppm. 
 
(R)-Ethyl 5-(1-(1,1-dimethylethylsulfinamido)pent-4-enyl)-4-methyl-3-(pent-4- 
enyloxy)-1H-pyrrole-2-carboxylate (22) 
Sulfinyl imine 17 (50 mg, 0.14 mmol) and but-3-enylmagnesium bromide (0.28 ml, 1.3 
M in Et2O, 0.35 mmol) were reacted according to the GP2. Flash-silica chromatography 
(Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) gave 40 mg (68%) 
of 22 in a diastereomeric syn/anti ratio of 90:7. The diastereomeric ratio was determined 
by 1H NMR and HPLC. 1H-NMR (600 MHz, CDCl3): δ = 1.24 (s, 9 H, (CH3)3), 1.37 (t, 
3J = 7.1, 3 H, H-13), 1.84-1.89 (m, 2 H, H-7), 1.97 (s, 3 H, CH3), 1.09-2.03 (m, 2 H, H-
15), 2.04-2.12 (m, 2 H, H-16), 2.24-2.29 (m, 2 H, H-8), 3.55 (d, 3J = 1.5, 1 H, N-H), 
4.04 (dt, 2J = 6.4, 3J = 2.7, 2 H, H-6), 4.30-4.37 (m, 2 H, H-12), 4.53 (dt, 3J = 7.1, 3J = 
1.9, 1 H, H-14), 5.00 (ddt, 3J = 10.3, 2J* and 4J*, 1 H, H-10cis), 5.03 (ddt, 3J = 10.3, 2J* 
and 4J*, 1 H, H-18cis), 5.05 (ddt, 3J = 16.9, 2J* and 4J*, 1 H, H-18trans), 5.07 (ddt, 3J = 
17.0, 2J and 4J*, 1 H, H-10trans), 5.78 (ddt, 3J = 16.9, 3J = 10.3, 3J = 6.6, 1 H, H-17), 
5.88 (ddt, 3J = 17.0, 3J = 10.3, 3J = 6.7, 1 H, H-19), 8.98 (bs, 1 H, pyrrole-H); 13C-NMR 
(150 MHz, CDCl3): δ = 7.5 (+, CH3), 14.5 (+, C-13), 22.6 (+, (CH3)3), 29.4 (−, C-7), 
30.1 (−, C-16), 30.2 (−, C-8, 35.0 (−, C-15), 51.6 (+, C-14), 55.7 (Cquat, C-(CH3)3), 59.9 
(−, C-12), 74.3 (−, C-6), 110.6 (Cquat, C-2), 111.1 (Cquat, C-4), 114.8 (−, C-10), 115.9 (, 
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C-18), 131.1 (Cquat, C-5), 137.0 (+, C-17), 138.2 (+, C-9), 150.0 (Cquat, C-3), 160.3 
(Cquat, C-11); IR (neat): ν~  [cm-1] = 3460, 3252, 3077, 2978, 2927, 2868, 1665 1468, 
1032, 911; MS (EI, 70 eV): m/z (%) = 424.2 [M+●] (6), 304.2 [M+● - ●NH-(S=O)(CH3)3] 
(100), 367.8 [M+●  - ●C4H9]; HR-MS  calcd. for C22H37N2O4S [MH+]: 425.2474 found 
425.2475 ± 0.3 ppm.  
*coupling constants smaller than 2 Hz are not precise and are therefore not documented.  
 
(R)-Ethyl 5-(1-(1,1-dimethylethylsulfinamido)hex-5-enyl)-4-methyl-3-(pent-4- 
enyloxy)-1H-pyrrole-2-carboxylate (23) 
Sulfinyl imine 17 (100 mg, 0.27 mmol) and pent-4-enylmagnesium bromide (0.73 ml, 
1.3 M in Et2O, 0.90 mmol) were reacted according to the GP2. Flash-silica 
chromatography (Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) 
gave 40 mg (71%) of 23 in a diastereomeric syn/anti ratio of 9:1. The diastereomeric 
ratio was determined by 1H NMR and HPLC. 1H-NMR (600 MHz, CDCl3): δ = 1.20 (s, 
9 H, (CH3)3), 1.35 (t, 3J = 7.0, 3 H, H-13), 1.22-1.46 (m, 2 H, H-16), 1.77-1.93 (m, 4 H, 
H-7, H-15) 1.95 (s, 3 H, CH3), 1.98-2.07 (m, 2 H, H-17), 2.22-2.29 (m, 2 H, H-8), 4.03 
(m, 3 H, H-6, N-H), 4.37 (m, 2 H, H-12), 4.43-4.48 (m, 1 H, H-14), 4.90-5.10 (m, 4 H, 
H-10, H-19), 5.67-5.75 (m, 1 H, H-18), 5.80-5.90 (m, 1 H, H-9), 9.30 (s, 1 H, N-H); 
13C-NMR (150 MHz, CDCl3): δ = 7.5 (+, CH3), 14.5 (+, C-13), 22.6 (+, (CH3)3, 25.2 (−, 
C-16),29.4 (−, C-7), 30.2 (−, C-8), 33.2 (−, C-17), 35.7 (−, C-15), 52.4 (+, C-14), 55.8 
(Cquat, C-(CH3)3), 60.0 (−, C-12), 74.3 (−, C-6), 110.4 (Cquat, C-2), 110.7 (Cquat, C-4), 
114.8 (−, C-10), 115.1 (−, C-19), 132.0 (Cquat, C-5), 137.9 (+, C-18), 138.2 (+, C-9), 
149.9 (Cquart, C-3), 160.6 (Cquat, C-11); IR (neat): ν~  [cm-1] = 3458, 3252, 3075, 2976, 
2928, 2866, 1665, 1468, 1273, 1032; MS (EI, 70 eV): m/z (%) = 438.2 (6) [M+●], 318.1 
(100) [M+●-●NH-(S=O)(CH3)3]; HR-MS calcd. for C23H38N2O4S [M+●]: 438.2555; 
found: 438.2550 ± 0.7 ppm. 
 
(R)-Ethyl 5-(1-(1,1-dimethylethylsulfinamido)hept-6-enyl)-4-methyl-3-(pent-4- 
enyloxy)-1H-pyrrole-2-carboxylate (24) 
Sulfinyl imine 17 (200 mg, 0.54 mmol) and hex-5-enylmagnesium bromide (1.27 mL, 
0.94 M in Et2O, 1.19 mmol) were reacted according to the GP2. Flash-silica 
chromatography (Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) 
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gave 159 mg (65%) of 24 in a diastereomeric syn/anti ratio of 93:7. The diastereomeric 
ratio was determined by 1H NMR. 1H-NMR (600 MHz, CDCl3): δ = 1.21 (s, 9 H, 
(CH3)3), 1.22-1.41 (m, 7 H, H-13, H-16, H-17), 1.77-1.91 (m, 4 H, H-7, H-15), 1.95 (s, 
3 H, CH3), 1.98-2.04 (m, 2 H, H-18), 2.21-2.32 (m, 2 H, H-8), 3,77-3.88 (m, 1 H, N-
H), 3.94-4.05 (m, 2 H, H-6), 4.23-4.38 (m, 2 H, H-12), 4.41-4.51 (m, 1 H, H-14), 4.88-
5.09 (m, 4 H, H-10, H-20), 5.69-5.78 (m, 1 H, H-19), 5.82-5.92 (m, 1 H, H-9), 9.23 (bs, 
1 H, N-H); 13C-NMR (150 MHz, CDCl3): δ = 7.5 (+, CH3), 14.5 (+, C-13), 22.6 (+, 
(CH3)3, 25.4 (−, C-17), 28.4 (−, C-16), 29.4 (−, C-7), 30.2 (−, C-8), 33.4 (−, C-18), 36.1 
(−, C-15), 52.4 (+, C-14), 55.8 (Cquat, C-(CH3)3), 60.0 (−, C-12), 74.3 (−, C-6), 110.4 
(Cquat, C-2), 110.8 (Cquat, C-4), 114.6 (−, C-10), 114.8 (, C-20), 132.0 (Cquat, C-5), 138.2 
(+, C-19), 138.4 (+, C-9), 149.9 (Cquart, C-3), 160.6 (Cquat, C-11); IR (neat): ν~  [cm-1] = 
3458, 3252, 3075, 2976, 2928, 2866, 1665, 1469, 1280, 1033, 910, 733; MS (FAB+): 
m/z (%) = 453 (20) [MH]+, 332 (100) [M - NH-(S=O)(CH3)3]+; HR-MS calcd. for 
C24H41N2O4S [M+●]: 453.2787; found: 453.2813 + 10 ppm. 
 
(R)-Ethyl 5-(1-(1,1-dimethylethylsulfinamido)pent-4-enyl)-3-(hex-5-enyloxy)-4-
methyl-1H-pyrrole-2-carboxylate (25) 
Sulfinyl imine 18 (63 mg, 0.14 mmol) and but-3-enylmagnesium bromide (0.33 mL, 1.3 
M in Et2O, 0.41 mmol) were reacted according to the GP2. Flash-silica chromatography 
(Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) gave 48 mg (68%) 
of 25 in a diastereomeric syn/anti ratio of 95:5. The diastereomeric ratio was determined 
by 1H.  
1H-NMR (400 MHz, CDCl3): δ = 1.23 (s, 9 H, (CH3)3), 1.28 (t, 3J = 7.1, 3 H, H-14), 
1.45-1.58 (m, 2 H, H-8), 1.62-1.75 (m, 2 H, H-7), 1.78-2.01 (m, 4 H, H-16 and H-17), 
1.88 (s, 3 H, CH3), 2.01-2.10 (m, 2 H, H-9), 3.85 (d, 3J = 2.9, 1 H, N-H), 3.93 (t, 3J = 
6.8 2 H, H-6), 4.13-4.29 (m, 2 H, H-13), 4.36-4.48 (m, 2 H, H-15), 4.75-5.07 (m, 4 H, 
H-11 and H-19), 5.54-5.91 (m, 2 H, H-10 and H-18), 8.15 (bs, 1 H, pyrrole-H); 13C-
NMR (100 Hz CDCl3): δ = 7.5 (+, CH3), 14.5 (+, C-14), 22.6 (+, (CH3)3), 25.3 (−, C-8), 
29.7 (−, C-7), 30.1 (−, C-17), 33.6 (−, C-9), 35.2 (−, C-16), 52.0 (+, C-15), 55.8 (Cquat, 
C-(CH3)3), 60.0 (−, C-13), 74.8 (−, C-6), 110.9 (Cquat, C-2), 111.1 (Cquat, C-4), 114.9 (−, 
C-11), 115.8 (−, C-19), 131.6 (Cquat, C-5), 137.1 (+, C-18), 138.7 (+, C-10), 150.0 (Cquat, 
C-3), 160.6 (Cquat, C-12); IR (neat): ν~  [cm-1] = 3461, 3300, 2978, 2933, 2867, 1663, 
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1272, 1031, 909; MS (FAB+): m/z (%) = 439 (26) [MH]+, 318 (100) [M - NH-
(S=O)(CH3)3]+; HR-MS calcd. for C23H39O4O2S: 439.2631; found: 439.2614 + 3.9 ppm. 
 
(R)-Ethyl 5-(1-(1,1-dimethylethylsulfinamido)hex-5-enyl)-3-(hex-5-enyloxy)-4-
methyl-1H-pyrrole-2-carboxylate (26) 
Sulfinyl imine 18 (63 mg, 0.14 mmol) and pent-4-enylmagnesium bromide (0.44 mL, 
0.94 M in Et2O, 0.41 mmol) were reacted according to the GP2. Flash-silica 
chromatography (Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) 
gave 36 mg (50%) of 26 in a diastereomeric syn/anti ratio of 91:9. The diastereomeric 
ratio was determined by 1H.  1H-NMR (400 MHz, CDCl3): δ = 1.14 (s, 9 H, (CH3)3), 
1.18-1.41 (m, 2 H, H-17) 1.28 (t, 3J = 7.1, 3 H, H-14), 1.46-1.57 (m, 2 H, H-8), 1.62-
1.84 (m, 4 H, H-7 and H-16), 1.88 (s, 3 H, CH3), 1.91-2.00 (m, 2 H, H-18), 2.01-2.10 
(m, 2 H, H-9), 3.62 (d, 3J = 2.5, 1 H, N-H), 3.88-3.98 (m, 2 H, H-6), 4.15-4.29 (m, 2 H, 
H-13), 4.36-4.45 (m, 1 H, H-15), 4.85-5.99 (m, 4 H, H-11 and H-20), 5.59-5.82 (m, 2 H, 
H-10 and H-19), 9.03 (bs, 1 H, pyrrole-H); 13C-NMR (100 MHz, CDCl3): δ = 7.5 (+, 
CH3), 14.5 (+, C-14), 22.6 (+, (CH3)3), 25.2 (−, C-17), 25.3 (−, C-8), 29.7 (−, C-7), 33.2 
(−, C-18), 33.6 (−, C-9), 35.6 (−, C-16), 52.2 (+, C-15), 55.8 (Cquat, C-(CH3)3), 60.0 (−, 
C-13), 74.8 (−, C-6), 110.5 (Cquat, C-2), 110.9 (Cquat, C-4), 114.6 (−, C-11), 115.2 (−, C-
20), 131.6 (Cquat, C-5), 137.9 (+, C-19), 138.7 (+, C-10), 150.0 (Cquat, C-3), 160.5 (Cquat, 
C-12); IR (neat): ν~  [cm-1] = 3420, 3257, 2978, 2931, 2864, 1664, 1468, 1273, 1032; 
MS (FAB+): m/z (%) = 453 (20) [MH]+, 332 (100) [M - NH-(S=O)(CH3)3]+; HR-MS 
calcd. for C24H41O4O2S: 453.2787; found: 453.2807 + 4.5 ppm. 
 
(R)-Ethyl 5-(1-(1,1-dimethylethylsulfinamido)hept-6-enyl)-3-(hex-5-enyloxy)-4-
methyl-1H-pyrrole-2-carboxylate (27) 
Sulfinyl imine 18 (63 mg, 0.16 mmol) and hex-5-enylmagnesium bromide (0.44 mL, 
0.94 M in Et2O, 0.41 mmol) were reacted according to the GP2. Flash-silica 
chromatography (Biotage SP4 chromatography system, EtOAc : cyclohexane = 7:3) 
gave 36 mg (72%) of 21 in a diastereomeric syn/anti ratio of 94:6. The diastereomeric 
ratio was determined by proton NMR. 1H-NMR (400 MHz, CDCl3): δ = 1.13 (s, 9 H, 
(CH3)3), 1.19-1.45 (m, 4 H, H-17 and 18) 1.28 (t, 3J = 7.1, 3 H, H-14), 1.46-1.58 (m, 2 
H, H-8), 1.60-1.84 (m, 4 H, H-7 and H-16), 1.88 (s, 3 H, CH3), 1.90-2.11 (m, 4 H, H-9 
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and H-19), 3.72 (d, 3J = 2.9, 1 H, N-H), 3.86-3.98 (m, 2 H, H-6), 4.16-4.31 (m, 2 H, H-
13), 4.33-4.43 (m, 1 H, H-15), 4.80-5.01 (m, 4 H, H-11 and H-21), 5.59-5.83 (m, 2 H, 
H-10 and H-20), 9.17 (bs, 1 H, pyrrole-H); 13C-NMR (100 MHz, CDCl3): δ = 7.5 (+, 
CH3), 14.5 (+, C-14), 22.6 (+, (CH3)3), 25.3 (−, C-8), 25.4 (−, C-18), 28.4 (−, C-17), 
29.7 (−, C-7), 33.4 (−, C-19), 33.7 (−, C-9), 36.1 (−, C-16), 52.3 (+, C-15), 55.8 (Cquat, 
C-(CH3)3), 59.9(−, C-13), 74.8 (−, C-6), 110.4 (Cquat, C-2), 110.8 (Cquat, C-4), 114.2 (−, 
C-11), 114.6 (−, C-21), 131.9 (Cquat, C-5), 138.4 (+, C-20), 138.7 (+, C-10), 150.0 (Cquat, 
C-3), 160.6 (Cquat, C-12); IR (neat): ν~  [cm-1] = 3460, 3256, 3076, 2977, 2930, 2861, 
1666, 1469, 1280, 1032, 994; MS (FAB+): m/z (%) = 467 (18) [MH]+, 346 (100) [M - 
NH-(S=O)(CH3)3]+; HR-MS calcd. for C25H42O4N2S: 466.2865; found: 466.2849 + 3.5 
ppm. 
 
(R)-1-tert-Butyl 2-ethyl 5-(1-(1,1-dimethylethylsulfinamido)hex-5-enyl)-4-methyl-3-
(pent-4-enyloxy)-1H-pyrrole-1,2-dicarboxylate 23-Boc and 
(R)-Ethyl 5-(1-(N-(tert-butoxycarbonyl)-2-methylpropan-2-ylsulfinamido)hex-5-
enyl)-4-methyl-3-(pent-4-enyloxy)-1H-pyrrole-2-carboxylate 23a-Boc 
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Scheme 4. Preparation of the Boc-protected diene 23. 
 
To a solution of 23 (130 mg, 0.30 mmol) in dry CH2Cl2 (20 mL) at room temperature 
DMAP (40.3 mg, 0.33 mmol) was added and the mixture was stirred for 10 min under 
dinitrogen atmosphere. (Boc)2O (131 mg, 0.60 mmol) was added and the mixture was 
stirred over night. The solution was washed with water (4x 10 mL) and dried over 
MgSO4. The solvent was evaporated in vacuum and the two products were separated by 
column chromatography on silica gel (cyclohexane : EtOAc = 8:2, Rf = 0.13 and 0.47) 
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to give 44 mg of 23-Boc (29 %) as a colourless oil and 99 mg of 23a-Boc (61 %) as a 
colourless oil. 
Compound 23-Boc: IR: ν~  [cm-1] = 3450, 3302, 3077, 2979, 2934, 2870, 1713; MS 
(EI, 70 eV): m/z (%) = 538.1 (0.2) [M+●], 318.2 (100) [M+● - ●NBoc-(S=O)(CH3)3]; HR-
MS calcd. for C28H46N2O6S [M+●]: 538.3077; found: 538.3075 ± 1.2 ppm. 
 
Compound 23a-Boc: 1H-NMR (600 MHz, CDCl3): δ = 1.15-1.23 (m, 2 H, H-16), 1.27 
(s, 9 H, TBS), 1.34 (t, 3J = 7.1, 3 H, H-13), 1.52 (s, 9 H, Boc), 1.69-1.79 (m, 1 H, H-
15A), 1.80-1.87 (m, 2 H, H-7), 1.95-2.05 (m, 2 H, H-17), 2.02 (s, 3 H, CH3), 2.19-2.29 
(m, 2 H, H-8), 2.67-2.80 (m, 1 H, H-15B), 3.95-4.00 (m, 1 H, H-6A), 4.01-4.07 (m, 1 H, 
H-6B), 4.23-4.36 (m, 2 H, H-12), 4.57-4.65 (m, 1 H, H-14), 4.89-5.11 (m, 4 H, H-10, 
H-19), 5.71 (dddd, 3J = 17.0, 3J = 10.3, 3J = 6.7, 3J = 6.7, 1 H, H-18), 5.86 (dddd, 3J = 
17.0, 3J = 10.3, 3J = 6.7, 3J = 6.7, 1 H, H-9), 9.70 (bs, 1 H, H-pyrrole); 13C-NMR (75 
MHz, CDCl3): δ = 7.4 (+, CH3), 14.5 (+, C-13), 22.8 (+, TBS, 26.3 (−, C-16), 28.3 (+, 
Boc), 29.5 (−, C-7), 30.2 (−, C-8), 33.2 (−, C-17), 33.5 (−, C-15), 45.5 (+, C-14), 59.6 
(−, C-12), 60.4 (Cquat, TBS), 74.2 (−, C-6), 83.7 (Cquat, Boc), 110.3 (Cquat, C-2), 112.5 
(Cquat, C-4), 114.7 (−, C-10), 114.9 (−, C-19), 130.8 (Cquat, C-5), 137.9 (+, C-18), 138.4 
(+, C-9), 149.2 (Cquart, C-3), 154.5 (Cquart, C-Boc amide), 160.6 (Cquat, C-11); IR: ν~  [cm-
1] = 3450, 3397, 3077, 2978, 2932, 1694; MS (EI, 70 eV): m/z (%) = 538.1 (7) [M+●], 
482.1 (13) [M – C4H8]+●, 318.2 (94) [M+● - ●NH-(S=O)(CH3)3], 276.1 (100) [M+● - 
●NH-(S=O)(CH3)3 – C2H2O]; HR-MS calcd. for C28H46N2O6S [M+●]: 538.3077; found: 
538.3079 ± 0.4 ppm. 
 
General procedure (GP3) for ring closing metathesis of sulfinyl imine dialkenes 
Sulfinyl imine dienes were dissolved as a 0.0005 M solution in anhydrous and degassed 
CH2Cl2 under an argon atmosphere. Bis(tricyclohexylphosphine) benzylidine 
ruthenium(IV) dichloride (Grubb’s I catalyst) (15 mol%), dissolved in anhydrous and 
degassed CH2Cl2 (50 mL), was added slowly over a period of 2 h by a syringe pump to 
the reaction mixture at 40 °C, and stirred for additional 24 h. Additional catalyst (15 
mol%) was added and the mixture was refluxed for 1 d. After 50 equivalents of DMSO 
were added, the mixture was stirred at room temperature for 1d. Concentration under 
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reduced pressure and filtration through a pad of silica afforded the crude product, which 
was purified by HPLC. 
 
Ethyl 11-((R)-1,1-dimethylethylsulfinamido)-15-methyl-2-oxa-13 azabicyclo-
[10.2.1]pentadeca-1(14),6,12(15)-triene-14-carboxylate (28) 
Compound 23 (20 mg, 0.05 mmol) was reacted following the GP3. Preparative HPLC 
afforded 7 mg of the ansa-bridged 28 (47%, conversion corrected yield, 5 mg of 23 
regained) as an inseparable 9:1 E:Z mixture and 3.5 mg of the larger macrocycle 29 
(12%), as a mixture of stereoisomers. Compound 28: 1H-NMR (600 MHz, CDCl3, 
DQF-COSY, HSQC, HMBC): δ = 0.84-0.92 (m, 1 H, H-8A), 0.92-1.02 (m, 1 H, H-
11A), 1.26 (s, 9 H, (CH3)3), 1.38 (t, 3 H, 3J = 7.13, H-16), 1.43-1.53 (m, 2 H, H-7A, H-
8B), 1.55-1.63 (m, 1 H, H-13A), 1.65-1.75 (m, 2 H, H-11B, H-12A), 2.00-2.13 (m, 4 H, 
H-7B, CH3), 2.15-2.21 (m, 2 H, H-12B, H-13B), 3.62 (bs, 1 H, N-H), 4.13-4.20 (m, 1 
H, H-6A), 4.24-4.34 (m, 2 H, H-6B, H-15A), 4.43-4.49 (m, 1 H, H-15B), 4.54 (dd, 1 H, 
2J = 11.96, 3J = 5.26, H-14), 5.13 (ddt, 1 H,  3J = 10.8, 3J = 3.3, 4J = 2.0, H-10), 5.21 
(ddt, 1 H,  3J = 10.8, 3J = 2.2, 4J = 2.2, H-9), 9.01 (bs, 1 H, H-pyrrole); 13C-NMR 
(assignment by HSQC, HMBC, 600 MHz, CDCl3): δ = 9.1 (+, CH3), 14.5 (−, C-16), 
22.6 (+, (CH3)3), 24.9 (−, C-11), 25.5 (−, C-12), 26.5 (−, C-8), 31.1 (−, C-7), 35.2 (−, C-
13), 51.8 (+, C-14), 55.6 (Cquat, C(CH3)3), 59.9 (−, C-15), 70.9 (−, C-6), 111.8 (Cquat, C-
2), 120.0 (Cquat, C-4), 128.5  (+, C-10), 130.2 (+. C-9), 131.0 (Cquat, C-5), 150.0 (Cquat, 
C-3), 160.6 (Cquat, C-ester); MS (ES, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 
411.2 (100) [M+H]+, 821.6 (13) [2M + H]+; HR-MS calcd. for C21H34N2O4S [M+●]: 
410.2232; found: 410.2233 ± 1.5 ppm.  
Compound 29: MS (ES, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 819.7 (100) 
[M-H+]−, 933.6 (10) [M+TFA]−, 879.7 (9) [M+CH3COO−], 855.6 (8) [M+Cl−]. 
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